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Background: Acute bronchiolitis is the most common cause of hospitalisation in infancy. Supportive care
and oxygen are the cornerstones of management. A Cochrane review concluded that the use of nebulised
3% hypertonic saline (HS) may significantly reduce the duration of hospitalisation.
Objective: To test the hypothesis that HS reduces the time to when infants were assessed as being fit for
discharge, defined as in air with saturations of > 92% for 6 hours, by 25%.
Design: Parallel-group, pragmatic randomised controlled trial, cost–utility analysis and systematic review.
Setting: Ten UK hospitals.
Participants: Infants with acute bronchiolitis requiring oxygen therapy were allocated within 4 hours
of admission.
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Interventions: Supportive care with oxygen as required, minimal handling and fluid administration as
appropriate to the severity of the disease, 3% nebulised HS every ± 6 hours.
Main outcome measures: The trial primary outcome was time until the infant met objective discharge
criteria. Secondary end points included time to discharge and adverse events. The costs analysed related to
length of stay (LoS), readmissions, nebulised saline and other NHS resource use. Quality-adjusted life-years
(QALYs) were estimated using an existing utility decrement derived for hospitalisation in children, together
with the time spent in hospital in the trial.
Data sources: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials and
other databases from inception or from 2010 onwards, searched ClinicalTrials.gov and other registries and
hand-searched Chest, Paediatrics and Journal of Paediatrics to January 2015.
Review methods: We included randomised/quasi-randomised trials which compared HS versus saline
(± adjunct treatment) or no treatment. We used a fixed-effects model to combine mean differences for LoS
and assessed statistical heterogeneity using the I2 statistic.
Results: The trial randomised 158 infants to HS (n= 141 analysed) and 159 to standard care (n= 149
analysed). There was no difference between the two arms in the time to being declared fit for discharge
[median 76.6 vs. 75.9 hours, hazard ratio (HR) 0.95, 95% confidence interval (CI) 0.75 to 1.20] or to
actual discharge (median 88.5 vs. 88.7 hours, HR 0.97, 95% CI 0.76 to 1.23). There was no difference in
adverse events. One infant developed bradycardia with desaturation associated with HS. Mean hospital
costs were £2595 and £2727 for the control and intervention groups, respectively (p= 0.657). Incremental
QALYs were 0.0000175 (p= 0.757). An incremental cost-effectiveness ratio of £7.6M per QALY gained
was not appreciably altered by sensitivity analyses. The systematic review comprised 15 trials (n= 1922)
including our own. HS reduced the mean LoS by –0.36 days (95% CI –0.50 to –0.22 days). High levels of
heterogeneity (I2= 78%) indicate that the result should be treated cautiously.
Conclusions: In this trial, HS had no clinical benefit on LoS or readiness for discharge and was not a
cost-effective treatment for acute bronchiolitis. Claims that HS achieves small reductions in LoS must be
treated with scepticism.
Future work: Well-powered randomised controlled trials of high-flow oxygen are needed.
Study registration: This study is registered as NCT01469845 and CRD42014007569.
Funding details: This project was funded by the NIHR Health Technology Assessment (HTA) programme
and will be published in full in Health Technology Assessment; Vol. 19, No. 66. See the HTA programme
website for further project information.
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Plain English summary
Acute bronchiolitis is the most common cause of babies being admitted to hospital. It can be causedby any of the common cold viruses, although most cases are caused by the respiratory syncytial
virus. If the virus gets into the lungs, it can cause difficulties in breathing on top of the head cold. The
worst-affected babies require oxygen and help with feeding until they clear the virus themselves. Many
treatments have been tried, but in all cases they were shown to be ineffective when properly tested. Most
recently, it has been suggested that inhaling a mist of 3% hypertonic saline (salt water) from a nebuliser
would reduce the length of time that babies spend in hospital. To test this suggestion, we undertook a
trial and recruited 317 babies from 10 hospitals. All had bronchiolitis that was severe enough at admission
for the babies to require treatment with oxygen. All received what is considered to be the best standard of
care. Half of the babies were also treated with nebulised 3% saline every 6 hours. We found that the
nebulised treatment had no effect on the time it took for babies to be ready for discharge and we were
unable to demonstrate any benefit from its use. The treatment itself caused side effects in a few babies,
such as excessive coughing and a fall in blood oxygen levels.
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Scientific summary
Background
Acute bronchiolitis is the most common cause of hospitalisation in infancy, with 1–3% of all infants
admitted in their first year. The disease is caused by a number of common respiratory viruses, especially
respiratory syncytial virus (RSV), and is associated with peaks in admissions in the winter months. Infants
develop signs of an upper respiratory tract infection with rhinitis followed by signs of lower respiratory
tract involvement due to lower airway obstruction. More laboured breathing, hyperinflation, cough
and widespread crackles on auscultation are all sometimes accompanied by wheeze. Babies are most
commonly admitted to hospital with this condition between 1 and 6 months of age.
Management consists of supportive care, supplemental oxygen, minimal handling and the provision of
fluids. Oxygen therapy was introduced over 60 years ago and reduced mortality rates from 20% in the
1940s to less than 1%, although acute bronchiolitis still is a major cause of infant death. Paediatric
inpatient services and paediatric intensive care units (ICUs) face enormous pressure from increasing
admissions for acute bronchiolitis, as admission increased from 21,330 in 2004/5 to 33,472 in 2010/11.
In the UK, the median duration of admission for all acute paediatric admissions is around 1.5 days, while
the mean duration of hospitalisation for acute bronchiolitis is around 3.3 days. Treatments, including oral
and inhaled steroids, antiviral agents and a variety of bronchodilators, have not impacted on the course of
the acute illness or decreased the duration of hospitalisation.
It has been suggested by some published studies that nebulised hypertonic saline (HS) could reduce
the duration of hospitalisation and alter the course of the illness. A Cochrane review concluded that
nebulised 3% HS may significantly reduce the duration of hospitalisation and may improve the clinical
severity score in infants with acute viral bronchiolitis. Included studies were undertaken using a
range of therapies and comparators in a range of health-care settings. The majority of studies used 3%
and 6% HS with and without a bronchodilator, with the control arm often involving nebulised normal
saline (NS) with or without a bronchodilator. NS is sometimes thought to positively affect clinical outcomes
and so could be considered an active comparator; older studies using distilled water as a comparator
have been criticised because hypo-osmolar water could induce bronchospasm. When interpreting these
studies it is important to consider that the term ‘acute bronchiolitis’ is used to describe phenotypically
different patients in various areas of the world. The UK, Australia and a number of other countries use the
definition in which widespread crackles are a characteristic, whereas in the USA and other countries it is
defined by the first episode of wheezing with an apparent viral infection. Although all these patients have
very similar underlying pathology, dominated by neutrophil influx into the airway, the second definition
would include infants experiencing a first viral exacerbation of asthma.
In response, the hypertonic Saline in Acute Bronchiolitis Randomised controlled trial (RCT) and Economic
evaluation (SABRE) study randomised infants requiring oxygen therapy for acute bronchiolitis to receive
usual care or usual care with 4ml nebulised 3% HS every 6 hours until they were fit for discharge.
As a number of RCTs had been published since the last update of the Cochrane review, a systematic
review was undertaken to put the trial in context.
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Objectives
The SABRE study
The purpose of the SABRE study was to evaluate the clinical effectiveness of nebulised HS in the treatment
of acute bronchiolitis. The primary objective of the study was to assess whether or not the addition of
nebulised 3% HS to usual supportive care resulted in a reduction in time to being declared ‘fit for
discharge’. Secondary objectives included an assessment of the impact of the intervention on other clinical
outcomes and the quality of life of infants and carers at 28 days post randomisation and an investigation
of the impact on outcomes between those infants with human RSV infection and those with acute
bronchiolitis due to other causes, including other viruses (non-RSV).
Health economics
The objective of the health economics component was an assessment of the economic impact of the
intervention on both the NHS and parents at 28 days post randomisation.
Systematic review
The objective of the systematic review was to put the SABRE study in context with other controlled
trials of nebulised HS for infants hospitalised with primary acute bronchiolitis, including an assessment
of heterogeneity.
Methods
The SABRE study
The trial was a parallel-group, pragmatic RCT in 10 UK hospitals. The hypothesis was that the intervention
would result in a 25% reduction in the primary outcome expressed as a hazard ratio (HR), the time to
when infants were assessed as being ‘fit for discharge’, defined as in air with saturations of > 92% for
6 hours. Secondary outcomes included actual time to discharge from randomisation [length of stay (LoS)],
admission to ICU/high-dependency unit (HDU), readmissions within 28 days, duration of respiratory
symptoms within 28 days, infant and parental quality of life using the Infant Toddler Quality of Life
Questionnaire (ITQoL) at 28 days following randomisation and adverse events (AEs). Analysts were blind
to allocation.
Health economics
The costs included in the analysis related to LoS by type of ward, readmissions, use of nebulised saline
and, in primary care, general practitioner contacts, NHS Direct contacts, and attendances at NHS walk-in
centres, minor injury units and emergency departments. Quality-adjusted life-years (QALYs) were
estimated using an existing utility decrement derived for hospitalisation in children, together with the
time spent in hospital derived from the data of the SABRE study. A cost–utility analysis was undertaken
from the NHS perspective with a time frame of 36 days post randomisation. This was supplemented
with a cost–consequences analysis (CCA), which considers the secondary clinical outcome measures
alongside costs.
Systematic review
The electronic databases searched included MEDLINE (via Ovid) (1946 to January 2015), EMBASE (1974 to
January 2015), the Cochrane Central Register of Controlled Trials, Google Scholar (Google, Mountain View,
CA, USA) (2010 to January 2015) and Web of Science (2010 to January 2015). The following trial registries
were searched, using the terms ‘bronchiolitis’ and ‘hypertonic saline’, to identify any unpublished data:
ClinicalTrials.gov; UK Clinical Trials Gateway; Centre for Reviews and Dissemination databases (Database of
Abstracts of Reviews of Effects, NHS Economic Evaluation Database, Health Technology Assessment
Database); controlled-trials.com; centrewatch.com; and National Research Register. We also hand-searched
the journals Chest, Paediatrics and Journal of Paediatrics in January 2015 using the terms ‘hypertonic saline’
and ‘bronchiolitis’. The reference lists of all eligible trial publications were checked to identify any further
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published trials. All searches were performed between January 2013 and January 2015. We included
randomised or quasi-randomised trials which compared HS and either NS (with or without adjunct
treatment) or no treatment. Two reviewers extracted data to calculate mean differences (MDs), length of
hospital stay (primary outcome), clinical severity scale (CSS) score and AEs with 95% confidence intervals
(CIs). Meta-analysis was undertaken in RevMan version 5.2 (The Cochrane Collaboration, The Nordic
Cochrane Centre, Copenhagen, Denmark) and Stata version 12 (StataCorp LP, College Station, TX, USA)
using both fixed- and random-effect models. We assessed statistical heterogeneity using the I2 statistic. The
Cochrane risk of bias tool was used to assess the potential for systematic error within individual studies.
Standard methods were used to assess the risk of outcome reporting bias and a funnel plot was generated
to explore the possibility of publication bias.
Setting
Participants were recruited from paediatric wards and assessment units from the 10 participating centres
between October 2011 and December 2013.
Participants
Randomised controlled trial and economic analysis
Previously healthy infants, aged less than 1 year, admitted to hospital with a clinical diagnosis of acute
bronchiolitis and requiring supplemental oxygen therapy on admission were consented and randomised
within 4 hours of admission. The following were excluded: wheezy bronchitis or asthma; gastro-oesophageal
reflux; previous lower respiratory tract infections; risk factors for severe disease; carer who was not fluent
in English where translation services were not available; and need for admission to HDU or ICU at the time
of recruitment.
Systematic review
Controlled trials involving children up to the age of 2 years who had been hospitalised as the result of an
episode of acute bronchiolitis.
Interventions
Randomised controlled trial and economic analysis
Randomisation was to standard supportive care with oxygen as required, minimal handling and fluid
administration as appropriate to the severity of the disease, 3% nebulised HS approximately every 6 hours.
Systematic review
Studies evaluating nebulised HS with or without an adjunct bronchodilator treatment given versus NS or
no intervention (control) with the following pre-specified subgroups:
1. nebulised HS alone versus NS
2. nebulised HS plus a bronchodilator (e.g. salbutamol) versus NS
3. nebulised HS plus a bronchodilator (e.g. salbutamol) versus NS plus same bronchodilator
4. nebulised HS alone or plus a bronchodilator (e.g. salbutamol) versus no intervention.
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Results
The randomised controlled trial
The trial recruited to target when 158 infants were randomised to HS (n= 141 analysed) and 159 to
standard care (n= 149 analysed). There was no difference between the two arms in the time to being
declared fit for discharge (HR 0.95, 95% CI 0.75 to 1.20) or to actual discharge (HR 0.97, 95% CI 0.76
to 1.23).
The median [interquartile range (IQR)] time until the infant was fit for discharge was 76.6 hours (IQR
46.1–113.3 hours) in the HS group and 75.9 hours (IQR 45.5–21.0 hours) in the standard care group. The
median time until actual discharge was 88.5 hours (IQR 51.6–120.9 hours) in the HS group and 88.7 hours
(IQR 50.9–123.6 hours) in the control group. Infants who were RSV positive (n= 179, median 80.7 hours)
took longer to be fit for discharge than RSV-negative children (n= 27, median 50.8 hours, HR 1.94,
95% CI 1.24 to 3.02 hours; p= 0.004), and somewhat longer to be actually discharged (median 91.1 hours
vs. 72.2 hours, HR 1.47, 95% CI 0.95 to 2.28 hours; p= 0.09), but we found no evidence of an interaction
between viral status and treatment effect. Differences in routine practice between centres meant that viral
testing was not undertaken in 79 patients.
There was no difference between treatment groups in the numbers admitted to HDU/ICU or readmitted
within 28 days of randomisation. We observed no important differences in score on any of the ITQoL
dimensions. There was no difference between groups in the number or severity of observed AEs. Six AEs
were possibly related to saline treatment. These included one serious adverse event (SAE), bradycardia
and desaturation during administration of the nebuliser, which had resolved by the following day.
The remaining five non-SAEs, each of which were observed in separate subjects, were bradycardia
(self-correcting), desaturation, coughing fit and increased respiratory rate (all of which were resolved
within 1 day), and a chest infection which resolved after 6 days.
Health economics
When individual cost components are combined with their unit costs, the mean hospital costs were £2595
and £2727 for the control and the intervention groups, respectively. The 95% CI around the difference of
£132 is –£520 to £785. QALYs were 0.0000175 greater in the intervention group but the difference was
not statistically significant. Mean primary care costs for available patients were £19 and £11 in the control
and the intervention groups, respectively. The difference in means was £8 (95% CI –£21 to £6; p= 0.25).
Given the large number of missing data, it was decided not to impute missing values or combine them
with the hospital costs. With numerically higher costs (£132) and QALYs (0.0000175), the incremental
cost-effectiveness ratio is approximately £7.6M per QALY gained. One-way sensitivity analyses examining
different unit costs for time spent on a ward, ICU or HDU did not alter the probability that nebulised saline
would be cost-effective. Across all the measures considered within the CCA, there is only one statistically
significant difference between the study arms, relating to the family cohesion domain of the ITQoL.
Given the uncertainties and biases associated with this result, the robustness of this difference is open
to question.
Systematic review
In 15 trials (n= 1922), HS reduced mean LoS by –0.36 days (95% CI –0.50 to –0.22 days). Risk of bias
and high levels of heterogeneity (I2= 78%) in the main analysis and one out of four intervention
subgroups suggest that the result should be treated cautiously. A reduction in CSS (five trials, n= 516,
MD –1.36, 95% CI –1.52 to –1.20) should also be treated cautiously. None of the trials reported
intervention-related SAEs.
Five trials (n= 385) combined HS with adrenaline and found a clinically important, statistically significant
difference compared with adrenaline alone (MD –0.61, 95% CI –0.94 to –0.28; p= 0.578; I2= 0%).
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Conclusions
The SABRE study
The addition of nebulised HS to good supportive care when treating infants admitted to hospital with
acute bronchiolitis does not appear to cause any harm but confers no benefit.
Health economics
The economic analysis used two forms of analysis to consider the cost-effectiveness of nebulised HS in
this patient population. The cost–utility analysis suggests that the intervention cannot be considered
cost-effective. Taking a broader view of benefits that includes any of the primary and secondary outcomes
measures does not appreciably alter this conclusion.
Systematic review
The systematic review suggests that there is too much heterogeneity to make a pooled estimate of effect
across thirteen studies of inpatient care a useful basis for decision-making, and it shows that large studies,
and those from northern Europe, have negative results which support the findings of the SABRE study.
Future work
Potentially beneficial interventions such as high-flow oxygen therapy and others to be identified in the
future should be subject to high-quality randomised trials before any recommendations regarding practice
are made.
Study registration
This study is registered as ClinicalTrials.gov NCT01469845 and PROSPERO CRD42014007569.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
DOI: 10.3310/hta19660 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 66
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Everard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxvii

Chapter 1 Introduction
Acute bronchiolitis is the most common reason for hospitalisation in infancy and childhood, with 1–3%of all infants being admitted to hospital during their first winter.1–9 Common respiratory viruses
infecting the lungs lead to severe difficulties in breathing by causing obstruction of the airways.1–8,10–13
The age of peak incidence of babies admitted with this condition is between 1 and 6 months.9 The acute
illness is distressing for the infant and is associated with considerable stress for parents of an acutely
unwell small infant.
The only intervention that has had a major impact on the survival of infants in the last 40 years of research
is oxygen therapy, which has reduced mortality rates from around 20% to less than 1%.14 Otherwise,
current treatment consists of providing good supportive care until the infant recovers.4,15,16 Admissions for
bronchiolitis increased from 21,330 in 2004/5 to 33,472 in 2010/11,17 placing enormous strains on
paediatric services and intensive care units (ICUs)4,8,18 which sometimes have to close because of the
number of infants with acute bronchiolitis.18–20 Despite many putative candidates, including antiviral
agents, inhaled steroids and bronchodilators, no treatment other than oxygen therapy has been shown to
have an impact on the course of the acute illness and an effective vaccine still appears some way off. The
median duration of hospitalisation in the UK is around 3 days, which compares with a median of 1 day for
all acute paediatric admissions. This relatively long duration of hospital stay combined with the large
number of such infants admitted to hospital between November and March accounts for the substantial
burden on hospital services resulting from the yearly winter epidemics.
At the time we were preparing the grant application for this project, a number of relatively small studies
had suggested that nebulised hypertonic saline (HS) may reduce the duration of hospital stay for infants
admitted with acute bronchiolitis.21–24 A Cochrane review, published in 2008,25 undertook a systematic
review of the literature, focusing on four trials which involved a total of 254 infants with acute viral
bronchiolitis ,of whom 189 were inpatients and 65 patients were treated in the emergency department.
The review concluded that ‘current evidence suggests nebulised 3% saline may significantly reduce the
length of hospital stay and improve the clinical severity score in infants with acute viral bronchiolitis.’25
The conclusions do not go beyond suggesting that this intervention may have an impact because
of the methodological limitations of the included studies and the potential for publication bias. The review
noted that the conclusions are further limited by the small number of subjects included in each study
and consequent low power; the different settings since inpatients and outpatients were included;
and the failure to show a difference in some outcomes such as the failure to reduce hospitalisation
in the outpatient groups. Despite these limitations, some hospitals in the UK had already adopted this
approach to treatment by the time we started the SABRE (Saline in Acute Bronchiolitis RCT and Economic
evaluation) trial. The subsequent development of the evidence base is discussed in Chapter 6, Strengths
and weaknesses compared with earlier systematic reviews.
The suggested mode of action of HS is through an alteration in mucus rheology as a result of improved
hydration and the breaking of ionic bonds within the mucus, leading to improvements in mucociliary
clearance of secretions.26,27 The observation that HS can increase ciliary beat frequency may further
enhance clearance.26 It is also suggested that this intervention reduces mucosal wall oedema through
osmotic effects. There is good evidence that bronchoconstriction does not contribute significantly to the
airways obstruction in infants with acute bronchiolitis, which explains why bronchodilators do not provide
any benefit.28–31 Instead, the obstruction appears to be in part because of oedema within the airway
wall and, probably more importantly, accumulation of inflammatory exudates in the airways. Significant
impairment of mucociliary clearance because of the shedding of ciliated cells compounds the problem
and contributes to accumulation of secretions in the small airways. Hence an intervention leading to
improvement in clearance of these secretions and reduced oedema of the airway wall may be of benefit in
infants with acute bronchiolitis.
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In contrast to these positive studies, a recent Canadian study based in an emergency department found
no benefit when nebulised 3% HS was added to ‘usual care’,32 while a second study from Turkey,33
again involving non-hospitalised children, found that 3% HS offered no advantage over nebulised
normal saline (NS) in addition to ‘usual’ care. In both cases the intervention was in addition to the use of
bronchodilators. Understanding the differences between terminology for bronchiolitis used in North America
and that used in the UK is key to understanding why these studies might be predicted to have a negative
outcome and are not directly relevant to UK practice.
In North America, and a number of other countries, the term ‘acute bronchiolitis’ is generally used to
describe an apparent viral infection in an infant or young child who is experiencing their first episode of
wheeze.2,5,34 In the UK, Australia and some northern European countries, the key feature of acute
bronchiolitis is the presence of widespread crepitations on auscultations rather than wheeze, which may or
may not be present.2,4,34 In general, those patients with wheezing illnesses labelled as acute bronchiolitis
are somewhat older (mean 9–15 months)35–37 than infants admitted in the UK with acute bronchiolitis,
among whom the peak age for admissions is around 4 months of age.35,38–41
The clinical phenotype of subjects included in a study has been shown to be important not just in the
acute illness but in terms of subsequent morbidity, with those having the North American phenotype being
much more likely to be subsequently shown to have asthma than those with acute bronchiolitis as defined
in the UK, which is not associated with development of atopic asthma.35,42
These subtle but very important differences in inclusion criteria are likely to explain some previous
apparently contradictory results in this area. For example, some,36,37 but not all, studies assessing the
possible efficacy of nebulised adrenaline in treating young children with acute bronchiolitis in
North America have had a positive outcome, but when trialled in the UK and Australia nebulised
adrenaline was found to be ineffective and was associated with potential side effects.38,39 In contrast to
experience with bronchodilators, it is possible that HS will be more effective in acute bronchiolitis as
understood in the UK in that its putative modes of action would address the dominant mechanisms of
airways obstruction in these patients, while it would be expected to have little or no effect in those
with wheeze in whom there was significant bronchoconstriction. The studies from Canada and Turkey
included children in an outpatient setting with an inclusion criterion of wheeze. Predictably, their
mean age was significantly higher than that of the population admitted to UK units with ‘acute
bronchiolitis’ and they represent a different phenotype, often referred to in the UK as wheezy bronchitis
or virus-associated wheezing.
The observation that the greatest benefit from the use of nebulised HS appears to be in hospitalised
infants with a similar age distribution (peak 2–6 months)28–30 to that seen in UK centres22–24 would
support the potential of this approach in a well-defined UK population of infants admitted with acute
bronchiolitis. Moreover, the mean duration of stay in the control group in all three studies was 3.5 days,
again consistent with UK practice. The reduction in duration of inpatient stay in the three positive studies
was 25–27%.28–30
An inexpensive intervention that reduces length of hospital stay by 25% would be of considerable value to
the NHS and is likely to have a significant impact on the levels of stress experienced by young parents with
an acutely ill infant. Some paediatric units in the UK have already adopted this approach on the basis of
the Cochrane review. However, it is possible that publication bias and poor study design has resulted in a
false-positive outcome and, if this were the case, there is the potential for an ineffective therapy to creep
into practice. Conversely, there is a significant risk that uncritical acceptance of the ambulatory studies may
lead to discarding a potentially effective therapy through inclusion of a different patient population given
the same clinical diagnosis.
INTRODUCTION
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In the light of the uncertainties surrounding this potential valuable therapy, it was essential to undertake
an appropriately powered study in a clearly defined UK population to determine whether or not there
is indeed reason for UK paediatric units to adopt this approach or if it should simply be added to the
list of potential therapies known not to have a significant clinical impact. The importance of undertaking
such a study had been recognised both by the Paediatric Respiratory Studies Group and by observers in
countries with similar health-care systems and diagnostic criteria, such as Australia.43
Research objectives
The purpose of the trial was to evaluate the clinical effectiveness and cost-effectiveness of nebulised HS in
the treatment of acute bronchiolitis. The trial had one main objective and three secondary objectives.
Primary objective
The primary objective of the study was to assess whether or not the addition of nebulised 3% HS to usual
supportive care resulted in a reduction in time to being declared fit for discharge.
Secondary objectives
1. Assessment of the impact of the intervention on other clinical outcomes and the quality of life of
infants and carers at 28 days post randomisation.
2. Investigation of the impact on outcomes between those infants with human respiratory syncytial virus
(RSV) infection and those with acute bronchiolitis due to other causes, including other viruses
(non-RSV).
3. Assessment of the economic impact of the intervention on both the NHS and parents at 28 days
post randomisation.
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Chapter 2 Methods
There are three sections to this chapter: The SABRE study methods, Health economic methods andSystematic review methods.
This report is concordant with the 2010 Consolidated Standards of Reporting Trials
(CONSORT) statement.44
The SABRE study methods
Trial design
The SABRE study was a multicentre, parallel-group randomised controlled trial (RCT), with a one-to-one
allocation ratio and economic evaluation. It aimed to determine whether or not the addition of nebulised
3% HS to usual care resulted in significant (25%) reduction in the duration of hospitalisation of infants
with acute bronchiolitis. Subjects were recruited from the paediatric wards and assessment units of the
participating centres in England and Wales between October 2011 and December 2013. A table of
changes made to the protocol over the course of the project is presented in Appendix 1.
Important changes to methods after trial commencement
Substantial amendment 1
The primary outcome definition for fit for discharge was amended from 12 hours to 6 hours. After
discussion with participating centres it was felt that 12 hours did not reflect current practice. This was
agreed by the trial management group (TMG) and the chairperson of the trial steering committee (TSC).
The time allowed to obtain full informed consent was also amended from 60 minutes to 90 minutes after
agreement at a TMG that 90 minutes would be more practical in the clinical setting.
Minor amendment 3
It was clarified that ‘the saline will be discontinued once oxygen therapy has been discontinued’ as this
had not been explicitly stated in the protocol previously. Clarification of one of the inclusion criteria was
also provided, ‘Requiring supplemental oxygen therapy on admission’. Clarification of the wording for
admissions to high-dependency unit (HDU)/ICU was provided, ‘Admission per se of a study participant to
the HDU and/or ICU as a result of normal clinical diagnosis of acute bronchiolitis will be reported as an
expected event not as [a serious adverse event]’.
Minor amendment 5
We further clarified when saline should be discontinued after discussion at a TMG meeting – the wording
was amended from ‘the saline will be discontinued once oxygen therapy has been discontinued’ to ‘the
saline will be discontinued once the “fit for discharge” criterion has been met – in air for 6 hours with
oxygen saturations of at least 92% and feeding satisfactorily’.
Substantial amendment 6
The protocol was simplified to ensure that eligible babies who were admitted on oxygen were recruited
within 90 minutes of admission. The web-based randomisation system was altered to request the
time of admission in order to raise an alert if health professionals tried to randomise outside the
90-minute window.
Substantial amendment 7
Clarification of permitted medications for trial participants was provided, to reflect local practice and how
these should be recorded. Inclusion criteria amended to clarify which staff can make ‘the decision to
admit’ in order to begin the 90-minute consent/randomisation window.
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Substantial amendment 8
The eligibility criteria for inclusion of patients in the trial were extended. Previously, in order for patients to
be eligible for inclusion in the trial, they were required to be consented and randomised within 90 minutes
of a decision to admit a patient to an inpatient ward. This amendment extended the time-based eligibility
criteria to 4 hours. This change was proposed for two main reasons: first, a substantial number of included
trial patients were retrospectively identified as protocol violations because of being randomised outside
this 90-minute cut-off point (approximately 50 out of 172 patients randomised); and, second, there
is no clinical rational basis for assuming that patients randomised in less than 90 minutes and patients
randomised between 90 minutes and 4 hours are clinically different. Previous inpatient trials of saline in
paediatric acute bronchiolitis have not included a strict time-based cut off for inclusion, as was operated
in this study. This extension of eligibility was supported by the funder for the study [Health Technology
Assessment (HTA) programme] and it also had the support of the study sponsor.
Participants and eligibility criteria
The target population was infants less than 12 months of age admitted to hospital with a clinical diagnosis
of acute bronchiolitis and requiring supplemental oxygen as part of routine supportive care. Subjects
were recruited from paediatric wards and assessment units from the 10 participating centres between
October 2011 and December 2013.
Inclusion criteria
l Previously healthy infants less than 1 year of age.
l Admitted to hospital with a clinical diagnosis of acute bronchiolitis, following the UK definition of an
infant with an apparent viral respiratory tract infection associated with airways obstruction manifest by
hyperinflation, tachypnoea and subcostal recession with widespread crepitations on auscultation.4
Admission was defined as the point the paediatrician, or paediatric advanced nursing practitioner,
made the decision to admit. (The perspective at the time was that advanced nursing practitioners were
equivalent of specialty trainee 1 – specialty trainee 3/senior house officer).
l Requiring supplemental oxygen therapy on admission (either the infant was already in oxygen or
oxygen was recommended at the point of admission).
l Consented and randomised within 4 hours of admission.
Exclusion criteria
l Had wheezy bronchitis or asthma – children with an apparent viral respiratory infection and wheeze
with no or only occasional crepitations.
l Had gastro-oesophageal reflux (if investigated and diagnosed in hospital).
l Had previous lower respiratory tract infections (which required assessment in hospital).
l Had risk factors for severe disease (gestation of < 32 weeks, immunodeficiency, neurological and
cardiac conditions, chronic lung disease).
l Subjects for whom the carer’s English was not fluent and translational services were not available.
l Required admission to HDUs or ICUs at the time of recruitment.
The principal ethical consideration was that the subject group were unable to provide their own consent,
but this is an issue for all paediatric studies involving infants and young children. For this study there were
no known risks associated with the intervention and the participating units were very familiar with the
ethical challenges in this population.
There was a small chance that participants were involved in other research studies and this question was
asked during the informed consent process. Patients for whom the investigating team felt that it would
have been inappropriate to include them in the study were excluded on this basis.
METHODS
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Every effort was made to avoid protocol non-compliances caused by the randomisation of participants
outside the time window (see Important changes to methods after trial commencement). Participating
centres were asked to note the following:
l In the case that the person consenting was called away in an emergency before randomising, the
centre was not to then attempt to randomise the patient if this would take place outside 4 hours
from admission.
l Patients were not to be randomised without written consent. The randomisation system requested that
randomising clinicians confirm that the parent/carer has provided consent for participation in the study.
Settings and locations where the data were collected
The data used in this study came from the following sources:
l for patients who were eligible for randomisation into the study (including patients who
were randomised):
¢ patient recruitment form, which contained the age, sex and details regarding entry criteria
l for patients who were randomised into the study:
¢ randomisation schedule, which contained randomisation codes and allocated intervention group
¢ case report form, which contained patient demographics, characteristics at presentation,
investigations and events during treatment, assessment of ‘fit for discharge’, resource use and
adverse events (AEs) over subsequent 28 days
¢ post-discharge data collection forms, comprised of the symptom and health service utilisation diary.
Interventions
Infants were randomly allocated to either standard supportive care (control) or standard supportive
care plus nebulised 3% HS solution (intervention) using a remote access, computer-generated
allocation algorithm.
Three per cent HS is licensed as a medical device in the UK under the brand name MucoClear® (PARI
GmbH, Starnberg, Germany) and is indicated for the mobilisation of secretions in the lower respiratory
tract in patients with persistent mucus accumulation such as those with acute bronchiolitis or cystic
fibrosis. It was presented as a 4-ml plastic ampoule for nebulisation and came in packs of 20 or 60. The
product contained no preservatives and had an expiry date of 3 years from manufacture. The product was
administered via the PARI Sprint nebuliser (PARI Medical Ltd, Surrey, UK). The dose was 4ml every 6 hours,
in accordance with previously published studies. It was administered by a nurse, with infants inhaling the
aerosolised saline. The saline was discontinued once the fit for discharge criteria had been met – in air for
6 hours with oxygen saturations of at least 92% and feeding satisfactorily.
For the purpose of this trial, MucoClear® 3% was sourced by and dispensed locally from each site’s
pharmacy department. Although this was not a clinical trial of a medicinal product and therefore not
subject to the Medicines for Human Use (Clinical Trials) Regulations 2004,45 the principal investigator in
conjunction with his or her local pharmacy department ensured that the principles of good clinical practice
(GCP) were applied to ensure robust accountability of the supply and administration of 3% HS.
Other medications
All concomitant medications were recorded. The use of antibiotics, saline nasal drops and HS given after
an infant was declared fit for discharge was investigated in additional analyses to assess the impact of
these possible confounding factors.
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There is no proven drug therapy for the treatment of bronchiolitis. Antipyretics (paracetamol and/or
ibuprofen) are recommended for pyrexia and pain management. Nappy rash cream, alginic acid, aluminium
hydroxide, magnesium carbonate (Gaviscon®, Reckitt Benckiser), sodium chloride (Dioralyte, A Nattermann
& Cie GmbH Cologne, Germany) and lactulose (and related generic medications) were permitted. Saline
was continued if bronchiolitis remained the primary diagnosis. Antibiotics were permissible for suspected
secondary bacterial infections (e.g. based on radiographic changes). It is routine clinical practice to
discontinue antibiotics previously prescribed by general practitioners (GPs). Antibiotics are not recommended
in any ‘bronchiolitis’ guideline, including the Scottish Intercollegiate Guidelines Network (SIGN) UK guideline,4
and published data have suggested their use has been associated with a significant level of AE with no
discernible benefit.
Outcomes
Table 1 shows the timing of outcome assessments.
Primary end point
The primary outcome was time to ‘fit for discharge’, and was taken as the period of time from
randomisation to when the infant was judged to be feeding adequately (taking > 75% of usual intake
orally) and had been in air with oxygen saturations of at least 92% for 6 hours, to reflect clinical practice.4
An oxygen saturation level of less than 92% as the trigger for starting supplemental oxygen is conservative
by US standards.5 The reasons for choosing time to fit for discharge as the primary end point were
twofold: first, its objectivity [actual length of stay (LoS) is influenced by policy, the timing of ward rounds
and other features not directly related to bronchiolitis]; and, second, because of its direct relevance both to
patients and to service providers.
TABLE 1 Data collection time points
Data collection time points
Before
baseline Baseline
Every
6 hours
After
discharge
28 days after
randomisation
Eligibility criteria applied by doctors ✓ – – – –
Participant information sheet offered by nurses ✓ – – – –
Informed consent by doctors or delegated
nursing staff
✓ – – – –
Baseline demographic data – ✓ – – –
Randomisation – ✓ – – –
Apply fit for discharge criteria – ✓ ✓ – –
Diary – symptoms and health service utilisation – – – ✓ ✓
ITQoL – – – – ✓
Nurse telephone call to confirm diary and health
service utilisation
– – – ✓ ✓
Safety assessments – – ✓ – ✓
Ongoing monitoring – ✓ ✓ ✓ ✓
Retrospective identification of additional AEs – – – ✓ ✓
ITQoL, Infant Toddler Quality of Life Questionnaire.
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Secondary end points
l Actual time to discharge, from randomisation.
l Admission to ICU/HDU.
l The number of readmissions and the reasons for readmission within 28 days of randomisation.
l Duration of respiratory symptoms post discharge and within 28 days of randomisation
(see Appendix 2).
l Health-care utilisation, after discharge and within 28 days of randomisation (see Appendix 2).
l Infant and parental quality of life, using the Infant Toddler Quality of Life Questionnaire (ITQoL) at
28 days following randomisation.46
l AEs.
Fitness for discharge was assessed at baseline, then six times hourly until ‘fit for discharge’ criteria had
been met. Research nurses recorded baseline demographic data, co-interventions and outcome data on
the case report form. Research nurses also collected basic anonymised details (e.g. age, reason for
admission) on all eligible patients to allow completion of a CONSORT flow chart. To assess worsening
of condition since discharge and maximise completeness of data, research nurses telephoned parents/guardians
approximately 14 days after randomisation. Non-responders after the 28 days were contacted by the
research nurse and sent a further ITQoL if appropriate. The involvement of parents/guardians and infants
ended at this point.
Readmission was defined as any readmission to hospital within 28 days of randomisation. These have been
tabulated by study group and are further classified according to whether or not the readmission was related
to the original bronchiolitis or was a new presenting complaint.
The ITQoL is a standardised quality-of-life questionnaire that has been validated for use in infants aged
2 months to 5 years.46 The questionnaire was completed by a parent or guardian. It covered nine
domains – six for the child and three for the parent – each of which was scored from 0 (worst health)
to 100 (best health). It had been used successfully in a respiratory illness sample similar to this study,
with a response rate of 79.7%.46
Site trial staff and delegated NHS staff were responsible for recording all AEs that occurred during routine
clinical care and making them known to the principal investigator. AEs were recorded on the case report form
and database, but did not need to be reported by fax to the sponsor and Clinical Trials Research Unit (CTRU).
AEs and serious adverse events (SAEs) were reported regularly in data reports to the oversight committees.
Admission per se of a study participant to the HDU and/or ICU as a result of normal clinical diagnosis of acute
bronchiolitis was reported as an expected event not as a SAE. The sponsor and CTRU were responsible for
assessing the seriousness and reporting to relevant regulatory bodies, where appropriate.
Changes to trial outcomes after the trial commenced, with reasons
Substantial amendment 1
Protocol version 1 (28 June 2011) was amended to update the primary outcome definition for fit for discharge
from 12 hours to 6 hours. After discussion with participating centres, it was felt that 12 hours did not reflect
current practice. This was agreed by the TMG and TSC chairperson, and implemented in protocol version 0.1
(28 June 2011) before the start of recruitment. In addition, protocol version 4 (17 November 2011) was
amended to provide further clarification of when the saline should be discontinued after discussion at a TMG
meeting – the wording was amended from ‘the saline will be discontinued once oxygen therapy has been
discontinued’ to ‘the saline will be discontinued once the “fit for discharge” criteria have been met – in air for
6 hours with oxygen saturations of at least 92% and feeding satisfactorily’.
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Sample size
Based on the current mean time to discharge of around 3 days, we felt that a 25% reduction would be
the minimum clinically significant effect, and this was the magnitude of the effect observed in previous
studies.47 As LoS varies considerably across different settings, we used UK Hospital Episode Statistics data
as the basis of our sample size justification. Assuming a log-normal distribution, the standard deviation
(SD) was estimated at 32 hours. While a similar, or smaller, SD was expected for our primary outcome
measure, a slightly inflated SD of 46 hours was used because of uncertainties over its derivation here. In
order to have 90% power to detect a 25% difference in time to meeting discharge criteria, the study
needed 139 patients per group at a two-sided α-level of 5%. The dropout rate was thought to be
negligible for the analysis of the primary outcome measure and therefore a conservative estimate of
sample size was 150 patients per group. Overall, 10 centres recruited patients to the study. Targets of
25 participants for district general hospitals and 40 participants for teaching hospitals were set.
Explanation of any interim analyses and stopping guidelines
The Data Monitoring and Ethics Committee (DMEC) charter allowed the study to be stopped prematurely
on the grounds of safety or futility based on recommendations from the DMEC or the funder. No formal
interim analyses were planned for efficacy and consequently no adjustment was initially made for
multiplicity. At the request of the DMEC, one interim analysis was subsequently undertaken in July 2012 to
assess efficacy, in order to inform a funding extension decision necessitated by recruitment being slower
than expected. An O’Brien–Fleming stopping rule was retrospectively employed in which superiority would
be declared if statistical significance was demonstrated at the 1% level in the interim analysis or at the
4.5% level at the final analysis.48 The DMEC had the authority to recommend that recruitment to the study
should be terminated if the primary outcome (time to fitness for discharge) was significantly shorter in the
saline group at the α= 1% level of statistical significance.
Method used to generate the random allocation sequence
A central web-based randomisation service delivered by the CTRU was used after patient eligibility and
written consent were confirmed. Patients were randomly allocated via the online system to receive either
(1) nebulised HS with usual care (n= 150) or (2) usual care (n= 150). The randomisation schedule was
computer generated prior to the study by the CTRU Randomisation Service.
Type of randomisation; details of any restriction (such as blocking and
block size)
Participants were individually randomised using centralised, web-based randomisation system.
Randomisation was conducted in randomly ordered blocks of size 2, 4 or 6, stratified by hospital.
Allocation concealment mechanism
The allocation schedule was concealed through the use of the centralised web-based randomisation
service, which also allowed unblinding in the case of emergency. The randomisation sequence was not
revealed to any person involved in patient recruitment. The data analysts were blind to treatment
allocation until after the statistical analysis plan was finalised, the database locked and the data review
completed. All unblinding (emergency and end of trial) would have been automatically logged by the
CTRU randomisation system, which would have included the date, time and user responsible.
Sequence generation, enrolment and assignation
The randomisation sequence was computer generated and was not revealed to any person involved in
patient recruitment. Recruitment was undertaken by GCP-trained trainee paediatricians, consultants or
staff with equivalent training (e.g. GCP-trained paediatric nursing staff responsible for acute admissions).
They approached parents/guardians to discuss the study at the point of first contact as soon as the
infant had been identified as eligible for the study. Written information was then provided to parents/guardians
willing to consider their infant taking part in the study. If agreed, written informed consent was obtained
from the parents/guardians.
METHODS
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A flow chart detailing the consent and randomisation procedure can be found in Appendix 3. Owing to
the acute nature of the condition, it was not possible to follow a usual time frame of at least 24 hours
between receiving information and giving written informed consent. However, every opportunity was
taken to ensure that parents/guardians fully understood the implications of taking part in our study. They
were invited to ask questions and reflect prior to signing the informed consent document. No payment
was offered to participants. The recruiter entered the participant’s details onto an online system and was
asked the following:
l to confirm written consent was received
l to confirm the participant was in oxygen
l to enter the time a paediatrician or paediatric advanced nursing practitioner made the decision
to admit.
Participants were then randomly allocated via the online system to receive either (1) nebulised HS with
usual care (n= 150) or (2) usual care (n= 150). The allocation was explained to participants by the hospital
staff member obtaining consent.
Blinding
The study compared the intervention plus usual care with usual care alone, with no placebo. The use of
placebo in this setting is ethically problematic as it would result in infants in the placebo arm receiving an
intervention that may have a significant effect on outcome. The extra handling involved in nebulised
therapy may have a deleterious effect, as has been shown to be associated with the increased handling
associated with physiotherapy.49 Similarly, the placebo agent may cause harm, as has been suggested in
previous studies using nebulised distilled water, or may have an unexpected positive impact for an agent,
such as NS.32
The randomisation codes were stored electronically on the CTRU randomisation system. All other electronic
data were held separately on the CTRU database system. Access to any data that would unblind the
study was limited to members of the CTRU who were independent of the trial. All summaries presented to
the DMEC were by treatment group. In order to maintain the blinding of the trial statistician, it was the
responsibility of the CTRU to provide this by-treatment group information to the DMEC. No member of the
study team had access to unblinded data sets or the unblinded reports until the final analyses.
Statistical methods
The detailed statistical analysis plan can be found in Appendix 4. As time to being declared ready for
discharge could be regarded as a survival time, initial differences between groups were assessed using the
log-rank test. In order to adjust for centre, a Cox proportional hazards regression model was used with
centre fitted as a fixed effect (FE). One centre, Rotherham NHS Foundation Trust, randomised one patient:
for the purposes of adjusting for centre, this patient was combined with those recruited from Doncaster and
Bassetlaw Hospitals NHS Foundation Trust, given the similarities that exist between these two geographically
proximate populations in south Yorkshire. The proportionality of the hazards was assessed by examining
the scatter of scaled Schoenfeld residuals against time.50 This model was further extended by inclusion of
viral status (RSV vs. non-RSV) to allow an examination of whether or not viral status had an impact on
the effectiveness of treatment. In order to answer this question, the coefficient for the interaction between
infection group (RSV vs. non-RSV) and treatment group was calculated together with its 95% confidence
interval (CI) and p-value. The collection of RSV test data was not a protocol requirement and such data were
not collected at any particular centre except as part of routine practice.
The analysis of actual time to discharge was similar to the primary outcome measure, time to ‘fit to
discharge’. Rates of admission to HDU/ICU and readmission rate within 28 days from randomisation were
compared using Fisher’s exact test; although it is possible that children could be readmitted multiple times
as a result of their single episode of bronchiolitis, it is much more likely that they will be readmitted just
once. Thus, the percentage of children readmitted at least once was used for these analyses. In order to
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test the assumption that the results between groups differed according to RSV status, a logistic regression
model was fitted and a coefficient for the interaction between infection group (RSV vs. non-RSV) and
treatment group was calculated together with its 95% CIs and p-value. Each of the nine dimensions of the
ITQoL used in this study was examined for differences between treatment groups, initially using a t-test.
Where the assumptions underlying the t-test do not hold, a Mann–Whitney U-test was used.
It was originally envisaged that symptom duration would be analysed as a survival outcome. However,
diary data were returned for only 108 individuals and, of these, data to 28 days were unavailable for
almost one-quarter (25 out of 108: 1 at 15 days; 1 at 17 days; 1 at 18 days; 22 at 27 days) and almost
one-quarter (24 out of 108) reported that they were still experiencing symptoms at 28 days. Although the
majority of infants whose carers stopped sending in data before 28 days were no longer experiencing
symptoms, because of the large amount of censoring at 28 days, we defined a new outcome variable that
evaluated whether or not the patient was still experiencing symptoms at 28 days. This was analysed using
the methods outlined above for binary outcomes.
The trial was originally designed to have a two-sided significance level of α= 5%. As a result of the
aforementioned interim analysis, the significance threshold for the final analysis was changed to 4.5%
in order to preserve the overall trial-wise significance level at 5%. All CIs remain two-sided 95% intervals.
Analyses were conducted using IBM SPSS version 20 (IBM Corporation, Armonk, NY, USA) and SAS
version 9.3 (SAS Institute Inc., Cary, NC, USA).
Analysis populations
Four populations were used in the analyses:
1. all screened patients: patients who were screened for eligibility to the study, including
those randomised
2. full analysis set (FAS): all randomised patients, with the following exclusions:
i. patients who had previously been randomised, in which case only data relating to the first admission
were analysed
ii. patients for whom no recorded informed consent was obtained from carers (oral or written)
iii. patients whose carers withdrew consent before any study medications were given
iv. patients whose carers withdrew consent retrospectively (i.e. requested that all the patient’s data
were removed)
3. per protocol (PP): the subset of patients in the FAS who did not deviate from the protocol
4. safety: all randomised patients, with the exception of those for whom there was no recorded
informed consent.
Summaries based on the FAS and PP populations were on an intention-to-treat basis, with patients
assigned to the treatment group as originally randomised. Summaries based on the safety population
analysed patients by the actual treatment received. Aside from RSV status (see Statistical methods) no
other subgroup analyses were planned.
All outputs presented to the DMEC were based on the FAS population unless otherwise requested.
Patient and public involvement
Study design
At the grant application stage, meetings involving parents confirmed the impression that this disease,
affecting very young babies, has a tremendous impact on parents and families. The handling required to
administer the nebuliser may occasionally cause the infant to cry, but feedback from the parental
METHODS
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involvement meetings indicated that parents do not find this unduly stressful and that parents were keen
for their children to participate in the study. Parental involvement meetings identified that the ITQoL was
by far the most relevant of the available quality of life instruments. This questionnaire also includes
questions relating to the well-being of parents and, as such, allowed us to develop the grant application
by removing the parental stress index from our secondary outcome measures.
Study oversight
The independent TSC contained a patient and public involvement representative throughout.
Health economic methods
Background
Nebulised HS is a relatively cheap intervention: approximately £50 for the nebuliser plus 12 doses of saline.
Consequently, a large reduction in LoS is not required to suggest that the introduction of nebulised HS may
be cost neutral or even cost saving. However, a broader economic evaluation that captures a wider set of
costs and also includes patient outcomes is preferred. For example, if the intervention is not cost neutral, it
may still be cost-effective once the value of patient health effects are also considered. Alternatively, the
intervention may be cost-saving from the perspective of the hospital, but worse symptoms and more
associated care following discharge may show the intervention not to be cost-effective.
Overview
A cost–utility analysis (CUA) was undertaken from the NHS perspective, with a time frame of 36 days
post randomisation. The economic evaluation was originally designed to have a 28-day follow-up,
but one patient in the study had a LoS of 35.7 days, so the time frame was extended to avoid censoring.
A longer time frame was relevant, as there are no long-term sequelae associated with acute bronchiolitis.
Given the difficulties of measuring utilities in the very young, the CUA was supplemented with a
cost–consequences analysis (CCA) which considers the secondary clinical outcome measures alongside
costs to allow a more qualitative assessment of cost-effectiveness.
Resource use
The main items of resource use collected were LoS by type of ward and number of readmissions. Nursing
time was not included because, although nurse time is required to set up the equipment in the intervention
group, increased monitoring time may be needed in patients who are not receiving active treatment.
Consequently, a detailed observational study would be required to measure these costs in both arms. It was
considered that any cost difference would be small, and inconsequential compared with any difference in
LoS, and that calculating any difference would incur huge costs . Furthermore, if there were no difference
in LoS, then clinical practice would not change based on small differences in nursing time.
Although other costs were also considered to be negligible in comparison with the inpatient costs, ease of
data collection led us to collect data on the use of nebulised saline, concomitant medications and use of
primary care services in the 28 days following discharge (e.g. GP or emergency department visits). Inpatient
resource use was collected by staff using the same case report forms as those used for the clinical
evaluation. Primary care resource use was collected using a patient diary, which was to be completed by
the parent or guardian on a daily basis; tick boxes were available for GP contacts, NHS Direct, NHS walk-in
centres, minor injury units and the emergency department.
Unit costs
All unit costs used were at 2012/13 price levels. Costs for a day in hospital were based on 2012–13 NHS
Reference Costs, nebuliser costs were supplied by one of the participating hospitals, saline and medication
costs were taken from the British National Formulary (BNF)51 and primary care costs were taken from
NHS reference costs52 and the Unit Costs of Health and Social Care publication produced by the Personal
Social Services Research Unit.53 These are summarised in Table 2.
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The cost per day on a ward was derived using the NHS reference costs52 for an admission for paediatric
acute bronchiolitis without complications (PA15B) and its associated number of bed-days. Separate costs
per day for paediatric intensive care and high-dependency care are available directly from NHS reference
costs.52 The cost for paediatric acute bronchiolitis with complications or comorbidities (PA15A) was not
considered relevant as our separate costing of paediatric intensive care and high-dependency care captures
the costs of complications.
NHS Direct costs were taken from a report by the Medical Care Research Unit, which used a Department of
Health contract value to derive a cost per call.54 Emergency care unit costs (defined here as walk-in centres,
minor injury units and emergency departments) relate to category 1 investigation (e.g. biochemistry) and
category 3–4 treatment (e.g. oxygen).
Outcomes
For the CUA, it is usual for utilities to be calculated based on utility instruments, such as the EQ-5D,
administered to patients. However, this is not possible for the participants in this trial, and even proxy
completion by a parent would not be valid, as the descriptive systems of available utility instruments do
not fit well with this patient group. Our original approach was to undertake a separate valuation study to
estimate quality-adjusted life-year (QALY) losses related to hospitalisation and recovery and then apply
these to the trial data. However, the National Institute for Health Research was not willing to fund this
work, so we identified a published estimate relating to hospitalisation in paediatric populations that could
be used.55
TABLE 2 Unit costs
Resource
Unit cost
(2012/13), £ Source
Nebuliser kits 44 Study hospital
Saline (4ml) 0.45 BNF 65.51 3%, 6% and 7% solutions all have identical prices (£27 for 60 doses)
Inpatient day on ward 547 Derived from NHS reference costs.52 Activity-weighted average across all
non-elective admissions relating to PA15B
Inpatient day on ICU 1946 Derived from NHS reference costs.52 Activity-weighted average across all
paediatric intensive care categories, excluding ECMO/ECLS
Inpatient day on HDU 1061 Derived from NHS reference costs.52 Activity-weighted average across all
paediatric high-dependency care categories
GP attendance 45 Unit Costs of Health and Social Care 2013.53 Per-patient contact lasting
11.7 minutes, including direct care staff costs and costs of qualifications
NHS Direct 25 £24, 2010/11 prices.54 Inflated using Hospital and Community Health Care Pay
and Prices Index53
Walk-in centre 41 Derived from NHS reference costs.52 Activity-weighted average across service
type 4, admitted and non-admitted. Category 1 investigation with category
3–4 treatment
Minor injuries unit 88 Derived from NHS reference costs.52 Activity-weighted average across service
type 3, admitted and non-admitted. Category 1 investigation with category
3–4 treatment
Emergency department 118 Derived from NHS reference costs.52 Activity-weighted average across service
types 1 and 2, admitted and non-admitted. Category 1 investigation with
category 3–4 treatment
ECLS, extracorporeal life support; ECMO, extracorporeal membrane oxygenation.
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Carroll et al.55 estimated the utility decrement from full health during hospitalisation as 0.05 (with a standard
error of 0.01) using the time trade-off technique. This then needs to be combined with the general population
value for infants of the same age. The best method for combining comorbidities is considered to be through
multiplication of the relevant values.56 Following a search of the literature, the most relevant general
population value using a paediatric utility instrument for the children recruited to the SABRE study was found
to be a Health Utilities Index-II survey of 8-year-old Canadian children. The general population value in that
study was 0.95 (compared with 0.82 for children of extremely low birthweight).57 For the SABRE study,
therefore, the non-hospitalised utility is 0.95 (taken from Saigal et al.57), while the hospitalised utility is 0.9025
(calculated as the product of the Saigal et al.57 and Carroll and Downs55 utility estimates).
Analysis
Differences in costs and QALYs were assessed using non-parametric permutation t-tests that allow robust
comparisons of the means in the presence of non-normal data. A permutation test samples from the
observed data to calculate the correct distribution of the test statistic under the null hypothesis. Paired cost
and QALY data were then bootstrapped with 5000 replications and plotted on the cost-effectiveness
plane. The focus of the economic analysis was the resultant cost-effectiveness acceptability curve and the
probability that the intervention will be cost-effective at £20,000 per QALY.
The main cost driver was expected to be hospital costs. Deterministic sensitivity analyses were planned for
the cost per day on a ward, in intensive care and in high-dependency care. Alternative plausible unit costs
to our preferred ward estimate of £547 are £558 per day (with the latter also including complicated
admissions) and £425 (derived using excess bed-days costs for uncomplicated admissions). Alternative
plausible unit costs to our preferred intensive and high-dependency care estimates of £1946 and £1061
are £1743 and £886, respectively (derived using only the basic care categories within each type of unit).
Probabilistic sensitivity analysis is undertaken through the bootstrapping procedure described previously,
thereby incorporating the sampling uncertainty related to all clinical effects and resource use items.
Probabilistic sensitivity analysis using distributions around unit costs and utility values is not routinely
undertaken in economic evaluations alongside trials.
Where appropriate, missing data were to be imputed using multiple imputation. This assessment would
be based on the degree of missingness and the mechanism by which missing data were generated
(e.g. random or non-random).
Systematic review methods
Rationale
To produce an overview of the clinical effectiveness of HS for the treatment of inpatients with
acute bronchiolitis.
Objective
The objective was to systematically review the evidence relating to the use of nebulised HS in young
children, hospitalised for the treatment of acute bronchiolitis. The primary outcome of consideration was
whether or not the use of this intervention resulted in a reduced hospital LoS.
Protocol and registration
The PROSPERO registration (registered 3 March 2014 and revised 18 December 2014) outlining the study
review protocol can be found in Appendix 5.
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Eligibility criteria
Types of participants
Studies involving children up to the age of 2 years who had been hospitalised as the result of an episode
of acute bronchiolitis were considered for the review. Confirmation of the presence of RSV was not
required for study inclusion as not all cases of bronchiolitis are a result of RSV, and therefore all cases of
bronchiolitis regardless of organism have been included.
Types of interventions
Studies evaluating nebulised HS with or without an adjunct bronchodilator treatment given compared with
NS or no intervention (control) were considered for the review. These pre-specified groups of studies were
as follows:
1. nebulised HS alone versus NS
2. nebulised HS plus a bronchodilator (e.g. salbutamol) versus NS
3. nebulised HS plus a bronchodilator (e.g. salbutamol) versus NS plus same bronchodilator
4. nebulised HS alone or plus a bronchodilator (e.g. salbutamol) versus no intervention.
Groups were based on those that were pre-specified in the Cochrane systematic review carried out by
Zhang and colleagues.58
No restrictions were applied in terms of the concentration, dose or the way the intervention (HS) or control
(NS with or without adjunct treatment) was administered in the trials. Studies in which HS was not the
principal intervention under review were excluded.
Types of studies
Published and unpublished RCTs and quasi-randomised trials which had completed participant accrual
were considered for inclusion. Quasi-randomised trials are those in which the allocation of intervention
may not be completely random. Observational studies were excluded.
Only studies available in English were considered, as defined in the protocol. Nine potentially relevant
studies in other languages with no English abstract or an unclear English abstract were excluded at the
abstract review stage.59–67 In addition, two studies in other languages were excluded at the full paper
review stage.68,69 The main database searches were performed from the start date of the database to
January 2015.
Outcome measures
There were no eligibility restrictions based on outcomes reported. The systematic review’s primary outcome
of interest is length of hospital stay calculated via the mean (SD) number of days (LoS) for each arm of
each trial, a relevant and meaningful outcome.70 Secondary outcomes of interest were (1) rate of
readmission to hospital; (2) any AEs however described, but particularly tachycardia, hypertension, pallor,
tremor, nausea, vomiting and acute urinary retention; and (3) final clinical severity scale (CSS) scores.
Information sources
The electronic databases searched included MEDLINE (via Ovid) (1946 to January 2015), EMBASE (1974 to
January 2015), the Cochrane Central Register of Controlled Trials, Google Scholar (Google Inc., Mountain
View, CA, USA) (2010 to January 2015) and Web of Science (2010 to January 2015). The full search
strategy used in each database is listed in Appendix 6. No restrictions or limits (e.g. age, language and
publication date) were applied to any of the databases other than Google Scholar and Web of Science,
which were searched for articles from 2010 onwards, when the Cochrane Systematic review by Zhang and
colleagues71 was last updated.
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The following trial registries were searched, using the terms ‘bronchiolitis’ and ‘hypertonic saline’, to
identify any unpublished data: ClinicalTrials.gov; UK Clinical Trials Gateway; Centre for Reviews and
Dissemination databases (Database of Abstracts of Reviews of Effects, NHS Economic Evaluation Database,
HTA Database); controlled-trials.com; centrewatch.com. The National Research Register was searched
using the terms ‘bronchiolitis and ‘hypertonic saline’ on 5 March 2014, as the website could not be
accessed when the searches were updated. We also hand-searched the journals Chest, Paediatrics and
Journal of Paediatrics in January 2015 using the terms HS and bronchiolitis. The reference lists of all
eligible trial publications were checked to identify any further published trials.
Search
A range of search strategies were employed, including pearl growing and checking reference lists.72,73 Pearl
growing involved identifying medical subject headings from articles identified from the previous systematic
review,25 which were then combined with initial search terms and the searches rerun again. The final
search strategy is outlined in Appendix 6. All searches were performed between January 2013 and
January 2015. Any duplicated articles were removed from the final list prior to applying the eligibility
criteria to the trials to select the studies of interest.
Study selection
After removal of duplicates, two researchers (CM and HC) independently screened titles and abstracts for
eligibility; differences were resolved by discussion with DH and ME. If the abstract suggested eligibility,
if no abstract was available for a particular citation or if the title was vague and unclear, the full paper was
retrieved. Full papers were screened for eligibility in the same way.
Unsuccessful attempts were made to contact trial investigators of two unpublished studies74,75 to request
additional unreported data. Although studies would not have been excluded based on the primary
outcome, all but three of the studies were appropriate to be included in the meta-analysis of the
primary outcome of interest, LoS.
Data collection process
The Cochrane risk of bias assessment tool76 was modified after piloting on one study of known eligibility.
Details of the modified data extraction tool can be found in Appendix 6 and Table 3. CM and HC then
used the modified tool independently to extract data. Attempts were made to contact study teams for
missing data, particularly for five studies74,75,84,88,89 for which data were available only on ClinicalTrials.gov
or in abstract form. Owing to the constraints in time, it was not possible to contact all the study authors
for each of the items of missing data, for example risk of bias assessment.
Data items
1. Study overview (country, year).
2. Participant characteristics (age, number randomised, baseline imbalances assessed by the authors in
trials, withdrawals, % allocated completing follow-up, illness severity, eligibility).
3. Intervention and control group details (number randomised in each group, intervention details:
duration, delivery, other drugs and compliance).
4. Outcomes data:
i. Continuous outcomes: LoS (mean LoS, SD and number of patients in each group, measured by
who); CSS score (mean final CSS score, SD, number of patients for both groups).
ii. AE data as available.
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Risk of bias in individual studies
The Cochrane risk of bias assessment tool allows reported trial results to be differentiated from the
methods used, with lower risk studies associated with more conservative effect estimates of risk.91 CM and
HC independently graded the quality of trials as ‘low’ where there is low risk, ‘high’ where there is high
risk of bias or ‘unclear’ where the risk is unclear. Discrepancies were resolved by discussion. Risk of bias
assessment was conducted at both study and outcome level. The Cochrane Handbook for Systematic
Reviews of Interventions,76 chapter 8.5.2, was used as a guide to make judgements on the methodological
quality of the trials for the following domains of bias: sequence generation; allocation concealment;
blinding, completeness of outcome data; and selective reporting. A supporting statement for each bias
domain was extracted where a grade is given. Where an unclear grade is given, effort was made to obtain
further information to categorise the trial by contacting the trial authors or searching for the study protocol
to identify sources of reporting bias. Risk of bias data were entered into the Cochrane Review Manager
(RevMan version 5.2, Cochrane, The Nordic Cochrane Centre, Copenhagen, Denmark) tool for analysis.
Both a risk of bias graph and risk of bias summary were derived from the data and are reported in the
results section.
Summary measures
All outcomes were continuous; the summary measure was the median difference and its associated
95% CI.
Synthesis of results
Analyses were undertaken using both RevMan version 5.2 and Stata version 12.1 (StataCorp LP,
College Station, TX, USA). A FE model was used to combine (unstandardised) median differences between
HS and the control. The FE model assumes that the LoS outcome would estimate the same effect size in
each of the studies and weights studies according to their precision (standard error), which in turn relates
to the sample size: the greater the sample size, the greater the weight assigned to the trial.92 In addition,
a second analysis was undertaken using the random-effects (RE) approach of DerSimonian and Laird,79
which incorporates the variability among trial estimates into the weighting of the trials.
Three-armed trials, which compared more than one concentration of HS with a control, were included in
the review. The Cochrane Handbook for Systematic Reviews of Interventions recommends combining
the active arms, but notes that heterogeneity can be better assessed by keeping dose arms separate.76
As high levels of heterogeneity were identified in our review (see Chapter 5, Primary outcome: results and
synthesis), this was the approach we adopted. To avoid double-counting of control patients, in three-arm
trials control group numbers were divided by 2.
Mean final (post-treatment) CSS scores for participants in each arm of the trial were also extracted.
A scoring system devised by Wang et al.78 was used to assign CSS scores at baseline. Some of the
studies reported a final CSS score for both the intervention and the control groups.
Data on AEs were synthesised narratively.
We used the I2-statistic to measure statistical heterogeneity with the following guidance on interpretation
from the Cochrane Handbook:76
1. I2-statistic of 0–40%= heterogeneity may not be important
2. I2-statistic of 30–60%=may mean moderate heterogeneity
3. I2-statistic of 50–90%=may mean substantial heterogeneity
4. I2-statistic of 75–100%= considerable heterogeneity
5. Overlapping CIs are an indication of lower heterogeneity within the trials.
Forest plots also display the chi-squared test to test for statistical heterogeneity, with corresponding
p-values at or below the threshold of 0.1 conventionally indicating a statistically significant heterogeneity.70
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Risk of bias across studies
A funnel plot was generated to explore the possibility of publication bias in the primary outcome, LoS, for
all trials. The main group was then split into subgroups to investigate reasons for heterogeneity.
Heterogeneity was explored by separating the group by comparator based on the following:
Intervention comparator:
1. nebulised HS alone versus NS alone (n= 4 trials)
2. nebulised HS plus a bronchodilator (e.g. salbutamol) versus NS alone (n= 0 trials)
3. nebulised HS plus a bronchodilator (e.g. salbutamol) versus NS plus same bronchodilator (n= 12 trials)
4. nebulised HS alone or plus a bronchodilator versus no treatment (n= 1 trial).
Further analyses were performed to separate the type of bronchodilator administered, for example beta-2
agonist compared with adrenaline. The subgroups for these are listed below:
5. nebulised HS alone versus NS alone (n= 4 trials)
6. nebulised HS plus a bronchodilator (e.g. salbutamol) versus NS alone (n= 0 trials)
7. NEBULISED HS plus a beta agonist versus NS plus same beta agonist (n= 7 trials)
8. nebulised HS plus adrenaline versus NS plus same adrenaline (n= 5 trials)
9. nebulised HS alone or plus a bronchodilator versus no treatment (n= 1 trial).
Outcome reporting bias arises from selectively picking outcome measures to report for the study based on
the results achieved.93 Smaller, lower-quality trials may in themselves introduce bias whereas larger, more
expensive studies which may be more methodologically sound are more likely to be published even with
negative results.94 Using methods suggested by Dwan and colleagues,95 we also assessed the risk of
outcome reporting bias.
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Chapter 3 Trial results
Recruitment and participant flow
Participants who were randomly assigned, received intended treatment and
were analysed for the primary outcome
Between 26 October 2011 and 23 December 2013, the trial recruited and randomised 317 participants,
with 158 patients allocated to the nebulised 3% HS group and 159 allocated to usual care (Figures 1 and 2).
There were five patients from the nebulised 3% HS group who did not receive the intended treatment.
Of the 317 patients randomised, 26 of these patients were excluded because they were randomised when
ineligible and for one patient primary outcome data were unavailable because their medical notes were lost;
therefore, 290 patients were included in the primary outcome analysis.
Losses and exclusions after randomisation
The number of post-randomisation exclusions together with the reason for exclusion is displayed in
Table 4. Overall, 26 patients were excluded from the study: 16 from the intervention group and 10 from
the control group.
Of the 317 randomised patients, 26 were excluded, as described previously. Of the remaining 291 patients,
five were not included in the PP analysis for the following reasons: four withdrew before receiving any
HS/intervention and one patient’s medical notes were lost (therefore no treatment data were available).
Of the remaining patients in the PP analysis, 32 withdrew from treatment having received at least one dose
of HS and three withdrew from the study, two from the standard care group and one from the standard
care plus intervention group.
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FIGURE 1 Participant recruitment curve.
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Infants less than 1 year of age
admitted with acute bronchiolitis
and requiring oxygen therapy.
 Screened for eligibility
(n = 772)
Obtained fully informed consent
within 4 hours of admission.
 Randomised at baseline to receive
nebulised 3% hypertonic saline
in addition to supportive care or
standard supportive care
(n = 317)
Post-randomisation
 exclusions
(n = 10)
No primary outcome
recorded
(n = 0)
Did not return
 diary and ITQoL
(n = 100)
Enrolment
Allocation
ITT analysis
Primary outcome
ITT analysis
Secondary outcomes
Did not return
 diary and ITQoL
(n = 87)
Post-randomisation
exclusions
(n = 16)
No primary outcome
recorded
(n = 1)
Allocated to standard
 supportive care
(n = 159)
Received standard 
supportive care
(n = 159)
Fit for discharge
(in air for 6 hours and
 feeding satisfactorily)
(n = 149)
Fit for discharge
(in air for 6 hours and
 feeding satisfactorily)
(n = 141)
28 days
Return diary  and ITQoL
(n = 49)
28 days
Return diary and ITQoL
(n = 54)
Allocated to nebulised
3% hypertonic saline
6 hourly in addition to
supportive care (n = 158)
Received intervention (n = 153)
Reason:
• Parental decision (n = 3)
• Adverse event (n = 1)
• No treatment form
• available (n = 1)
Excluded (n = 455)
• Not identified, n = 175
• Failed inclusion, n = 211
• Declined, n = 60
• Others, n = 9
FIGURE 2 The CONSORT flow diagram. ITT, intention to treat.
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Dates defining the periods of recruitment and follow-up
The trial consisted of three recruitment seasons. The study recruited patients during winter 2011/12, winter
2012/13 and from October 2013 to December 2013. Patients were followed up for a period of 28 days
after randomisation to collect data on readmissions, duration of respiratory symptoms post discharge,
health-care utilisation post discharge and infant and parental quality of life.
Why the trial ended or was stopped
The trial closed to recruitment after reaching the accrual target on 23 December 2013.
Baseline data
Table 5 shows the characteristics of the recruited and non-recruited patients, the former being further
subdivided according to whether or not the patient was subsequently excluded. There were no notable
differences between these groups in terms of age or sex.
Baseline characteristics are shown in Table 6. There were no notable differences between the study groups
but the control group was slightly older, heavier and contained more males.
Seven out of 10 centres collected RSV test data routinely, if not always completely. The viral status by
season is shown in Table 7.
TABLE 4 Post-randomisation exclusions
Post-randomisation exclusion reasons
Standard care plus
(intervention group)
Standard care
(control group)
Randomised outside the 4-hour recruitment window 2 4
Received HS prior to randomisation 3 0
Verbal consent was obtained prior to randomisation with written consent
being obtained after randomisation
3 0
No decision to admit prior to randomisation 1 0
No recommendation for oxygen at the point of admission 1 0
Previously investigated and diagnosed in hospital with reflux 1 0
Previous lower respiratory tract infection requiring assessment in hospital 4 6
Patient’s study documentation was lost 1 0
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TABLE 5 Characteristics of recruited and non-recruited
Variable
Non-recruited Recruited
Total
(n= 455)
Total
(n= 317)
Included
(n= 291)
Excluded
(n= 26)
Site, n (%)
Alder Hey Children’s NHS Foundation Trust 66 (14.5) 63 (18.8) 58 (19.9) 5 (19.2)
Bradford Teaching Hospitals NHS Foundation Trust 67 (14.7) 38 (12.0) 34 (11.7) 4 (15.4)
University Hospital of North Staffordshire NHS Trust 21 (4.6) 63 (19.9) 59 (20.3) 4 (15.3)
Doncaster and Bassetlaw Hospitals NHS Foundation
Trust
19 (4.1) 12 (3.8) 12 (4.0) –
Calderdale and Huddersfield NHS Foundation Trust 24 (5.2) 18 (5.7) 15 (5.2) 3 (11.5)
Leeds Teaching Hospitals NHS Trust 136 (29.2) 38 (12.0) 35 (12.0) 3 (11.5)
Rotherham NHS Foundation Trust 4 (0.8) 1 (0.3) 1 (0.3) –
Sheffield Children’s NHS Foundation Trust 41 (9.0) 54 (17.0) 48 (16.5) 6 (23.1)
University Hospital of Wales 8 (1.7) 21 (6.6) 20 (6.9) 1 (3.9)
Oxford University Hospitals NHS Trust 69 (15.2) 9 (2.8) 9 (3.1) –
Age (months)
Mean (SD) 3.5 (2.8) 3.5 (2.7) 3.4 (2.7) 4.7 (3.3)
Median (IQR); range 2.5 (1.2–5.0);
0.2–12.0
2.5 (1.2–5.0);
0.2–11.5
2.5 (1.2–4.8);
0.2–11.5
4.1 (2.4–7.0);
0.2–11.5
Sex, n (%)
Male 264a (58.4) 172 (54.6) 158 (54.3) 14 (58.3)
Female 188a (41.6) 143 (45.4) 133 (45.7) 10 (41.7)
IQR, interquartile range.
a Data were missing for two in the excluded group.
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TABLE 6 Demographics (FAS)
Variable
Standard care plus
intervention (n= 142)
Standard care (control)
(n= 149)
Site, n (%)
Alder Hey Children’s NHS Foundation Trust 30 (21.1) 28 (18.8)
Bradford Teaching Hospitals NHS Foundation Trust
University
16 (11.3) 18 (12.1)
Hospital of North Staffordshire NHS Trust 29 (20.4) 30 (20.1)
Doncaster and Bassetlaw Hospitals NHS Foundation Trust 6 (4.2) 6 (4.0)
Calderdale and Huddersfield NHS Foundation Trust 6 (4.2) 9 (6.0)
Leeds Teaching Hospitals NHS Trust 18 (12.7) 17 (11.4)
Rotherham NHS Foundation Trust – 1 (0.7)
Sheffield Children’s NHS Foundation Trust 23 (16.2) 25 (16.8)
University Hospital Wales 10 (7.0) 10 (6.7)
Oxford University Hospitals NHS Trust 4 (2.8) 5 (3.4)
Age (months)
Mean (SD) 3.3 (2.6) 3.4 (2.8)
Median (IQR); range 2.3 (1.3–5.0); 0.3–11.5 2.5 (1.5–4.8); 0.3–11.5
Birthweight (kg)
Mean (SD) 3.31 (0.77) 3.36 (0.78)
Median (IQR); range 3.25 (2.90–3.70); 1.87–9.40 3.37 (3.0–3.70); 1.81–8.20
Missing, n 2 3
Weight at presentation (kg)
Mean (SD) 5.61 (1.84) 5.98 (2.00)
Median (IQR); range 5.10 (4.10–6.80); 2.20–11.20 5.70 (4.56–7.15); 2.60–11.9
Gestation (weeks)
Mean (SD) 39.3 (1.7) 39.2 (1.8)
Median (IQR); range 39.9 (38.0–40.3); (33.0–42.0) 40.0 (38.0–40.6); (32.7–42.4)
Sex, n (%)
Male 73 (51.4) 85 (57.0)
Female 69 (48.6) 64 (43.0)
Ethnicity, n (%)
Caucasian 117 (82.4) 123 (83.1)
Asian or Asian British 17 (12.0) 13 (8.8)
Mixed 4 (2.8) 4 (2.7)
Black or Black British – 3 (2.0)
Other 4 (2.8) 5 (3.4)
Missing, n – 1
Smoker in household
No, n (%) 81 (58.3) 86 (57.7)
Yes, n (%) 58 (41.7) 63 (42.3)
Missing, n 3 –
continued
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TABLE 6 Demographics (FAS) (continued )
Variable
Standard care plus
intervention (n= 142)
Standard care (control)
(n= 149)
Infant in childcare
No, n (%) 132 (94.3) 133 (93.0)
Yes, n (%) 8 (5.7) 10 (7.0)
Missing, n 2 6
Feeding on admission
Breast, n (%) 27 (19.0) 24 (16.2)
Bottle, n (%) 103 (72.5) 120 (81.1)
Breast and bottle, n (%) 12 (8.5) 4 (2.7)
Missing, n – 1
Number of siblings
0, n (%) 33 (23.2) 27 (18.1)
1, n (%) 52 (36.6) 62 (36.6)
2, n (%) 33 (23.2) 29 (19.5)
3, n (%) 14 (9.9) 15 (10.1)
4, n (%) 7 (4.9) 10 (6.7)
5 or more, n (%) 3 (2.1) 6 (4.0)
Mean (SD) 1.45 (1.3) 1.6 (1.4)
Median (IQR); range 1 (1–2); 0–7 1 (1–2); 0–7
First-degree relative with asthma
No, n (%) 79 (57.7) 77 (54.6)
Yes, n (%) 58 (42.3) 64 (45.4)
Missing, n 5 8
First-degree relative with eczema
No, n (%) 91 (66.9) 81 (57.4)
Yes, n (%) 45 (33.1) 60 (42.6)
Missing, n 6 8
First-degree relative with hay fever
No, n (%) 89 (65.4) 82 (58.6)
Yes, n (%) 47 (34.6) 58 (41.4)
Missing, n 6 9
Referral route, n (%)
GP (referral) 60 (42.3) 70 (47.0)
ED (walked in) 41 (28.9) 47 (31.5)
ED (ambulance) 30 (21.1) 25 (16.8)
Other 11 (7.7) 7 (4.7)
Previous conditions, n (%)
Bronchiolitis (non-hospital diagnosed) 6 (4.2) 6 (4.0)
Reflux (non-hospital diagnosed) 4 (2.8) 7 (4.7)
Respiratory problems 2 (1.4) 3 (2.0)
Heart murmur 4 (2.8) 2 (1.3)
Jaundice 2 (1.4) 5 (3.4)
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TABLE 6 Demographics (FAS) (continued )
Variable
Standard care plus
intervention (n= 142)
Standard care (control)
(n= 149)
Antibiotics, n (%)
Prior to admission 14 (9.9) 9 (6.0)
In hospital 29 (20.4) 24 (16.1)
Antireflux medications, n (%)
Prior to admission 3 (2.1) 7 (4.7)
In hospital 3 (2.1) 8 (5.4)
Ipratropium, n (%)
Prior to admission 4 (2.8) 4 (2.7)
In hospital 6 (4.2) 3 (2.0)
Oral steroids, n (%)
Prior to admission 2 (1.4) 0 (0)
In hospital 3 (2.1) 1 (0.7)
Beta-2 agonist, n (%)
Prior to admission 4 (2.8) 10 (6.7)
In hospital 10 (7.0) 4 (2.7)
Intravenous fluids in hospital 9 (6.3) 7 (4.7)
Induction therapy in hospital 3 (2.1) 2 (1.3)
Sedatives in hospital 7 (4.9) 4 (2.7)
Other medications in hospital 10 (7.0) 10 (6.7)
ED, emergency department; IQR, interquartile range.
TABLE 7 Viral status by season
Viral status Season 1 (2011–12; N= 134) Season 2 (2012–13; N= 111) Season 3 (2013–14; N= 46)
RSV+, n (%) 84 (63) 64 (58) 31 (67)
Non-RSV+,
n (%)
13 (10) 12 (11) 2 (4)
No virus
identified, n (%)
3 (2) 3 (2) 0 (0)
Not tested,
n (%)
34 (25) 32 (28) 13 (28)
RSV+, RSV positive.
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Numbers analysed
In the intention-to-treat (ITT) population, in which patients were analysed by their original assigned groups,
there were 142 participants in the HS arm and 149 in the control arm. In one patient in the intervention
group, date and time of fitness for discharge were not recorded and are not included in any of these
analyses, but the patient was known to have been discharged on day 6 (i.e. between 120 and 144 hours);
this LoS is similar enough to the LoS of the other trial participants that the missing data is unlikely to have
had any material impact. In the PP analysis, five participants did not receive treatment as scheduled and so
were removed, leaving 136 participants in the HS arm with complete data; 149 remained in the control arm.
Outcomes and estimation
There was no evidence of any difference between the two treatment arms in the primary outcome, the time
to being declared fit for discharge [hazard ratio (HR) 0.95, 95% CI 0.75 to 1.20; p= 0.66], or in the time to
actual discharge (HR 0.97, 95% CI 0.76 to 1.23) (Table 8 and Figures 3 and 4). In absolute terms, the median
difference between HS and control (adjusted for site) was 2.5 hours (95% CI –13.8 to 18.7 hours) for time to
TABLE 8 Time to being declared fit for discharge and time to discharge (hours)
Variable Intervention (n= 142) Control (n= 149) HR (95% CI) p-value
Time to fit for discharge
Mean (SD) 90.4 (73.2) 88.9 (67.9) – –
Median (IQR); range 75.6 (46.1–113.3);
7.1–576.1
75.9 (45.5–121.0);
6.8–565.9
– –
Median (95% CI) 75.6 (67.8 to 83.3) 75.9 (65.7 to 86.1) – –
Univariate analysis (log-rank test) – – 0.99 (0.79 to 1.24) 0.97
HR (Cox regression, adjusted
for centre)
– – 0.95 (0.75 to 1.20) 0.66
Missing, n 1 0 – –
Median (95% CI) time to fit for discharge by viral status
RSV+ 79.1 (66.3 to 98.2) 80.3 (68.9 to 96.4) 0.94 (0.70 to 1.26) 0.68
RSV– 50.8 (27.1 to 75.8) 48.8 (21.4 to 115.1) 1.09 (0.50 to 2.39) 0.83
Time to discharge
Mean (SD) 100.6 (76.9) 101.3 (84.4) – –
Median (IQR); range 88.5 (51.6–120.9);
16.6–595.4
88.7 (50.9–123.6);
4.2–857.4
– –
Median (95% CI) 88.5 (74.6 to 102.5) 88.7 (76.9 to 100.5) – –
Univariate analysis (log-rank test) – – 1.02 (0.81 to 1.28) 0.86
HR (Cox regression, adjusted
for centre)
– – 0.97 (0.76 to 1.23) 0.80
Missing, n 1 0 – –
Median (95% CI) time to fit for discharge by viral status
RSV+ 91.7 (72.7 to 100.2) 90.8 (76.0 to 108.7) 0.88 (0.64 to 1.21) 0.43
RSV– 72.2 (42.3 to 101.0) 70.2 (40.2 to 124.1) 0.86 (0.34 to 2.17) 0.75
IQR, interquartile range; RSV–, RSV negative; RSV+, RSV positive.
One patient in the intervention group had no time to fit for discharge recorded; they were discharged on day 6
(i.e. between 120 and 144 hours).
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FIGURE 4 Cumulative survival plot for actual time to discharge.
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discharge and 0.5 hours (95% CI –18.0 to 19.1 hours) for actual discharge. For both groups, the time to
being declared fit for discharge was nearly 76 hours from admission and the time to actual discharge was
nearly 89 hours.
Figures 5 and 6 show the time to discharge by treatment and RSV status [RSV positive (RSV+) vs. RSV negative
(RSV–)]. RSV+ was associated with prolonged time to fitness to discharge and (less strongly) with time to actual
discharge, but there was no indication that HS had a differential effect in relation to RSV status.
Admission to HDU/ICU and readmission rates are displayed in Table 9. There was a lack of evidence to suggest
that there was a difference between treatment groups in terms of the numbers admitted to HDU/ICU or
readmitted within 28 days of randomisation. In addition, as there was little evidence that the effect differed
between treatment group by RSV status for readmission rates, there was some evidence of an interaction for
admission to ICU/HDU, although the numbers were small and the study was not powered to detect this
(RSV+ 3.7%, 95% CI –5.2% to 12.6% vs. non-RSV –26.7%, 95% CI –56.2% to 2.8%; p= 0.07).
The ITQoL results are displayed in Table 10. There were no important differences between treatment group
scores on any of the ITQoL dimensions and a lack of evidence that outcomes differed between groups
according to RSV status (Figure 7).
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FIGURE 5 Cumulative survival plot for time to being declared fit for discharge by study arm and viral status.
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TABLE 9 Admission to HDU/ICU, readmission rates and symptoms to 28 days
Variable
Intervention Control
Difference (%),
(95% CI)
Odds ratio
(95% CI) p-valuen/N
% admitted
(95% CI) n/N
% admitted
(95% CI)
Admitted to ICU/HDU
FAS 12/142 8.5 (4.4 to 14.3) 15/149 10.1 (5.7 to 16.1) –1.6 (–8.3 to 5.0) 0.96 (0.43 to 2.13) 0.91
PP 12/137 8.8 (4.6 to 14.8) 15/149 10.1 (5.7 to 16.1) –1.3 (–8.1 to 5.5) 0.85 (0.39 to 1.90) 0.71
RSV vs. non-RSV
RSV 10/83 12.1 (5.9 to 21.0) 8/96 8.3 (3.7 to 15.8) 3.7 (–5.2 to 12.6) 1.51 (0.57 to 4.02) 0.41
Non-RSV 1/15 6.7 (0.2 to 32.0) 4/12 33.3 (9.9 to 65.1) –26.7 (–56.2 to 2.8) 0.14 (0.01 to 1.51) 0.11
Readmitted with 28 days
FAS 4/128 3.1 (0.9 to 7.8) 7/140 5.0 (2.0 to 10.0) –1.9 (–6.6 to 2.8) 0.61 (0.18 to 2.14) 0.44
PP 4/124 3.2 (0.9 to 8.1) 7/140 5.0 (2.0 to 10.0) –1.8 (–6.5 to 3.0) 0.63 (0.18 to 2.22) 0.48
RSV vs. non-RSV
RSV 2/72 3.8 (0.3 to 9.7) 6/91 6.6 (2.5 to 13.8) –3.8 (–10.2 to 2.5) 0.40 (0.08 to 2.07) 0.28
Non-RSV 2/15 13.3 (1.7 to 40.5) 0/10 0.0 (0.0 to 30.9) 13.3 (–3.9 to 30.5) – –
Symptoms to 28 days
FAS 9/53 17.0 (6.9 to 27.1) 15/55 27.3 (15.5 to 39.0) –10.3 (–25.8 to 5.2) 0.55 (0.22 to 1.38) 0.20
PP 9/52 17.3 (7.0 to 27.6) 15/55 27.3 (15.5 to 39.0) –10.0 (–25.6 to 5.7) 0.56 (0.22 to 1.42) 0.22
RSV vs. non-RSV
RSV 4/29 13.8 (1.2 to 26.3) 9/34 26.4 (11.6 to 41.3) –12.7 (–32.1 to 6.8) 0.44 (0.12 to 1.63) 0.22
Non-RSV 1/3 33.3 (0.0 to 86.7) 2/5 40.0 (0.0 to 82.9) –6.7 (–75.2 to 61.8) 0.75 (0.04 to 14.97) 0.85
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FIGURE 6 Cumulative survival plot for time to being declared fit for discharge.
DOI: 10.3310/hta19660 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 66
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Everard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
41
TABLE 10 The ITQoL results
Variable
Intervention Control
Difference (95% CI) p-valuen (crude) Mean (95% CI) n (crude) Mean (95% CI)
Overall health
FAS 50 82.0 (77.5 to 86.5) 52 77.7 (71.8 to 83.6) 4.3 (–3.0 to 11.7) 0.25
PP 49 81.9 (77.4 to 86.5) 52 77.7 (71.8 to 83.6) 4.3 (–3.1 to 11.6) 0.26
RSV vs. non-RSV
RSV 28 83.9 (78.4 to 89.5) 32 77.3 (69.7 to 85.0) – 0.34
Non-RSV 3 81.7 (31.5 to 131.9) 6 88.3 (71.9 to 104.8) – –
Physical abilities
FAS 24 90.0 (84.1 to 95.8) 29 87.3 (79.1 to 95.5) 2.7 (–7.6 to 12.9) 0.60
PP 23 89.8 (83.7 to 96.0) 29 87.3 (79.1 to 95.5) – 0.63
RSV vs. non-RSV
RSV 12 96.4 (91.8 to 101.0) 18 86.5 (74.4 to 98.6) 2.5 (–7.9 to 13.0) 0.48
Non-RSV 3 85.1 (30.8 to 139.4) 5 86.7 (62.5 to 110.8) – –
Growth and development
FAS 56 90.7 (87.7 to 93.7) 53 94.0 (91.0 to 97.1) –3.4 (–7.6 to 0.9) 0.12
PP 55 90.5 (87.5 to 93.5) 53 94.0 (91.0 to 97.1) – 0.10
RSV vs. non-RSV
RSV 32 90.7 (86.4 to 94.9) 34 92.4 (87.2 to 96.9) –3.5 (–7.8 to 0.7) 0.73
Non-RSV 4 95.0 (85.8 to 104.2) 6 99.6 (98.5 to 100.7) – –
Bodily pain
FAS 55 66.7 (60.2 to 73.1) 53 68.6 (61.8 to 75.3) –1.9 (–11.1 to 7.3) 0.69
PP 54 66.7 (60.1 to 73.2) 53 68.6 (61.8 to 75.3) – 0.69
RSV vs. non-RSV
RSV 32 65.1 (57.8 to 72.4) 34 65.2 (56.5 to 73.9) –1.9 (–11.2 to 7.4) 1.00
Non-RSV 4 70.8 (19.5 to 122.1) 6 70.8 (36.4 to 105.3) – –
Temperament
FAS 56 70.6 (66.2 to 75.0) 53 70.7 (66.2 to 75.1) –0.06 (–6.3 to 6.2) 0.98
PP 55 70.6 (66.1 to 75.1) 53 70.7 (66.2 to 75.1) – 0.99
RSV vs. non-RSV
RSV 32 69.6 (64.5 to 74.7) 34 71.0 (65.8 to 76.3) –0.04 (–6.3 to 6.2) 0.79
Non-RSV 4 63.1 (5.5 to 120.6) 6 61.2 (31.5 to 91.0) – –
General health perceptions
FAS 55 65.4 (61.1 to 15.8) 51 63.2 (59.5 to 66.8) 2.2 (–3.4 to 7.8) 0.44
PP 54 65.2 (60.9 to 69.5) 51 63.2 (59.5 to 66.8) – 0.48
RSV vs. non-RSV
RSV 31 63.1 (57.2 to 69.0) 32 63.3 (59.3 to 67.3) 2.0 (–3.6 to 7.7) 0.51
Non-RSV 4 71.6 (38.1 to 105.1) 5 65.0 (47.2 to 82.9) – –
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TABLE 10 The ITQoL results (continued )
Variable
Intervention Control
Difference (95% CI) p-valuen (crude) Mean (95% CI) n (crude) Mean (95% CI)
Parental impact: emotional
FAS 55 73.9 (67.3 to 80.5) 50 76.5 (70.5 to 82.5) –2.6 (–11.5 to 6.3) 0.56
PP 54 73.6 (66.9 to 80.3) 50 76.5 (70.5 to 82.5) – 0.52
RSV vs. non-RSV
RSV 32 74.0 (67.1 to 80.9) 32 77.1 (69.8 to 84.5) –2.9 (–11.8 to 6.1) 0.26
Non-RSV 4 67.0 (–6.9 to 140.8) 4 50.9 (–6.8 to 108.5) – –
Parental impact: time
FAS 56 78.3 (72.2 to 84.3) 50 73.2 (65.8 to 80.5) 5.1 (–4.3 to 14.4) 0.28
PP 55 79.1 (73.2 to 85.0) 50 73.2 (65.8 to 80.5) – 0.21
RSV vs. non-RSV
RSV 32 76.0 (68.0 to 84.0) 32 71.0 (61.4 to 80.7) 5.9 (–3.3 to 15.2) 0.59
Non-RSV 4 66.7 (5.7 to 127.6) 4 51.2 (2.7 to 99.7) – –
Family cohesion
FAS 56 90.5 (87.3 to 93.8) 50 83.9 (77.7 to 90.1) 6.6 (–0.1 to 13.3) 0.05
PP 55 90.6 (87.4 to 93.9) 50 83.9 (77.7 to 90.1) – 0.05
RSV vs. non-RSV
RSV 32 90.2 (85.8 to 94.6) 32 90.2 (85.8 to 94.6) 6.7 (–0.01 to 13.5) 0.33
Non-RSV 4 88.8 (76.8 to 100.7) 4 78.8 (25.8 to 131.7) – –
Intervention
Control
Overall health
Physical abilities
Growth and
development
Bodily pain
Temperament
Health
perceptions
Parental impact
emotional
:
:Parental impact
time
Family cohesion
100
80
60
40
20
0
FIGURE 7 The ITQoL dimensions by study group: FAS.
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All important harms or unintended effects in each group
Adverse events are reported in Tables 11–13. Six events were probably or possibly related to saline
treatment, including one SAE. The SAE was bradycardia and desaturation during administration of the
nebuliser, which resolved the following day. The remaining five non-SAEs, each of which occurred in
different subjects, were bradycardia (self-correcting), desaturation, coughing fit, increased respiratory rate
(all of which were resolved within 1 day) and a chest infection (which resolved after 6 days).
TABLE 11 Adverse events
Variable
Intervention (N= 142) Control (N= 149)
Events n (%) Events n (%)
Overall 51 35 (24.6) 43 35 (23.5)
Secondary bronchiolitis 2 2 (1.4) 6 5 (3.4)
Cough 7 7 (4.9) 8 8 (5.4)
Chest infection 3 3 (2.1) 0 0
LRTI 7 7 (4.9) 3 3 (2)
Other 32 23 (16.2) 26 20 (13.4)
LRTI, lower respiratory tract infection.
TABLE 12 Adverse event details: saline group
Saline group
Category Diagnosis Frequency (related)
Secondary bronchiolitis Bronchiolitis 1
Ongoing symptoms of bronchiolitis – readmission 1
Chest infection Chest infection 1 (1)
Chest radiograph changes? Chest infection 1
Secondary chest infection 1
Cough Attended GP with cough 1
Coughing fit 2 (1)
Difficulty feeding and sleeping, still coughing 1
Increased work of breathing 1
Ongoing cough 1
Vomiting with cough 1
LRTI ? pneumonia 1
? LRTI (chest radiograph showed right-sided
collapse)
1
LRTI 1
Secondary bacterial LRTI 2
Secondary LRTI 1
Secondary LRTI with effusion 1
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TABLE 12 Adverse event details: saline group (continued )
Saline group
Category Diagnosis Frequency (related)
Other Accident/fall 1
Apnoea. Emergency visit to A&E.
Discharged home
1
Blood and protein in urine 1
Bradycardia (self-correcting) during nebuliser 1 (1)
Chest radiograph showing upper lobe shadowing 1
Chickenpox 1
Choking episode 1
Constipation 2
Desaturation/bradycardias during the
administration of 3% MucoClear and nebuliser
1 (1a)
Desaturation 1 (1)
Difficulty sleeping 1
Fever 1
Increase respiratory rate post nebuliser 1 (1)
Influenza 1
Large vomit no cough mentioned post feed 1
Lumbar puncture performed 1
Pyrexia 4
Pyrexia/discomfort 2
Rash to left cheek 1
Readmission as struggling to breathe 1
Readmission 1
Secondary bacterial infection 2
Secondary infection 1
Soft systolic murmur detected on USS 1
Spherocytosis 1
Thrush (eye) 1
A&E, accident and emergency; LRTI, lower respiratory tract infection; USS, ultrasound scan.
a Denotes serious AE with possible relationship to HS.
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TABLE 13 Adverse event details: standard treatment group
Standard treatment group
Category Diagnosis Frequency
Secondary bronchiolitis Bronchiolitis 1
Bronchiolitis (readmission) 1
Readmission to hospital with acute bronchiolitis 1
Right lower respiratory tract infection 1
RSV+ bronchiolitis 1
RSV+ bronchiolitis right upper lobe collapse 1
Cough Cold 2
Cough 2
Cough and breathing problems 1
Cough and wheeze 1
Uncomfortable following coughing bout 1
Wheezy 1
LRTI Pneumonia 1
Secondary bacterial LRTI 2
Other Admission with measles 1
Apnoeic episode 1
Bradycardias 1
Conjunctivitis 1
Constipation 4
Large vomit 1
Loose stools 1
Not sleeping well 1
Periorbital cellulitis 1
Pyrexia 3
Pyrexia/discomfort 2
Rash on toes, and around mouth, torso and chin 1
Rash to torso/arms/legs 1
Reduced feeding 1
Self-correcting bradycardias × 2 1
Snotty, coughing 1
Urinary tract infection 1
Viral illness 1
Viral illness/upper respiratory tract infection 1
Vitamin deficiency 1
LRTI, lower respiratory tract infection.
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Impact of post-randomisation exclusions
Of the 26 babies retrospectively excluded from analysis after randomisation, outcome data were available
for 24. The time to fit for discharge and to actual discharge are summarised in Table 14. These times were
similar to those of the 291 participants included in the trial, and the comparison of HS with control
virtually unchanged if these were included.
TABLE 14 Time (hours) to fit for discharge and actual discharge in the analysis population and those excluded
post-randomisation
Variable Intervention (n= 142) Control (n= 149)
Post-randomisation
exclusions (n= 26)
Time to fit for discharge
Mean (SD) 90.4 (73.2) 88.9 (67.9) 113.6 (128.6)
Median (IQR); range 75.6 (46.1–113.3); 7.1–576.1 75.9 (45.5–121.0); 6.8–565.9 74.9 (39.5–113.8); 7.0–573.9
Missing, n 1 0 2
Time to fit for discharge
Mean (SD) 100.6 (76.9) 101.3 (84.4) 132.1 (144.8)
Median (IQR); range 88.5 (51.6–120.9); 16.6–595.4 88.7 (50.9–123.6); 4.2–857.4 84.2 (49.2–139.4); 3.0–619.2
Missing, n 1 0 2
IQR, interquartile range.
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Chapter 4 Health economic results
Complete hospital data were available for all patients, except for the duration of ward stay for onepatient in the intervention group. Consequently, this patient was excluded from the analysis, but this is
not thought to have any material effect on the results. Only small, non-statistically significant differences
are seen in all measures of hospital stay (Table 15). A difference is seen in the number of doses of saline,
with the intervention group receiving on average 10.4 doses of nebulised saline over their hospital stay,
while no nebulised saline was used in the control group.
Concomitant medication data were analysed, but it was decided not to incorporate these into the
economic evaluation. The two main reasons for this were that the medications were all low-cost
treatments, for example salbutamol, and assumptions would be required to convert usage into costs, for
example whether the patient was prescribed the full pack of tablets or it was taken from the ward supply,
and what size of pack was used. It was decided, therefore, that given that the costs of the medications
used were negligible in comparison to overall hospital costs, and additional assumptions were needed in
their calculation, their inclusion would provide only spurious accuracy.
Resource use in primary care following discharge was self-completed by guardians. The overall response
rate was low, with complete follow-up in 53 (37%) and 54 (36%) participants in the control and
intervention groups, respectively. Of the remaining patients, the guardians of 57 (40%) and 72 (48%),
respectively, were contacted by telephone and provided basic health resource usage; we include this
information in Table 16 but have not included it in the economic analysis. One (control group) remained
an inpatient at 28 days and their resource usage is included only in Table 15. The remaining 55 guardians
were unable to be contacted after multiple attempts.
Use of primary care services was low and was similar in both patient groups (see Table 15). There were no
reported attendances at NHS walk-in centres or minor injury units. In cases for which the brief resource
information had been obtained by telephone, the resource use was lower than that obtained via
questionnaire response, but again was similar between the randomised groups.
TABLE 15 Resource use by group in hospital
Variable
Intervention (n= 142)a Control (n= 149)a
Difference p-valueMean SD Mean SD
Hours on ward 91.8 62.9 94.5 80.4 –2.7 0.752
Hours in ICU 4.8 30.5 1.67 11.8 +3.1 0.257
Hours in HDU 4.0 17.7 5.2 19.8 –1.2 0.589
Day readmitted 0.0 0.2 0.1 0.8 –0.1 0.129
Number of doses of saline 10.4 7.6 0.0 0.0 +10.4 < 0.001
a Except for ‘Hours on ward’, which has one missing value.
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When individual cost components are combined with their unit costs, the mean hospital costs were
£2595 in the control and £2727 in the intervention group (Table 17). The 95% CI around the difference
of £132 is –£520 to £785. QALYs were calculated using the total LoS in hospital, then transformed
into quality-adjusted life-days (QALDs) over the 36 days following randomisation in order to aid the
presentation in the table of very small numbers. The difference in mean QALDs was 0.006 greater in the
intervention group (or 0.0000175 QALYs) and was not statistically significant.
Mean primary care costs relating to the services described previously were £19 and £11 in the control and
intervention groups, respectively (see Table 16). The difference in means is £8, with a 95% CI of –£21 to
£6 (p= 0.25). Given the large number of missing data, it was decided not to impute missing values or
combine them with the hospital costs.
With numerically higher costs (£132) and QALYs (0.0000175), an incremental cost-effectiveness ratio
(ICER) can be produced, which is approximately £7.6M per QALY gained. The uncertainty around
this is represented by plotting the incremental costs and QALYs on the cost-effectiveness plane from
the non-parametric bootstrap of the trial data in Figure 8. This shows a cloud of observations centred,
approximately, around the origin (representing zero cost difference and zero QALY difference).
The estimates used to generate the cost-effectiveness plane are then transformed into a cost-effectiveness
acceptability curve (Figure 9). This shows that there is a 34% probability of nebulised saline being cost-effective
at a funding threshold of £20,000 per QALY. This probability is constant over the funding range that is typically
considered by the NHS (£20,000–30,000).96 One-way sensitivity analyses examining different unit costs for time
spent on a ward, ICU or HDU did not alter the probability that nebulised saline would be cost-effective.
TABLE 16 Resource use by group in primary care
(1) Participants completing detailed resource use questionnaire
Variable
Intervention (n= 53) Control (n= 54)
Difference p-valueMean SD Mean SD
GP contacts 0.19 0.44 0.26 0.52 –0.07 0.548
NHS Direct contacts 0.02 0.14 0.04 0.19 –0.02 1.000
A&E attendances 0.02 0.14 0.06 0.23 –0.04 0.610
(2) Participants with brief resource use via telephone
Variable Intervention (n= 57) Control (n= 72) Difference p-value
n (%) with any GP contact 6 (11%) 6 (8%) – 0.764
n (%) with any A&E attendance 2 (4%) 1 (1%) – 0.583
A&E, accident and emergency.
TABLE 17 Total costs and QALDs
Variable
Intervention (n= 141) Control (n= 149)
Difference p-valueMean SD Mean SD
Total hospital costs (£) 2726 3204 2595 2345 132 0.675
QALDs 33.999 0.152 33.993 0.172 0.006 0.757
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FIGURE 9 Cost-effectiveness acceptability curve for the use of nebulised saline.
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Chapter 5 Results of the systematic review
In this chapter we describe the results obtained from the review, incorporating the data from our study.The search strategy and identification is described in Study selection. The study characteristics of the
individual studies are described in Study characteristics, followed by the results of the risk of bias
assessment for individual studies in Risk of bias within studies. The results and meta-analyses of the effect
of the intervention (HS) are summarised in Results and meta-analyses, Primary outcome: results and
synthesis and Secondary outcomes: results and synthesis. Finally, the risk of bias across studies is
considered in Risk of bias across studies.
Study selection
The search criteria outlined in Chapter 2, Systematic Review Methods (see also Appendix 6), and the
number of titles retrieved from each search are outlined in Figure 10.
Records identified through 
database searching 
(n = 163)
Additional records identified 
through other sources 
(n = 1456)
• MEDLINE (Ovid), n = 43
• EMBASE, n = 102
• CENTRAL, n = 18 
• Google Scholar, n = 915
• Registries, n = 400
• Journals and hand
   searching, n = 59
• Web of Science, n = 81
• The SABRE Trial, n = 1
Records after duplicates
removed (n = 1489)
Titles/abstracts reviewed 
(n = 1489)
Records excluded 
(n = 1443)
Full-text articles
excluded (n = 28)
• Wrong setting, n = 7
• Not in English, n = 2
• Wrong population or
   intervention, n = 15
• Not a controlled trial, n = 4
Full-text articles and 
abstract assessed for 
eligibility (n = 46)
Studies included in
qualitative synthesis (n = 18)
Studies included in
quantitative synthesis
(meta-analysis) (n = 15)
FIGURE 10 Study flow diagram.
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The searches identified a total of 1619 citations. After removal of duplicates, 1489 records were assessed at
title and abstract stage. The main searches were all downloaded into reference manager software (RevMan
version 5.2) and details of the search strategies can be found in Appendix 6. In total, 1443 records were
excluded at this stage for reasons that include not being a RCT, not evaluating the intervention of interest
and having the wrong population or intervention when this was apparent from the title and abstract. Nine
potentially relevant studies were rejected at the abstract stage, because it was obvious that the full papers were
not available in English.59–67
In total, 46 full papers (including the SABRE study report) were retrieved for further review, and these included
studies for which the title and abstract (if available) were ambiguous. Of these, 28 studies were excluded
because they did not consider hospitalised infants (n= 7),32,33,97–101 they were not available in English (n= 2),68,69
they did not consider the intervention in the appropriate population of interest (n= 15)21,38,39,102–113 or they were
not a controlled trial (n= 4)114–117 (Table 18).
Eighteen studies were accepted for final inclusion in the review (see Figure 10), all being methodologically
appropriate. All but three of the studies were appropriate to be included in the meta-analysis of the
primary outcome of interest: LoS.
TABLE 18 Studies excluded at full paper review stage
Studies excluded at full paper review Reason for exclusion
Ipek et al., 2011101 Wrong setting
Anil et al., 201033 Wrong setting
Grewal et al., 200932 Wrong setting
Kuzik et al., 201097 Wrong setting
Sezer et al., 201098 Wrong setting
Jacobs et al., 201499 Wrong setting
Wu et al., 2014100 Wrong setting
Park et al., 200568 Not in English
Zheng et al., 201269 Not in English
Gutpa et al., 2012102 Wrong population or intervention
Khashabi et al., 2005103 Wrong population or intervention
Lines et al., 1992104 Wrong population or intervention
Milner et al., 1995105 Wrong population or intervention
Patel et al., 2002106 Wrong population or intervention
Tinsa et al., 2009107 Wrong population or intervention
Wainwright et al., 200338 Wrong population or intervention
Postiaux et al., 2011108 Wrong population or intervention
Hariprakash et al., 200339 Wrong population or intervention
Sarrell et al., 200221 Wrong population or intervention
Chowdhury et al., 1995109 Wrong population or intervention
Nenna et al., 2009110 Wrong population or intervention
Bertrand et al., 2001111 Wrong population or intervention
Nenna et al., 2013112 Wrong population or intervention
Bueno Campaña et al., 2014113 Wrong population or intervention
Mandelberg et al., 2010114 Not a controlled trial
Principi et al., 2011115 Not a controlled trial
Hom et al., 2011116 Not a controlled trial
Sauvaget et al., 2012117 Not a controlled trial
RESULTS OF THE SYSTEMATIC REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
54
Study characteristics
Eighteen trials comprising 2225 participants in total were identified via the searches described in
Appendix 6; the number of recruited participants was unavailable for one trial.75 All the trials included
children under the age of 2 years, although five studies included only children under the age of
12 months.22,23,85,87,88 Luo and colleagues79,80 studied bronchiolitis in separate children over two distinct
winter seasons for each of the studies.
Data on the study overview are given in Table 3. Studies were performed across a variety of countries:
India, Canada, Israel, Argentina, the United Arab Emirates, the People’s Republic of China, Italy, Qatar,
Georgia, the Netherlands, Mexico, Turkey, the USA, Nepal and the UK. Overall, 11 of the trials described
appropriate allocation sequence generation methods.23,24,77,80–83,85,87,88,90 The number of participants ranged
from 40 to 317. All studies included children hospitalised on their first episode of bronchiolitis only. Full
details of the eligibility criteria are given in Appendix 5. Fifteen of the studies22–24,77,79,80,82–90 reviewed
baseline characteristic variability between both arms; however, the unpublished data74,75 and one other
study81 do not give sufficient evidence of this having been done.
The Wang et al. CSS system78 was used to classify disease severity in eight of the trials.22,23,77,79–82,86 Three
trials24,85,88 used the Respiratory Distress Assessment Instrument score,118 one trial used the Bronchiolitis
Severity Score,83 one trial used the Bronchiolitis Clinical Score,84 one did not specify which scoring system
was used74 and one did not assess disease severity.87 In addition, one used the Respiratory Assessment
Score,89 one used the Respiratory Distress Scale of the Sant Joan de Déu Hospital75 and another trial used a
clinical scoring system.90 The Wang scale uses different symptomatic characteristics (including wheezing,
retractions and the general condition of the patient) to allocate a score: a score of 0–4.9 indicates mild
distress, a score of 5–8.9 moderate distress and a score of 9–12 severe distress.79 This scoring system was
used by study authors to classify their cohort into one of the three groups, although trials included a
combination of mild/moderate,89,84,79,81,86 moderate22–24,82 or moderate/severe74,75,77,80,83,85,87 participants.
A severity classification was not provided by Ojha et al.90 or Silver.88 A simplified guide to interventions is
shown in Table 19.
Nemsadze et al.,84 Sosa-Bustamante75 and Ozdogan et al.89 could not be included in the meta-analysis, as
the data were available only in abstract form or on ClinicalTrials.gov and therefore the primary outcome
LoS data were not available. We contacted the authors of Silver,88 who provided the mean and SD LoS,
along with additional data requested.
Data on the intervention and comparators are given in Tables 20 and 21: study characteristics, intervention
and comparator. All of the studies used 3% HS as the study intervention administered via a nebuliser,
three of which were three-arm studies in which either 5% HS89,83 or 6% HS86 was also compared.
The amount administered was stated for 15 out of 18 trials, and varied, being 3ml74,81 in two studies,
4 ml22–24,75,79,80,82,85–88,90 in 12 studies and 5ml for one study.83 The flow rate of the nebulisers used to
administer this was stated for 10 trials and ranged from 5 to 10ml/minute.22,23,77,81–83,85–88 There were
clear differences in the additional drugs administered alongside the intervention in the studies: five trials
gave HS alone,24,80,87,88,90 seven studies administered a beta-2 agonist (salbutamol, albuterol) alongside
HS,74,75,79,81,82,86,89 five trials gave adrenaline alongside HS22,23,77,83,85 and one trial was reported in abstract
form only and did not list additional drugs administered.84 Only five of the trials drew any inference about
compliance with treatment by stating that the nebulisers were administered until empty.22,23,82,86,88 Studies
are similar enough in population and interventions delivered to be comparable with each other.
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TABLE 19 Simplified guide to interventions in studies included in meta-analysis (n= 13)
Intervention
Groups Intervention Control Studies
1 Nebulised HS alone NS Luo et al., 201180
Kuzik et al., 200724
Silver, 201488
Ojha et al., 201490
2 Nebulised HS plus a bronchodilator
(e.g. salbutamol)
NS No trials
3 (pre-specified
subgroup)
Nebulised HS plus a bronchodilator
(e.g. salbutamol)
NS plus
same bronchodilator
Trials by pre-specified
subgroup
3.1 (post-hoc
subgroup)
Nebulised HS plus a beta-2 agonist NS plus same beta-2
agonist
Espelt, 201274
Luo et al., 201079
Maheshkumar et al., 201381
Sharma et al., 201382
Teunissen et al., 201486
Ozdogan et al., 201489
Sosa-Bustamante, 201475
3.2 (post-hoc
subgroup)
Nebulised HS plus adrenaline NS plus adrenaline Al-Ansari et al., 201083
Mandelberg et al., 200322
Giudice et al., 201277
Pandit et al., 201385
Tal et al., 200623
4 Nebulised HS alone or plus a bronchodilator
(e.g. salbutamol)
No intervention Everard et al., 201487
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Risk of bias within studies
The risk of bias assessments for each of the domains described above are summarised in Table 22. With
the exception of four studies,74,75,84,89 the methodological quality of the included studies was generally high
based on the Cochrane suggested domains for assessing internal study validity. All studies were RCTs;
seven trials do not give a detailed description on random sequence generation,22,74,75,79,84,86,89 but none was
adjudged clearly inappropriate.
The local pharmacy prepared the solutions for two trials.24,77 Use of sequential identical containers was
employed by three studies,23,82,86 sealed envelopes by three studies80,83,85 and one study adopted both
methods.90 Four studies are not clear on their technique for allocation concealment but simply state that
‘patients were selected and randomly assigned’,79 ‘patients were recruited sequentially and randomised’81
or ‘infants were randomly assigned’.22,84 A clear description was not given by three studies.74,75,89
A web-based randomisation system was used for two of the studies.87,88 All studies are stated as being
double blind, except three which were open-label trials74,85,87 and one in which no statement was provided.84
It was possible to assess detection bias for six of the trials in which the attending physicians who made a
decision to discharge were stated as being blinded to the intervention,22,23,79,80,86,88 but no statement was
provided in the other trials. Attrition bias was assessable in all studies as a description of withdrawals
was provided apart from Sosa-Bustamante75, Ozdogan et al.89 and Nemsadze et al.,84 as information was
available only in abstract form or on ClinicalTrials.gov. Potential bias due to selective outcome reporting
was not possible to ascertain for 14 of the 18 trials. Of the remaining four, Giudice et al.77 published their
study protocol and made information available on ClinicalTrials.gov, Sharma et al.82 did not fully report the
final CSS score (secondary analysis), Teunissen et al.86 made information available on The Dutch Trial
Register and, finally, of course, the study protocol for our own trial87 is available.
The risk of bias summary outputs from RevMan can be seen in Figures 11 and 12. These relate to the
review authors’ judgements about each risk of bias item presented as percentages across all included
studies and then as a summary representing each risk of bias item for each included study.
Fourteen of the 18 trials were double blind, allocation concealment was appropriately described in 11 trials
and a random sequence was correctly generated in 11 studies. Conversely, an unclear judgement was
made for the majority of trials in relation to selective reporting because of the unavailability of pre-specified
outcomes making this difficult to judge. Four studies74,75,84,89 scored the lowest in terms of internal validity;
however, all were available only in abstract form or on ClinicalTrials.gov. Other bias was mainly assessed as
‘unclear’ as there were no apparent other sources of bias observed in the study reports.
None of the trials was classified as being at 100% low risk of bias across each of the criteria. One of the
trials74 was open label and also reported marked differences in withdrawal rates between groups, with no
explanation given, and as such scored high risk of bias for both counts. Blinding of outcome measures was
assessed as being at low risk of bias in 6 of the 18 trials.22,23,79,80,86,88 Selective outcome reporting was
difficult to assess without the availability of pre-specified outcomes, for example in the form of a published
protocol, for 14 of the 18 trials, and it was high for one study82 as the secondary outcome was not fully
reported. There were no other apparent sources of bias on examination of the literature from the studies.
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Results and meta-analyses
Primary outcome: results and synthesis
The data extracted for the primary outcome are displayed in Table 23. Although all trials stated that LoS
was being measured, a closer review of the methods revealed that most in fact had measured the time to
being fit for discharge (variably defined). To avoid confusion among those familiar with the included trials,
we will continue to use the term LoS for the remainder of this section, but will revisit this issue of
nomenclature in Chapter 6, Discussion.
The mean LoS, SD and sample size in each trial for each group. Data are provided for all of the trials;
however, Nemsadze et al. did not provide the number of patients in each group and so cannot be
included in the meta-analysis.84 In addition, the mean, SD and sample size for LoS were not available for
two trials, as information was available only in abstract form or on ClinicalTrials.gov.75,89
To avoid double-counting of control patients, in the case of three-arm trials we divided control group
numbers by two (see Chapter 2, Synthesis of results). Teunissen et al.86 (3% HS group, n= 84; 6% HS
group, n= 83; and control, n= 80) was included as two effective studies in the analysis [‘Teunissen
(3% HS)’, n= 84 vs. 40; ‘Teunissen (6% HS)’, n= 83 vs. 40],86 and the same approach was taken with
Al-Ansari83 [3% HS group, n= 58; 5% HS group, n= 57; and control, n= 56; ‘Al-Ansari (3% HS)’ n= 58
vs. 28; ‘Al-Ansari (5% HS)’ n= 57 vs. 28].
Figures 13 and 14 present the LoS for each trial, together with the pooled difference between HS and
control, using both FE and RE methods. The weighted average of the effect sizes observed across 15 RCTs
(n= 1922 participants) would indicate that HS, alone or in combination with other therapies, reduces the
LoS in children with acute bronchiolitis by just over one-third of a day [mean difference (MD) –0.36,
95% CI –0.50 to –0.22] compared with no HS (see Figure 13). However, the level of statistical
heterogeneity associated with this estimate is too high for it to be a safe basis for clinical decision-making,
with over three-quarters of the between-study variability not attributable to the play of chance alone
(I2= 78%). Of particular note is that our own trial was one of the largest of the 15 trials included, yet it
received a mere 4.2% weight in the FE analysis. The most probable reason for this apparent incongruity is
the excessive heterogeneity among the studies, with differential case mix (e.g. patient severity or discharge
policies) being typified by differences among the SDs and hence study weights. RE analyses have been
advocated to address this; this method yields a larger MD (–0.48 days; 95% CI –0.81 to –0.15 days).
Nevertheless, this does not overcome the problem of excessive heterogeneity; the between-trial variation
dominates the within-trials variation and effectively allocates similar weights to each study irrespective of
their size.119,120 The same pattern was observed when combining standardised MDs (i.e. dividing the MD by
the underlying SD78).
Within the pre-planned, protocol-specified intervention subgroups (see Figure 13) there are lower levels of
statistical heterogeneity, suggesting that clinical heterogeneity deriving from differences in care regimens
could underlie some of the observed between-trial differences in treatment effect. However, the risk of
bias from other sources (see Risk of biases across studies and Chapter 6, Strengths and weaknesses of the
systematic review) means that the summary estimates even from the subgroup analyses should be treated
with great caution.
The main analysis as presented in Figure 13 includes only comparisons of 3% concentrations of HS with
control interventions, as in the SABRE study. Two trials also included third arms delivering higher doses of
HS. When these arms were included, the pooled effect size and associated heterogeneity are reduced
marginally without altering the results appreciably (MD –0.34, 95% CI –0.48 to –0.21, using a FE analysis;
MD –0.44, 95% CI –0.74 to –0.14, using RE; see Figure 14).
RESULTS OF THE SYSTEMATIC REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
68
TA
B
LE
23
Le
n
g
th
o
f
h
o
sp
it
al
st
ay
b
y
st
u
d
y
(p
ri
m
ar
y
o
u
tc
o
m
e)
M
ai
n
au
th
o
r
D
is
ea
se
se
ve
ri
ty
In
te
rv
en
ti
o
n
C
o
n
tr
o
l
M
ea
n
(d
ay
s)
SD
(d
ay
s)
N
u
m
b
er
o
f
p
ar
ti
ci
p
an
ts
M
ea
n
(d
ay
s)
SD
(d
ay
s)
N
u
m
b
er
o
f
p
ar
ti
ci
p
an
ts
G
iu
di
ce
et
al
.,
20
12
77
Se
ve
re
4.
9
1.
3
52
5.
6
1.
6
54
K
uz
ik
et
al
.,
20
07
24
M
od
er
at
e
2.
6
1.
9
45
3.
5
2.
9
46
Ta
le
t
al
.,
20
06
23
M
od
er
at
e
2.
6
1.
4
21
3.
5
1.
7
20
Lu
o
et
al
.,
20
10
79
M
ild
/m
od
er
at
e
6
1.
2
50
7.
4
1.
5
43
Lu
o
et
al
.,
20
11
80
M
od
er
at
e/
se
ve
re
4.
8
1.
2
57
6.
4
1.
4
55
M
an
de
lb
er
g
et
al
.,
20
03
22
M
od
er
at
e
3
1.
2
27
4
1.
9
25
Es
pe
lt,
20
12
74
M
od
er
at
e
5.
8
2.
7
37
5.
47
2.
1
45
M
ah
es
hk
um
ar
et
al
.,
20
13
81
M
ild
/m
od
er
at
e
2.
25
0.
89
20
2.
88
1.
76
20
Sh
ar
m
a
et
al
.,
20
13
82
M
od
er
at
e
2.
64
0.
88
12
5
2.
66
0.
93
12
3
A
l-A
ns
ar
ie
t
al
.,
20
10
83
M
od
er
at
e
to
se
ve
re
1.
4
(3
%
H
S)
1.
41
(3
%
H
S)
58
(3
%
H
S)
1.
88
1.
76
56
1.
56
(5
%
H
S)
1.
38
(5
%
H
S)
57
(5
%
H
S)
N
em
sa
dz
e
et
al
.,
20
13
84
M
ild
to
m
od
er
at
e
4.
4
1.
1
U
nk
no
w
n
–
ab
st
ra
ct
on
ly
4.
9
1.
2
U
nk
no
w
n
–
ab
st
ra
ct
on
ly
Pa
nd
it
et
al
.,
20
13
85
M
od
er
at
e/
se
ve
re
3.
92
1.
72
51
4.
08
1.
90
49
Te
un
is
se
n
et
al
.,
20
14
86
M
ild
to
m
od
er
at
e
3.
23
(3
%
H
S)
2.
02
(3
%
H
S)
84
(3
%
H
S)
3.
17
1.
83
80
3.
24
(6
%
H
S)
2.
06
(6
%
H
S)
83
(6
%
H
S)
Ev
er
ar
d
et
al
.,
20
14
87
Se
ve
re
3.
77
3.
05
14
1
3.
7
2.
83
14
9
Si
lv
er
,
20
14
88
U
nk
no
w
n
2.
49
1.
64
93
2.
47
1.
76
97
O
zd
og
an
et
al
.,
20
14
89
M
ild
to
m
od
er
at
e
U
nk
no
w
n
–
ab
st
ra
ct
on
ly
U
nk
no
w
n
–
ab
st
ra
ct
on
ly
U
nk
no
w
n
–
ab
st
ra
ct
on
ly
U
nk
no
w
n
–
ab
st
ra
ct
on
ly
U
nk
no
w
n
–
ab
st
ra
ct
on
ly
U
nk
no
w
n
–
ab
st
ra
ct
on
ly
So
sa
-B
us
ta
m
an
te
,
20
14
75
M
od
er
at
e
to
se
ve
re
U
nk
no
w
n
–
C
lin
ic
al
Tr
ia
ls
.g
ov
on
ly
U
nk
no
w
n
–
C
lin
ic
al
Tr
ia
ls
.g
ov
on
ly
U
nk
no
w
n
–
C
lin
ic
al
Tr
ia
ls
.g
ov
on
ly
U
nk
no
w
n
–
C
lin
ic
al
Tr
ia
ls
.g
ov
on
ly
U
nk
no
w
n
–
C
lin
ic
al
Tr
ia
ls
.g
ov
on
ly
U
nk
no
w
n
–
C
lin
ic
al
Tr
ia
ls
.g
ov
on
ly
O
jh
a
et
al
.,
20
14
90
U
nk
no
w
n
1.
87
0.
96
28
1.
82
1.
18
31
DOI: 10.3310/hta19660 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 66
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Everard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
69
St
u
d
y
H
yp
er
to
n
ic
 s
al
in
e
C
o
n
tr
o
l
W
ei
g
h
ts
Fi
xe
d
(I
V
)
(D
&
L)
R
an
d
o
m
M
ea
n
SD
N
M
ea
n
SD
N
H
yp
er
to
n
ic
 s
al
in
e 
vs
. n
o
rm
al
 s
al
in
e 
al
o
n
e
K
u
zi
k 
20
07
24
 (
3%
)
Lu
o
 2
01
18
0  
(3
%
)
O
jh
a 
20
14
90
 (
3%
)
Si
lv
er
 2
01
48
8  
(3
%
)
IV
 s
u
b
to
ta
l (
I2
 =
 8
9.
5%
; p
 =
 0
.0
00
)
D
&
L 
su
b
to
ta
l
2.
6
4.
8
1.
87
2.
49
1.
9
1.
2
.9
6
1.
64
45 57 28 93
3.
5
6.
4
1.
82
2.
47
2.
9
1.
4
1.
18
1.
76
46 55 31 97
1.
9
8.
3
6.
5
8.
3
5.
0
7.
9
7.
5
7.
9
Es
p
el
t 
20
12
72
 (
3%
)
Lu
o
 2
01
07
9  
(3
%
)
M
ah
es
h
ku
m
ar
81
 2
01
3 
(3
%
)
Sh
ar
m
a 
20
13
82
 (
3%
)
Te
u
n
is
se
n
 2
01
48
 (
3%
)
IV
 s
u
b
to
ta
l (
I2
 =
 8
2.
3%
; p
 =
 0
.0
00
)
D
&
L 
su
b
to
ta
l
H
yp
er
to
n
ic
 s
al
in
e 
p
lu
s 
ß
2-
ag
o
n
is
t 
vs
. n
o
rm
al
 s
al
in
e 
p
lu
s 
ß
2-
ag
o
n
is
t
5.
8
6 2.
25
2.
64
3.
23
2.
7
1.
2
.8
9
.8
8
2.
02
37 50 20 12
5
84
5.
47
7.
4
2.
88
2.
66
3.
17
2.
1
1.
5
1.
76
.9
3
1.
83
45 43 20 12
3
40
1.
7
6.
2
2.
6
38
.2
3.
8
4.
8
7.
4
5.
7
9.
0
6.
6
A
l-
A
n
sa
ri
 2
01
08
3  
(3
%
)
G
iu
d
ic
e 
20
12
78
 (
3%
)
M
an
d
el
b
er
g
 2
00
32
2  
(3
%
)
Pa
n
d
it
 2
01
38
5  
(3
%
)
Ta
l 2
00
62
3  
(3
%
)
IV
 s
u
b
to
ta
l (
I2
 =
 0
.0
%
; p
 =
 0
.5
78
)
D
&
L 
su
b
to
ta
l
H
yp
er
to
n
ic
 s
al
in
e 
p
lu
s 
ep
in
ep
h
ri
n
e 
vs
. n
o
rm
al
 s
al
in
e 
p
lu
s 
ep
in
ep
h
ri
n
e
1.
4
4.
9
3 3.
92
2.
6
1.
41
1.
3
1.
2
1.
72
1.
4
58 52 27 51 21
1.
88
5.
6
4 4.
08
3.
5
1.
76
1.
6
1.
9
1.
9
1.
7
28 54 25 49 20
3.
5
6.
3
2.
6
3.
8
2.
1
6.
4
7.
5
5.
7
6.
6
5.
3
Ev
er
ar
d
 2
01
48
7  
(3
%
)
IV
 s
u
b
to
ta
l (
I2
 =
 N
/A
; p
 =
 N
/A
)
D
&
L 
su
b
to
ta
l
H
yp
er
to
n
ic
 s
al
in
e 
al
o
n
e 
o
r 
p
lu
s 
b
ro
n
ch
o
d
ila
to
r 
vs
. n
o
 in
te
rv
en
ti
o
n
3.
77
3.
05
14
1
3.
7
2.
83
14
9
4.
2
6.
8
H
et
er
o
g
en
ei
ty
 b
et
w
ee
n
 g
ro
u
p
s:
 p
 =
 0
.0
29
IV
 o
ve
ra
ll 
(I
2  =
 7
7.
8%
; p
 =
 0
.0
00
)
D
&
L 
o
ve
ra
ll
M
D
 (
95
%
 C
I)
–0
.9
0 
(–
1.
91
 t
o
 0
.1
1)
–1
.6
0 
(–
2.
08
 t
o
 –
1.
12
)
0.
05
 (
–0
.5
0 
to
 0
.6
0)
0.
02
 (
–0
.4
6 
to
 0
.5
0)
–0
.5
8 
(–
0.
86
 t
o
 –
0.
30
)
–0
.6
0 
(–
1.
49
 t
o
 0
.3
0)
0.
33
 (
–0
.7
3 
to
 1
.3
9)
–1
.4
0 
(–
1.
96
 t
o
 –
0.
84
)
–0
.6
3 
(–
1.
49
 t
o
 0
.2
3)
–0
.0
2 
(–
0.
25
 t
o
 0
.2
1)
0.
06
 (
–0
.6
5 
to
 0
.7
7)
–0
.2
0 
(–
0.
39
 t
o
 –
0.
00
)
–0
.3
6 
(–
1.
00
 t
o
 0
.2
7)
–0
.4
8 
(–
1.
23
 t
o
 0
.2
7)
–0
.7
0 
(–
1.
25
 t
o
 –
0.
15
)
–1
.0
0 
(–
1.
87
 t
o
 –
0.
13
)
–0
.1
6 
(–
0.
87
 t
o
 0
.5
5)
–0
.9
0 
(–
1.
86
 t
o
 –
0.
06
)
–0
.6
1 
(–
0.
94
 t
o
 –
0.
28
)
–0
.6
1 
(–
0.
94
 t
o
 –
0.
28
)
0.
07
 (
–0
.6
1 
to
 0
.7
5)
0.
07
 (
–0
.6
1 
to
 0
.7
5)
0.
07
 (
–0
.6
1 
to
 0
.7
5)
–0
.3
6 
(–
0.
50
 t
o
 –
0.
22
)
–0
.4
8 
(–
0.
81
 t
o
 –
0.
15
)
–2
–1
Fa
vo
u
rs
 h
yp
er
to
n
ic
 s
al
in
e
Fa
vo
u
rs
 c
o
n
tr
o
l
M
D
 (
d
ay
s)
0
1
FI
G
U
R
E
13
D
if
fe
re
n
ce
in
le
n
g
th
o
f
h
o
sp
it
al
st
ay
b
y
in
te
rv
en
ti
o
n
su
b
g
ro
u
p
,3
%
H
S.
D
&
L,
D
er
Si
m
o
n
ia
n
an
d
La
ir
d
;I
V
,i
n
ve
rs
e-
va
ri
an
ce
;
N
/A
,
n
o
t
ap
p
lic
ab
le
.
RESULTS OF THE SYSTEMATIC REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
St
u
d
y
H
yp
er
to
n
ic
 s
al
in
e
C
o
n
tr
o
l
W
ei
g
h
ts
Fi
xe
d
(I
V
)
(D
&
L)
R
an
d
o
m
M
ea
n
SD
N
M
ea
n
SD
N
H
yp
er
to
n
ic
 s
al
in
e 
vs
. n
o
rm
al
 s
al
in
e 
al
o
n
e
K
u
zi
k 
20
07
24
 (
3%
)
Lu
o
 2
01
18
0  
(3
%
)
O
jh
a 
20
14
90
 (
3%
)
Si
lv
er
 2
01
48
8  
(3
%
)
IV
 s
u
b
to
ta
l (
I2
 =
 8
9.
5%
; p
 =
 0
.0
00
)
D
&
L 
su
b
to
ta
l
2.
6
4.
8
1.
87
2.
49
1.
9
1.
2
0.
96
1.
64
45 57 28 93
3.
5
6.
4
1.
82
2.
47
2.
9
1.
4
1.
18
1.
76
46 55 31 97
1.
8
7.
7
6.
0
7.
7
4.
4
7.
0
6.
7
7.
0
Es
p
el
t 
20
12
72
 (
3%
)
Lu
o
 2
01
07
9  
(3
%
)
M
ah
es
h
ku
m
ar
81
 2
01
3 
(3
%
)
Sh
ar
m
a 
20
13
82
 (
3%
)
Te
u
n
is
se
n
 2
01
48
6  
(3
%
)
Te
u
n
is
se
n
 2
01
48
6  
(6
%
)
IV
 s
u
b
to
ta
l (
I2
 =
 7
8.
4%
; p
 =
 0
.0
00
)
D
&
L 
su
b
to
ta
l
H
yp
er
to
n
ic
 s
al
in
e 
p
lu
s 
ß
2-
ag
o
n
is
t 
vs
. n
o
rm
al
 s
al
in
e 
p
lu
s 
ß
2-
ag
o
n
is
t
5.
8
6 2.
25
2.
64
3.
23
3.
24
2.
7
1.
2
0.
89
0.
88
2.
02
2.
06
37 50 20 12
5
84 83
5.
47
7.
4
2.
88
2.
66
3.
17
3.
17
2.
1
1.
5
1.
76
.9
3
1.
83
1.
83
45 43 20 12
3
40 40
1.
6
5.
8
2.
4
35
.6
3.
6
3.
5
4.
1
6.
6
5.
0
8.
2
5.
8
5.
8
A
l-
A
n
sa
ri
 2
01
08
3  
(3
%
)
A
l-
A
n
sa
ri
 2
01
08
3  
(5
%
)
G
iu
d
ic
e 
20
12
77
 (
3%
)
M
an
d
el
b
er
g
 2
00
32
2  
(3
%
)
Pa
n
d
it
 2
01
38
5  
(3
%
)
Ta
l 2
00
62
3  
(3
%
)
IV
 s
u
b
to
ta
l (
I2
 =
 0
.0
%
; p
 =
 0
.6
43
)
D
&
L 
su
b
to
ta
l
H
yp
er
to
n
ic
 s
al
in
e 
p
lu
s 
ep
in
ep
h
ri
n
e 
vs
. n
o
rm
al
 s
al
in
e 
p
lu
s 
ep
in
ep
h
ri
n
e
1.
4
1.
56
4.
9
3 3.
92
2.
6
1.
41
1.
38
1.
3
1.
2
1.
72
1.
4
58 57 52 27 51 21
1.
88
1.
88
5.
6
4 4.
08
3.
5
1.
76
1.
76
1.
6
1.
9
1.
9
1.
7
28 28 54 25 49 20
3.
5
3.
3
5.
9
2.
4
3.
6
2.
0
5.
6
5.
6
6.
7
5.
0
5.
8
4.
6
Ev
er
ar
d
 2
01
48
7  
(3
%
)
IV
 s
u
b
to
ta
l (
I2
 =
 N
/A
; p
 =
 N
/A
)
D
&
L 
su
b
to
ta
l
H
yp
er
to
n
ic
 s
al
in
e 
al
o
n
e 
o
r 
p
lu
s 
b
ro
n
ch
o
d
ila
to
r 
vs
. n
o
 in
te
rv
en
ti
o
n
3.
77
3.
05
14
1
3.
7
2.
83
14
9
3.
9
6.
0
H
et
er
o
g
en
ei
ty
 b
et
w
ee
n
 g
ro
u
p
s:
 p
 =
 0
.0
25
IV
 o
ve
ra
ll 
(I
2  =
 7
5.
1%
; p
 =
 0
.0
00
)
D
&
L 
o
ve
ra
ll
M
D
 (
95
%
 C
I)
–0
.9
0 
(–
1.
91
 t
o
 0
.1
1)
–1
.6
0 
(–
2.
08
 t
o
 –
1.
12
)
0.
05
 (
–0
.5
0 
to
 0
.6
0)
0.
02
 (
–0
.4
6 
to
 0
.5
0)
–0
.5
8 
(–
0.
86
 t
o
 –
0.
30
)
–0
.6
0 
(–
1.
49
 t
o
 0
.3
0)
0.
33
 (
–0
.7
3 
to
 1
.3
9)
–1
.4
0 
(–
1.
96
 t
o
 –
0.
84
)
–0
.6
3 
(–
1.
49
 t
o
 0
.2
3)
–0
.0
2 
(–
0.
25
 t
o
 0
.2
1)
0.
06
 (
–0
.6
5 
to
 0
.7
7)
0.
07
 (
–0
.6
5 
to
 0
.7
9)
–0
.1
8 
(–
0.
36
 t
o
 0
.0
1)
–0
.2
9 
(–
0.
82
 t
o
 0
.2
4)
–0
.4
8 
(–
1.
23
 t
o
 0
.2
7)
–0
.3
2 
(–
1.
06
 t
o
 0
.4
2)
–0
.7
0 
(–
1.
25
 t
o
 –
0.
15
)
–1
.0
0 
(–
1.
87
 t
o
 –
0.
13
)
–0
.1
6 
(–
0.
87
 t
o
 0
.5
5)
–0
.9
0 
(–
1.
86
 t
o
 0
.0
6)
–0
.5
6 
(–
0.
86
 t
o
 –
0.
27
)
–0
.5
6 
(–
0.
86
 t
o
 –
0.
27
)
0.
07
 (
–0
.6
1 
to
 0
.7
5)
0.
07
 (
–0
.6
1 
to
 0
.7
5)
0.
07
 (
–0
.6
1 
to
 0
.7
5)
–0
.3
4 
(–
0.
48
 t
o
 –
0.
21
)
–0
.4
4 
(–
0.
74
 t
o
 –
0.
14
)
–2
–1
Fa
vo
u
rs
 h
yp
er
to
n
ic
 s
al
in
e
Fa
vo
u
rs
 c
o
n
tr
o
l
M
D
 (
d
ay
s)
0
1
FI
G
U
R
E
14
D
if
fe
re
n
ce
in
Lo
S
b
y
in
te
rv
en
ti
o
n
su
b
g
ro
u
p
,a
ll
co
n
ce
n
tr
at
io
n
s
o
f
H
S.
D
&
L,
D
er
Si
m
o
n
ia
n
an
d
La
ir
d
;I
V
,i
n
ve
rs
e-
va
ri
an
ce
;
N
/A
,n
o
t
ap
p
lic
ab
le
.
DOI: 10.3310/hta19660 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 66
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Everard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
71
What is clear is that a large amount of the heterogeneity is driven by two trials from the same team,
led by Luo,79,80 with outlying results, relatively small sample sizes but narrow CIs (around 1 day, compared
with a 1.5 days in the SABRE study87 and the other large northern European study, Teunissen et al.86).
Together, the Luo et al. trials contribute 14.5% of the weight in the main analysis (see Figure 13). Their
central estimates of clinical effect, –1.4 days79 and –1.6 days,80 are included in the CIs of only four of
the remaining trials.22–24,81 The removal of these two studies from the main analysis considerably reduces
the effect sizes and statistical significance in the analyses of HS versus NS alone (MD –0.07 days, 95% CI
–0.41 to 0.27 days; p= 0.67) and HS+ beta-2 agonist versus NS+ beta-2 agonist (MD –0.03 days, 95% CI
–0.24 to 0.17 days; p= 0.74). The elimination of Luo79 from the beta-2 agonist subgroup reduces the
heterogeneity from I2= 82% to I2= 0%. The elimination of these two studies reduces the overall FE pooled
effect size from 0.36 days (95% CI –0.50 to –0.22 days; p< 0.00001; test for heterogeneity p< 0.00001,
I2= 78%) down to –0.16 days (–0.31 to –0.01 days; p= 0.03; test for heterogeneity p= 0.02, I2= 32%).
On the other hand, the elimination of even the three most negative studies from the main analysis
(see Figure 13) makes little difference.74,86,87 In short, the Luo studies are major drivers of heterogeneity.
Secondary outcomes: results and synthesis
There was no mention of AEs in seven studies;74,75,77,81,84,89,90 however, Maheshkumar et al.81 stated ‘HS is
safe’, implying that no AEs were observed, and Nemsadze et al.84 was published only as an abstract.
Tal et al.23 stated that no AEs were observed in either of the groups.23 Kuzik et al. reported that there
were no withdrawals because of AEs by medical staff; however, two patients in the intervention
group were withdrawn on parental request (one because the infant cried vigorously during two inhalations
and the other because of agitation on one inhalation).24 Luo et al.79 stated in the first season that all
patients completed treatment and that wheezing and coughing did not worsen over course of treatment.
In the second season, Luo et al.80 highlight that no infants were withdrawn as a result of AEs and that
coughing and wheezing never worsened during treatment. Five infants (two in the intervention group)
experienced hoarse voices but this improved after 3 or 4 days. Mandelberg et al.22 report that no AEs were
observed. Pulse rate and room air saturation did not differ between the two groups on any day. One
patient was excluded from analysis because of a need for mechanical ventilation. Sharma et al.82 also
concur that no AEs related to any of the patients were reported by parents, caregivers or treating medical
attendants in either group. Al-Ansari et al.83 also state that no safety concerns or adverse reactions were
identified. Pandit et al.85 reported that vomiting and diarrhoea occurred in four infants, all in the control
group; in addition, they noted no tremors or paleness during treatment. Teunissen et al.86 reported
95 AEs in the 3% HS group, 119 in the 6% HS group and 76 in the NS group. Silver88 stated that only
nine participants in the 3% HS group and four in the NS group did not complete the study because of
AEs. According to additional information provided by the author, 10 participants in the HS arm and
nine in the control arm were transferred to ICU/clinical worsening. Finally, for the SABRE study,87 AEs are
described in detail in Table 10; overall, there were 51 AEs recorded in the standard care plus intervention
group and 43 in the standard care group.
Readmission rate was not reported in 15 trials. Al-Ansari et al.83 state that short-stay readmission was
required for 10 infants in the 5% HS group, eight infants in the 3% HS group and seven infants
in the 0.9% saline group.83 Silver88 reported that four participants in the 3% HS group and three in
the 0.9% NS group were readmitted within 7 days. In addition, Everard et al.87 showed a lack
of evidence to suggest that there was a difference between treatment groups in terms of the
numbers admitted to HDU/ICU and readmitted within 28 days of randomisation. The final mean
CSS scores were also analysed for the five studies for which data were available23,77,79,80,86 (Table 24).
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The average change of –1.36 points (95% CI –1.52 to –1.20 points) on the CSS observed in participants
given HS (Figure 15) should be treated with caution because of the number of studies contributing data to
this analysis and the risk of bias discussed in Risk of biases across studies and Chapter 6, Strengths and
weaknesses of the systematic review.
Risk of bias across studies
Publication bias
A funnel plot (plotting standard error against the MD) was generated to further assess the risk of bias
across studies in relation to publication bias (Figure 16).
This is not a classically symmetrical funnel plot, in which the study with the smallest standard error (in this
case Sharma et al.82) sits at the top of the inverted funnel indicated by the dashed lines, which show the
expected 95% CIs around the FE summary effect. But neither does it show the typical absence of small
studies in the bottom right-hand corner, characteristic of meta-analyses affected by publication bias,121
although there are fewer studies to the right-hand side of the Sharma study82 than one would expect.
Instead, we see four studies with comparatively small standard errors outside the dashed lines. These
include the second and third largest studies (Sharma82 and Teunissen,86 respectively) as well as the two
studies by Luo and colleagues.79,80 A plausible explanation for this shape may be the high levels of
heterogeneity discussed in Primary outcome: results and synthesis.121
Outcome reporting bias
The results of the steps suggested by Dwan et al.95 can be seen in Table 25.
The primary outcome was scored as ‘high risk’ for outcome reporting bias for one of the studies, owing to
hospital LoS being stated as a secondary outcome, but no results were reported.95 The majority returned a
score of no risk (rate of readmission) or low risk/no risk where outcomes had been measured but partially
reported, not necessarily analysed or not measured or analysed. Outcome reporting bias is concluded to be
low for the review outcomes.
TABLE 24 Final CSS scores in both groups
Main author
Intervention Control
Mean SD
Number of
participants Mean SD
Number of
participants
Giudice et al., 201277 6.5 1.6 52 7.7 1.6 54
Tal et al., 200623 5.35 1.3 21 6.45 1 20
Luo et al., 201079 1.50 0.50 50 2.9 0.7 43
Luo et al., 201180 1.7 0.6 57 3.1 0.7 55
Teunissen et al., 201486 3.87 (3% HS) 3.15 (3% HS) 84 (3% HS) 4.61 5.38 80
5.16 (6% HS) 4.20 (6% HS) 83 (6% HS)
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Chapter 6 Discussion
Main findings
The addition of nebulised 3% HS every 6 hours to usual care when treating infants admitted to hospital
with acute bronchiolitis does not have discernible beneficial or harmful consequences when compared
with usual care. In particular, the distributions of time taken for infants to be assessed as being fit for
discharge were almost identical between the two arms, as was the actual time to discharge; the
pre-specified minimum clinically important difference (18 hours or a 25% relative reduction) was at
the very edge of the 95% CIs. Furthermore, the data showed no statistically significant differences
in regards to readmission rates, admission to HDU/ICU or reported morbidity in the month following the
acute illness.
There was considerable statistical heterogeneity in the analysis of the systematic review’s primary outcome,
LoS (I2= 75%), reflecting underlying clinical and methodological heterogeneity and indicating that formal
pooling of studies is not a sound basis for decision-making in this instance.
The CUA estimated small and statistically insignificant differences in costs and QALYs between the control
and intervention groups. The resultant ICER of £7.6M per QALY gained is the result of the very small
difference in QALYs. When the uncertainty around the costs and QALYs is considered, nebulised saline has
only a 34% chance of being cost-effective. This estimate may be considered high, given the very high ICER;
however, it is completely in keeping with small differences associated with great uncertainty: there is
approximately a 50% chance of it being cost-saving and approximately a 50% chance of it being effective.
Based on this analysis, it is clear that the use of nebulised saline in this patient population is not cost-effective.
Strengths and weaknesses
Strengths and weaknesses of the trial
The sample size was calculated based on a difference in mean times but analysed using Cox regression.
Although not ideal, doing so enabled us to calculate a minimum clinically important effect size in absolute
units while analysing the data by methods which allow both for the likely skewed data and for any loss to
follow-up. We presented both absolute and relative differences between time to fit for discharge and time
to discharge. In the event, the use of Cox regression was unnecessary; only one patient had partial
notes available.
Some readers may consider the absence of blinding a potential limitation of the study. A number of
previous studies involving HS and other nebulised interventions such as the antiviral agent ribavirin have
used a randomised blinded approach using either distilled water or NS as the nebulised placebo agent.
These approaches have been criticised because hypo-osmolar distilled water can induce bronchoconstriction,
thereby hindering the infant’s recovery, while proponents of hypertonic therapy have argued that failure to
show a difference when compared with nebulised NS is because of the beneficial effects of the depositing
NS in the lower airways.26 The SABRE study team consider the use of an open pragmatic study design a
strength, in that it avoids potential confounders and determines whether or not the use of nebulised HS
may have a place in routine clinical practice. We believe that the primary outcome, assessed through
routine records of hourly oxygen saturations, is robust against the risk of bias, regardless of the absence of
blinding. To introduce systematic bias would have required multiple nurses across shifts and across 10 sites
deliberately falsifying routine observations, which we do not believe is credible.
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Among the strengths of this study was the multicentre design using teaching hospitals and district general
hospitals, which ensures that the results are generalisable to all paediatric secondary care units admitting
such infants while the numbers of subjects recruited are such that there can be considerable confidence
in the conclusions drawn from the data. Moreover, the study was designed to assess the potential role
of this intervention in the most severely affected infants, namely infants admitted to hospital requiring
supplemental oxygen therapy. Such patients place a significant burden on the NHS and other health-care
systems around the world. This is because of both the large numbers of infants admitted to hospital every
winter and the duration of their hospitalisation which is significantly prolonged when compared with a
median acute paediatric stay of around 24 hours. Hence they place a significant burden on paediatric
units in terms of bed-days occupied. Nebulised 3% HS was used because this was the concentration used
in the majority of previous studies and because there is a commercial product on the market being sold for
this indication. For comparison, the concentration of salt in blood is 0.9% and that in sea water is 3.4%
(range 3.2–3.8%).
Attrition rates were low for this study, although follow-up for some secondary outcomes was less
satisfactory. Only 49 out of 149 participants returned the diary and ITQoL in the control group and only
54 out of 141 did in the intervention group. Of 142 participants from the control group, 40 were not RSV
tested; in the intervention group 39 out of 149 were not tested.
Strengths and weaknesses of the economic analysis
There are some uncertainties in the health economic analysis. LoS data were missing for one patient, and
after excluding those with only limited resource use we have 64% missing data relating to primary care
use. We also elected not to include the costs of concomitant medications into estimates. However, it is not
considered plausible that any of these will materially affect the results of the CUA. Uncertainties around
unit costs for the major cost drivers were explored in sensitivity analyses and were found to have no impact
on the results, owing to the lack of any differences in LoS.
There are also some uncertainties with the methods employed. The two most important relate to
hospital cost calculations and the utility values. In terms of the hospital costs, the cost per day figures
shown in Table 2 are derived from NHS Reference Costs 201352 by dividing the relevant total cost by the
number of hospital days. It is well recognised that, in some circumstances, such average costs will not
accurately represent the costs attributable to a marginal change in the LoS. In other words, the cost
of a patient’s final day in hospital is different from the average because typically they are less unwell
just prior to discharge. Although this argument is relevant to surgical and long-stay patients, it is not
thought to be particularly pertinent to the patient population within this trial. It should also be recognised
that these costs are economic, not financial; they represent the value of the resource rather than an
identifiable expenditure.
The utility values used in the analysis are probably best described as notional. The generation of utility
values for such a young population is extremely challenging and it would take a separate study to
produce values that would be considered robust. Given the context of the study – a cheap intervention
and large cost reductions associated with any reduction in LoS – the methods employed were considered
appropriate. It could be argued that the use of a generic hospitalisation decrement might underestimate
the impact of a severe, acute condition. However, the utility value for ICU hospitalisation was only slightly
lower (0.87 vs. 0.94)57 and, so, even using this much more severe health state would have no significant
effect on the results or conclusions. There is one further methodological uncertainty associated with the
utility values from Saigal et al.,57 which is that, while the authors describe their results as population values,
the description of the elicitation task used does not make it clear whether the responses relate to those of
a parent, those of a patient or a mixture of both. Consequently, in the light of the clinical results of the
study, and the lack of robust evidence of a difference in LoS, it could be argued that the estimated QALY
differences should be ignored.
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The limitations of the utility estimates were highlighted at the design stage of the study and so, to guard
against an over-reliance on the CUA and resultant ICER, we proposed that a CCA also be undertaken.
In contrast to a CUA, a CCA does not focus on a single measure of outcome (i.e. the QALY) or produce a
single definitive measure of cost-effectiveness (i.e. the ICER). A CCA is merely the comparison of costs
and all relevant outcomes between the two arms of the study. As such, it requires readers to make their
own assessment of whether or not the differences in outcomes are valued more highly than the costs.
In the context of the SABRE study, the relevant outcomes are defined by the protocol as primary and
secondary outcome measures: time to fit for discharge, actual time to discharge, admission to ICU/HDU,
readmissions, duration of respiratory symptoms, health-care use, infant/parental quality of life and AEs.
Across all these measures there is only one statistically significant difference between the study arms,
relating to the family cohesion domain of the ITQoL. Given that no allowance has been made for multiple
significance testing and the ITQoL result relates to a small self-selected subsample of the trial population,
the robustness of this difference is open to question. Consequently, the CCA simplifies down to the cost
difference reported in Chapter 4 (£132; p= 0.694) and no evidence of patient benefit.
Less importantly, another source of uncertainty is that the additional staff time required to manage a
patient while on a nebuliser was not included in our analysis. Therefore, the costs in the intervention
groups would be considered to be underestimated, albeit by a small amount.
Finally, the analysis employed a time frame of 36 days post randomisation, rather than the planned 28 days.
This was because one patient had a time to discharge of 857 hours (35.7 days) and, thus, there were
important costs beyond the time frame of the planned analysis. In order to conform to NICE economic
evaluation guidelines, the time horizon of the analysis was adjusted to the first whole day following
discharge of all patients. A sensitivity analysis was conducted that truncated time to discharge at 28 days
and this did not have any noticeable impact on the results or conclusions.
Strengths and weaknesses of the systematic review
The results of the systematic review are problematic to interpret because of high levels of statistical
heterogeneity. While it was not within the scope and resources of our review to investigate this between-study
variation with a formal meta-regression, some notable sources of clinical and methodological heterogeneity
may provide an explanation (Table 26). Across intervention subgroups, some of this heterogeneity may be
explained by the presence of concomitant medications, with the effect of HS being largest in trials in which
concomitant medications were not given. This notwithstanding, two trials conducted in China with small
sample sizes (n= 9379 and n= 11280) but small standard errors appear to be driving the I2 value (see Chapter 5,
Results and meta-analyses). As the quality of the studies seems adequate, it may be unfair to assume that
there is some kind of fault with the individual trials. On the other hand, with the funnel plot (see Figure 16)
suggestive of publication bias, it may be that there are a large number of trials missing as a result both of our
restrictive eligibility criteria (the inclusion of only English-language publications) and of the documented
publication bias associated with certain countries.122
The systematic review was restricted to English-language articles because of the time and resource
available for this review. The effect of this eligibility criterion has unknown consequences for the effect
size, precision, heterogeneity and overall risk of bias associated with our meta-analysis. Although such
restrictions can be seen as acceptable,123 we acknowledge the resulting exclusion of two trials of definite
relevance at the full-paper stage68,69 and eight studies of possible relevance at the abstract stage59–64 is a
limitation.124 The use of language restrictions in systematic review-based meta-analyses is not always
thought to cause systematic error, although it will potentially reduce the precision of pooled estimates.125
The availability of adequate primary outcome data for all but one of the studies was a strength of the review,
allowing for meta-analysis, subgroup analyses and investigation of publication bias. However, complete
data were not available for all secondary outcomes or on features of trial design. The availability of more
complete trial data may have enabled investigation of the underlying causes of statistical heterogeneity through
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TABLE 26 Summary of potential sources of heterogeneity as discussed in text
Source Example Potential impact
Diagnostic l UK and others – infant with LRTI associated
with a respiratory virus and widespread crackles
l USA and others – first episode of wheeze with
a viral respiratory tract infection
l US definition tends to result in studies with
slightly older infants and toddlers, most of
whom would have a wheezy bronchitis, some
of whom may have asthma
l Severity of airways obstruction likely to be
greater in UK definition cohorts as reflected in
need for oxygen therapy
l This may influence ability of aerosol to
penetrate to distal lung
Management l Review of studies shows marked differences in
severity of those admitted ranging from mean
saturation of 97% (normal)83 to 90%.85 Many
studies do not provide this objective assessment
of physiological impact
l Historical studies show marked differences in
duration of hospitalisation14 from a mean of
approximately 3–4 days to 8–9 days with
no evidence of difference in severity of
those admitted
l Studies such as that of Wu et al.100 suggest
significant differences in the rates of admission
and LoS even between hospitals in the same
health-care setting and apparently using the
same protocols
l Studies by Luo et al.79,80 have a huge impact
on the systematic review. These studies
illustrate the heterogeneity of outcomes in that
those in the milder study group had a longer
LoS than those in the severe group (7.4 days
vs. 6.4 days in non-intervention groups).
The duration of stay was significantly greater
than in the UK in all groups including the
intervention groups
l Despite lack of any evidence, many countries
and studies have used agents such as
adrenaline or salbutamol
l Again, severity may influence effect of an
inhaled agent but such mild patients would not
be admitted in UK
l Longer stays are associated with increased
nosocomial infection
l Lack of objective criteria can permit subjective
decisions regarding discharge
l The probability is that this should not impact
on results but it is just possible that synergistic
effects results in a positive impact when
individually the interventions have no effect
Outcomes l Different outcomes are used as primary
outcomes such as LoS and severity scores.
l Severity scores are widely used but have not
been robustly validated, particularly when used
by multiple observers
l From a health-economic perspective the LoS is
a key outcome. Amelioration of symptoms
should not be ignored, but there is no robust
evidence that severity scores reflect the distress
the infants experience any better than objective
criteria such as oxygen saturation
Publication
bias
l Studies fall outside dashed lines indicating
95% CIs in funnel plots (see Figure 16)
l A major source of potential bias in any
systematic review and appears to be even more
prevalent in some countries than others
LRTI, lower respiratory tract infection.
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
80
metaregression,126 although this is not recommended when adequate data are only available for fewer than
10 studies.76 It seems likely that disease severity and concomitant medications as well as local service
configuration may be affecting between-study variation in effect size, but there are several other potential
sources of heterogeneity which severely limit the use of aggregated level meta-regression analyses. In the
absence of extensive individual patient data, the impact of these must remain speculative.
Unsuccessful attempts were made to contact trial investigators of one unpublished study74 to request additional
unreported data. Although studies would not have been excluded based on the primary outcome, all but one
of the studies were appropriate to be included in the meta-analysis of the primary outcome of interest, LoS.
A number of the domains in the risk of bias assessment could not be assessed because of inadequate
reporting. The biggest issue was with the ‘selective outcome reporting’ domain for which the absence of
published protocols or responses from study teams made it difficult to assess pre-specified outcome measures.
Attempts to contact the authors of one trial were unsuccessful,74 and the data retrieved from another author
were of limited utility, being only in abstract form.84 Similarly, incomplete and heterogeneous reporting the
analysis of the final CSS score involved only five studies. Finally, there were two trials with three arms, in each
case an arm with no HS, a 3% HS arm and an arm with a higher concentration of HS, either 5% (Al-Ansari) or
6% (Teunissen). We chose to compare both doses against control rather than combine them into one arm,
since this might have helped in understanding and explaining some of the heterogeneity – although it seems
unlikely that concentration of HS alone would explain all of the heterogeneity.
The synthesis of the systematic review’s primary outcome (LoS) is not in itself straightforward. The included
studies were conducted in different countries and health-care settings with local guidelines on the assessment
of infants as fit for discharge. No study reported on whether or not investigators adhered to these guidelines.
We have no way of telling whether or not the difference between fitness for discharge and actual discharge
(caused by the time and day of, consultant availability, etc.) was even across study arms, with only one study
acknowledging this as a limitation.23 Certainly, the definition of discharge fitness criteria differed across the
trials – as indeed did the starting point, being sometimes from admission, sometimes from randomisation and
sometimes from treatment start.
Of the 14 studies in the review, two of the studies reported hospital readmission rate. As previously
discussed, this is an outcome of clinical relevance, certainly in the UK, as suggested by SIGN4 and NICE, but
only two of the trials (both of which were non-UK based studies) reported on this outcome, which has
potential health and economic implications. The Outcome Reporting Bias In Trials (ORBIT) classification
(see Table 25) showed that the majority of readmission rates were classified as I (no risk of outcome bias),
as this was potentially not considered important by trials included. However, lack of readmission data may
mean that although the treatment is effective in the short term, patients are being readmitted and,
therefore, the intervention may not be as economically beneficial as the summary result suggests. AEs may
also be omitted by this scenario.
Overall, the defining feature of this systematic review is its heterogeneity, which limits any attempt to
synthesise the evidence. The dissimilarity of the SDs of LoS indicates that the studies have taken place in
very different settings. Two trials (n= 9679 and n= 11280) reported SDs of less than 1 day, indicating
that their patients were typically discharged within a reasonably short time of each other. At the other
extreme, the SABRE study and the other large northern European study86 reported SDs of over 3 days.
This has consequences for the statistical analysis, as larger SDs lead to less study weight. The SABRE
study87 contributed less than 4% of the total weight, despite being the largest of the 15 studies in the
meta-analysis, and the Teunissen et al. study86 (n= 247) contributed 7.1% of the weight. The fact that
large trials are contributing so little weight is counterintuitive and makes any overall summary of the
15 trials highly contentious. Of the possible sources of heterogeneity, the background care (in particular,
concomitant medications) seems a likely explanation for at least some of these differences. In view
of the number of ways by which the studies differed, however, we have not undertaken any formal
meta-regression to attempt to explain this.
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The question of whether to favour a FE or RE approach for the analysis – and for meta-analyses in
general – is a controversial and unresolved issue.92,127,128 The FE assumes a common underlying effect of
treatment, which is highly questionable in the presence of heterogeneity.92 The RE approach reweights
studies to incorporate both the precision of the individual trial and the variability among trials into the
weighting, but as a consequence all studies receive similar weights when between-trial variability is
excessive and unexplained.129 Neither approach seems satisfactory for situations such as this, and indeed
we recommend against using an overall average however calculated. Rather, we suggest that the reader
consider the specific setting within which each study was undertaken and apply findings only of those
which appear consistent with their own setting.
Doing so, our recommendation for the UK NHS setting is unequivocal: hospital stay is not affected by
adding HS to the care package. Although findings varied across the trials identified by the systematic
review, the trials carried out in systems most comparable to the UK demonstrated almost zero difference
between HS and the control treatments. The findings within our own trial were consistent across the
10 centres that recruited into the trial. Patients testing positive for RSV tended to remain in hospital longer
than those testing negative, but HS did not appear to act differentially between the two subgroups.
The trial in context – other studies and differences in results
The SABRE study
This study was designed to understand the effects of regular nebulised 3% HS on reducing the time until
an infant is ready for discharge and does not address another disputed and key question. We were
precluded from assessing whether or not 3% HS provides short-term temporary symptomatic relief due to
the lack of blinding and the subjective nature of current scoring systems; previous studies have shown a
correlation between scores produced with, for example, the Wang score and objective physiological
assessments such as those obtained with pulse oximetry.78
The results presented in the SABRE study appear to conflict with the conclusions of a Cochrane review and the
update to it presented herein.25 The review reported a significant reduction in the LoS of patients admitted with
acute bronchiolitis.25 Of the five studies included, two were conducted by the same group (but with different
patients), with Tal et al.23 (n= 41) being an extension of the original study from Mandelberg et al.22 (n= 52).
The same centre has also published a positive study in a group of ambulatory subjects. Two studies followed
from China,79,80 using 0.9% or 3% saline to deliver salbutamol in ‘mild to moderate subjects’ and 0.9% or 3%
saline apparently without salbutamol in more severe patients. The severity of entry was assessed using the
Wang score but there is no report of saturations, need for oxygen therapy or other assessments of severity.78–80
Although the LoS was reduced in the group treated with 3% HS (twice hourly for three doses, four times
hourly for five doses, then six times hourly) the mild to moderate group had a significantly longer stay than the
moderate to severe group (7.4 days vs. 6.4 days in the 0.9% HS treated groups).79,80 It is of interest to see how
many studies use the Wang scoring system despite the conclusion in the abstract from the Wang et al.
publication that ‘the limited agreement for clinical signs makes comparison of patient illness severity between
studies difficult’.78 This is one of the reasons that we did not use scoring systems, as they are not validated
and almost certainly generate fewer robust data than, for example, the saturation recorded in room air and
duration of oxygen therapy. One study from Italy reported a decrease in LoS when 0.9% or 3% HS was used
to nebulise adrenaline but, interestingly, not a single patient was discharged prior to day 4.77 The final study
included 64 patients from the United Arab Emirates and 32 from Canada, with LoS being defined by a
physician as being ready for discharge.24
One study83 reporting a non-significant difference in LoS in those treated with 0.9%, 3% and 5% HS
involving 165 patients was left out of the inpatient analysis in the Cochrane review58 for reasons that are
unclear. These relatively mild patients were admitted to a short stay unit, with a short stay being defined as
fewer than 8 days, so in effect they were hospitalised.83 Two studies, which had been presented in 2011
as abstracts, that failed to identify a significant difference in LoS were also not included. One study from
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The Netherlands involving 160 subjects found no difference in LoS when 0.9%, 3% and 6% saline
nebulised four times hourly were compared,130 while an Italian study involving 30 patients comparing
2.5 ml of 0.9% saline with 7% saline plus 0.1% hyaluronic acid at a dose of 2.5ml twice a day for 3 days
was also negative for the primary end point of LoS.112
Since the Cochrane review25 was published, results from a number of studies have consistently found no
reduction in hospitalisation rates from the use of HS. These include 250 participants from a comparison of
0.9% and 3% HS reported by Sharma from India, 82 participants from an Argentinian study comparing
the same interventions and 40 participants from a second Indian study also comparing the two
interventions.74,81,82 Another study from Georgia was reported in abstract form in 2013, in which HS was
associated with a reduction in LoS of half a day (albeit not statistically significant) in comparison with NS.84
The abstract states that 42 patients were randomised, but it does not state the number in each group, or
how many were included in the analysis. Since this study would account for at most 2% weight in a FE
analysis, we have excluded it from this analysis. Thus, in total, 455 patients have participated in studies
which have failed to show an impact on LoS, in addition to the 291 participants included in this study.
Sources of heterogeneity
In undertaking this systematic review it has become apparent that there are a number of semantic,
methodological and cultural differences across the studies, all of which impact on the results obtained and
the generalisability of an individual trial’s findings. We propose some of these factors and offer an
explanation for how these may impact on the interpretation of the review’s findings.
1. The definition of ‘acute bronchiolitis’
The definition of ‘acute bronchiolitis’ differs between countries and indeed across clinicians in the same
institution. Inevitably this diversity was reflected in the description of infants included, which variously
specified wheeze and/or crackles (n= 4);24,83,86,87 a first episode of wheezing (n= 5);77,79,80,82,85 ‘bronchiolitis’
(n= 4);23,88,81,90 or bronchiolitis with a temperature > 38°C (n= 1);22 while information was absent in four
others.74,75,84,89 The term ‘wheeze’ is itself open to interpretation (and sometimes misinterpretation) within
the medical profession;131–135 using this as a criterion may have led to the inclusion of asthmatic patients
in whom bronchospasm is a feature. Pre-school children who are wheezing and who have a respiratory viral
infection are more likely to have a ‘wheezy bronchitis’ than asthma, but among school-age children the
opposite is true. Therefore, patients with clear wheeze and no (or few) crackles are likely to include a number
of patients experiencing their first exacerbation of asthma and a much larger number of patients with what
might be termed wheezy bronchitis – patients with a viral bronchitis who wheeze due to airways oedema and
intraluminal secretions but without significant bronchoconstriction. The risk of including asthmatic subjects is
therefore reduced by concentrating on the younger patients. Five studies limited inclusion to children under
12 months22,23,85,87,88 and a further two studies included up to 18 months;24,83 the remainder extended up to
24 months.74,75,77,79–81,84,89,90,86 The mean age at study entry varied from 2.3 months to 8.61 months. This may
have impacted the findings in the two Luo et al. studies79,80 (mean ages between 5.6 and 6.0 months),
although positive results were also reported in the studies with the youngest mean age (mean ages between
2.3 and 3 months).22,23
The patients included in this study met the definition of acute bronchiolitis as used in the UK, Australia and
parts of Europe. In these health-care settings, the term ‘acute bronchiolitis’ refers to an infant with an apparent
viral infection who develops signs of lower respiratory tract disease with airflow obstruction manifested as
increased work of breathing, hyperinflation of the chest and widespread crackles; they may or may not
intermittently exhibit wheeze. Clearly, however, there are considerable differences in setting and in the types
of patients included in different studies, with many RCTs of HS involving patients seen in the emergency
department and the use of wheeze as the key criteria for making a diagnosis of acute bronchiolitis.
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By including both RSV+ and RSV– patients, we have been able to show that the viral status does not alter
the response to therapy and hence the results can be generalised to all units looking after infants with
acute bronchiolitis irrespective of whether or not the unit undertakes viral testing. Consistent with previous
studies, more than 85% of tested infants were positive for RSV.
2. Variation among discharge criteria
The consistency of the outcomes – specifically ‘length of stay’ and ‘fit for discharge’ – is self-evidently defined
and assessed in very different ways across the studies, as noted above. In our study, LoS was calculated as the
time between admission and leaving the hospital but this was not the case elsewhere. Studies set (sometimes
arbitrary) criteria regarding when the patient stay started, including ‘from study entry, which was within
12 hours of admission’ (n= 2);24,77 from hospital admission (n= 3);82,83,87 or from first dose of study medication
(n= 2);88,86 information was absent for the remaining 11 studies.22,23,74,75,79–81,84,85,89,90 The reported time to entry
into study varied from 3 hours to 24 hours and generally did not specify whether or not ‘entry’ corresponded
to consent or first treatment. Delays of up to 24 hours prior to entry into the study would represent a huge
proportion of admissions in units with mean stays of 72 hours or less.
The restrictive eligibility criteria in our trial resulted in the exclusion of a large number of infants who
would have been eligible in other trials. However, of much greater significance are the criteria used to
determine the end of the LoS period. There is an understandable desire to separate the impact of the
disease and/or treatment from extraneous social factors that may impact on a patient leaving the ward
(lack of transport, carers are ill, etc.) Hence, the studies have determined that the inpatient stay is
terminated at the point a clinician deems them to be fit for discharge.
This in turn carries two major components that will impact on LoS, namely how the decision is made that
a patient is fit for discharge and how often it is possible to make that decision. In our study we used a
definition which is calculated from the routine nursing observations recorded hourly for each patient, and
which can thereby be corroborated. Elsewhere, discharge criteria are largely determined by the prevalent
medical culture within their setting. In one study,87 a continuous discharge criteria was used, but in at least
five studies the decision to discharge was made only once a day,22,23,79,82,85 meaning the time of discharge is
effectively a discrete outcome which occurs at intervals of 24 hours. This inevitably overestimates the real
time taken to be fit for discharge. It is far from obvious if this overestimation would affect the treatment
groups differentially, but we note that most of the positive studies are based on a once-daily clinical
assessment. In the remaining studies the frequency of assessment for discharge was unclear.
The criteria for discharge ranged from in air of oxygen saturation 92% or greater (equivalent to a severe
rating – greater than 8.9 points on theWang et al. scale) and oral feeding > 75% of usual intake87 to no
respiratory signs or symptoms for the previous 12 hours.79,80 In countries with relatively short LoS, discharge was
based largely on in-air oxygen saturation 92% or greater87,136 or 93% or greater118 and taking sufficient oral feeds
to maintain hydration. In contrast, other studies,87,137 presumably based on local medical cultural convention,
specified variously that the saturation should be 95% or greater, although patients could go earlier on clinical
grounds; that the air saturation should be 96% or greater; or that the patient should be completely well with no
signs or symptoms. The criteria that patients should be free of any signs or symptoms is curious, as it has been
well documented that the symptoms associated with acute bronchiolitis persists for many days or weeks. In the
largest and most detailed follow-up of patients hospitalised for bronchiolitis,137 fewer than one-third were
symptom free by 10 days and the figure for those most severely affected was less than 10%. Clearly, therefore,
the criteria for discharge differ considerably across health-care settings, as previously noted by Becker et al.,47
who observed a marked variation in LoS of patients admitted with RSV bronchiolitis with very short admissions
(median approximately 72 hours) in North America, the UK and northern Europe compared with significantly
longer admissions in Germany and southern Europe. These longer admissions were associated with increased
comorbidities, such as diarrhoea, which may be as a result of nosocomial infection resulting from longer
admission times. This cultural difference is again noted, with none of the Italian patients in the study of Giudice
being discharged before 72 hours, a period beyond the mean ‘length of stay’ in the Dutch, UK and North
American studies.47,86,87 Finally, the subjects in the Luo studies with mild to moderate79 bronchiolitis remained in
hospital longer than those with more severe disease,80 a finding which is somewhat difficult to explain.
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
84
3. Publication, generalisability and other biases
This difference in practice may also, in large part, explain the differences in observed treatment effects in
the large UK, Dutch and North American studies which found no benefit compared with the apparently
large effect observed in other studies.86-88 While early indications of a potential benefit may have been
attributable to publication bias,138,139 the positive effects of later large studies may be attributable to study
design and cultural effects. The history of treatment of acute bronchiolitis is littered with therapies initially
embraced enthusiastically only to be found to have no impact when subject to more rigorous scrutiny.
Current guidelines, in essence, note that the management remains much as it did 50 years ago with good
supportive care based on correcting hypoxia, minima handling and ensuring adequate fluid intake. The list
of therapies suggested and subsequently abandoned include selective beta agonists, the non-selective beta
agonist adrenaline, the antiviral agent ribavirin, theophylline, physiotherapy, French physiotherapy, inhaled
and/or systemic corticosteroids and montelukast.4 It is of note that all the recent studies of HS have failed
to demonstrate any benefit, yet the meta-analysis still appears to favour the treatment. This effect is largely
driven by the relatively large studies of Luo et al.79,80 and it is likely that this is explicable when considering
discharge criteria in more detail (see 2. Variation among discharge criteria).
Since completion of the SABRE study, a study conducted in Scotland140 found that the use of oxygen
saturation of 90% for the initiation of oxygen therapy resulted in better outcomes and shorter LoS than
92% without any increase in readmissions or other complications, which makes studies in very different
cultural settings such as China of doubtful relevance to the UK and similar countries.
Strengths and weaknesses compared with earlier systematic reviews
As the results of both the SABRE study and our systematic review and meta-analysis contradict the findings of
the Cochrane review team, it is worth outlining the timeline over which these pieces of work have been
conducted. The first, the 2008 version of Zhang et al.’s Cochrane review25 included three inpatient trials that
were comparable to the SABRE study: Mandelberg et al. in 2003,22 Tal et al. in 200623 and Kuzik et al. in
2007.24 These trials suggested that HS reduced the MD in length of inpatient stay by –0.94 days (95% CI
–1.48 to –0.40 days; p= 0.0006), with no heterogeneity. The SABRE study grant application was made on
8 January 2010. The Zhang et al. Cochrane review25 was assessed as up to date on 6 June 2010. The SABRE
study commenced on 6 October 2011 and recruited its first participant on 26 October 2011. Although the
Cochrane website does not register this, the Zhang review was updated in 201171 to contain one additional
inpatient trial (a total of four trials) comparable to the SABRE study: Luo et al.79 At this time, HS appeared to
reduce the MD in length of inpatient stay by –1.16 days (95% CI –1.55 to –0.77 days; p< 0.00001), with no
heterogeneity. Finally, the review was updated by Zhang et al. in 2013,141 including two additional inpatient
trials, Luo et al. 201180 and Giudice et al. 201277 At this time they also included, in their review of studies
recruiting in the emergency department, a study which we have classified as an inpatient trial (Al-Ansari et al.
201083). We found the following studies that could have been identified by Zhang et al.’s searches in April,
week 4, 2013:141 Espelt in 201274 and Maheshkumar et al. in January 2013.81 In addition, the following studies
were captured by our review but were published after the Zhang et al. 2013141 update: Pandit et al. in
May 2013,85 Sharma et al. in 2013,82 Nemsadze et al. in 2013,84 Teunissen et al. in 2014,86 Silver in 2014,88
Ojha et al. in 2014,90 Ozdogan et al. in 2014,89 Sosa-Bustamante et al. in 201475 and Everard et al. in 2014.87
Overall, 11 additional studies (n= 1367 participants, excluding Sosa-Bustamante et al. in 201475 as the number
of patients randomised is unknown) were included in our review, eight of which were included in the
meta-analysis in addition to those in the Cochrane review 2013 update. Our systematic review protocol was
registered on PROSPERO on 3 March 2014 and the protocol was revised on 18 December 2014 following
peer-review comments. The searches for this systematic review were run up to 14 January 2015.
The meta-analysis in the 2013 update of the Cochrane review by Zhang and colleagues contained
six RCTs (n= 480) evaluating the effect of HS on length of inpatient stay, the largest of which randomised
112 participants.58 Our meta-analysis contains 15 RCTs (n= 1922), including three much larger studies,
all of which show null results. The eligibility criteria and search strategies of the two reviews differed, as a
result of which our review picked up a number of publications which, we believe, are relevant to clinical
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decision-making and which might have been picked up the Cochrane review team’s searches in
April–May 2013. With more than 10 studies, we were able to investigate the potential for publication
bias.76 Importantly, our meta-analysis also identified much higher levels of statistical heterogeneity
than those reported by the Cochrane team, beyond what would be expected from the addition of this
number of studies.142 The Cochrane review provided what might have seemed a secure basis for
clinical decision-making, suggesting that HS reduced inpatient stay by over 1 day (six studies, n= 480,
MD –1.15 days, 95% CI –1.25 to –0.15 days; p< 0.0001, I2= 30%). Our review suggests that the
evidence base is far more equivocal, heterogeneous and, with publication and other biases at work,
unsafe as a platform for decision-making (15 studies, n= 1922, MD –0.34 days, 95% CI –0.48 to
–0.21 days; p< 0.00001, I2= 75). In the long-run, the resources and standards of Cochrane may allow
non-English-language and unpublished studies not identified by, or excluded from, our study to be
incorporated into a research synthesis. Nonetheless, these salient differences, observed between closely
contemporary reviews, confirm that duplicate systematic reviews can sometimes be valuable143,144 rather
than wasteful.145
Meaning of the study and implications for clinicians or
policy-makers
The results from this study would suggest that there is no benefit to be gained by the introduction of
nebulised 3% HS into the routine care of infants with acute bronchiolitis. As such, it joins a long list of
other interventions that have been advanced as therapy only to be shown subsequently to be ineffective in
reducing the morbidity of this condition. These include selective beta-2 agonists, adrenaline, anticholinergic
agents, inhaled and systemic steroids, leukotriene antagonists, specific monoclonal antibodies and antiviral
agents. Management remains essentially as was the case more than 50 years ago, with good supportive
care, including oxygen when required, being the cornerstone of optimal care. A strength of this study is
the comparison with usual care, as a criticism of negative studies by those who are advocates of this
intervention is that nebulised NS in itself is a beneficial treatment. This cannot be argued in the case of this
study and it is hard to argue bias because the data regarding fit for discharge were obtained from the
routine nursing and clinical notes and if there were a bias it would be more likely be in favour of the
intervention, as many are keen to find an effective intervention. Those advocating HS may argue that the
current data suggest that HS is only beneficial when used with another agent such as adrenaline. Previous
studies have been heterogeneous in the use of co-therapies either specifying the use of drugs such as
adrenaline and salbutamol with the saline or permitting ‘physician’-ordered therapies. Studies of selective
and non-selective beta-agonists in the same setting as this study in the UK and Australia have failed to
show any benefit and, hence, one must argue that there is synergy producing a therapeutic effect when
neither alone appears to work. In the setting of very young infants with acute bronchiolitis in whom
bronchoconstriction does not appear to be a factor, it is hard to understand how this might work.
The 3% HS product used in this study, MucoClear® 3%, is currently on the market and being marketed
as an effective treatment for bronchiolitis. The Pari website notes ‘this can afford patients with acute
bronchiolitis or cystic fibrosis considerable relief’.146 Interestingly, the product was licensed not as a drug
but as a ‘device’, thereby avoiding the considerable regulatory hurdles posed by the drug regulators and
highlighting the low threshold for devices to become registered.
The robust data generated in this study and other recent studies do not support the suggestion that this
intervention be subject to any further studies either alone or in combination with other agents shown
not to be effective. The quest for an effective therapy may be fraught with difficulties because of the
intensity of the host neutrophil response at the time of presentation. For most infants the illness peaks at
around 24 hours after admission, plateaus and then resolves spontaneously. Viral titres and the intensity of
inflammation that viral replication induces appear to peak and then start to wane relatively soon after the
onset of lower respiratory tract symptoms which in part probably accounts for the lack of efficacy of antiviral
and anti-inflammatory agents. There is little to suggest that bronchospasm is a significant contributing factor in
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
86
the airways obstruction experienced during acute bronchiolitis while the intense neutrophilia is unlikely to
respond to steroid therapy. If an agent, be it antiviral or anti-inflammatory, were to be effective, it appears to
be likely that it would need to be administered during the interval between developing upper respiratory tract
symptoms and significant lower respiratory tract symptoms, the interval often being 2 to 3 days. However,
this is challenging. If the agent had general effects on the neutrophilic-dominated inflammation then viral
testing is unlikely to be required but if viral specific this would require rapid testing of all infants who develop
upper respiratory symptoms. Moreover, the number needed to treat in order to prevent an admission is likely to
be high, with less than 2% of all infants with a cold developing a lower respiratory tract illness of such severity
as to require hospitalisation and the risk being greatest in the youngest patients. This is reflected in the median
age of admission, in weeks, among patients recruited to this study. Much higher numbers develop a less severe
LRTI and there may well be benefit in addressing this morbidity above that gained from preventing admissions.
As yet no such strategy has been developed.
Recommendations for future research
1. There are a number of ongoing controlled trials evaluating the use of HS for acute bronchiolitis
(ClinicalTrails.gov NCT02233985 and NCT02029040). Updated systematic reviews and meta-analysis
will be required as results for these studies become available.
2. Meta-analysis of therapy trials in acute bronchiolitis is hampered by the use of different outcomes
between trials. Further research is needed, using the methods promoted by the COMET (Core Outcome
Measures in Effectiveness Trials) initiative,147 to produce a core outcome set for acute bronchiolitis. This
should include a validated severity score.148
3. The benefit of high-flow oxygen, used at one centre during this study, is still uncertain, although it is
rapidly being adopted in many hospitals in the UK and worldwide. An emergency care-based feasibility
study has confirmed that high-flow oxygen is safe and that a RCT is feasible.149 High-quality RCTs are
needed to definitively answer whether or not high-flow oxygen is clinically effective and cost-effective
compared with standard oxygen therapy in acute settings.
4. Although neither HS nor adrenaline is as effective as monotherapy for the treatment of acute bronchiolitis,
the meta-analysis indicates the possibility of a synergistic interaction. At present, statistical heterogeneity
suggests that the evidence base is insufficient to inform commissioning. The next update of the Cochrane
review will have access to non-English language publications and unpublished data excluded by our
review; this may result in the inclusion of sufficient studies to reduce statistical heterogeneity to levels
which are, by convention, considered satisfactory for decision-making (< I2= 50%). If this is not the case,
then the commissioning of a further large study evaluating oxygen and best supportive care with or
without combination HS and adrenaline may be warranted.
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Chapter 7 Conclusions
The results from this large pragmatic study indicate that the addition of nebulised HS to good supportive carewhen treating infants admitted to hospital with acute bronchiolitis does not appear to cause any harm but
confers no benefit. The economic analysis used two forms of analysis to consider the cost-effectiveness of
nebulised HS in this patient population. A CUA based on hospital costs and patient health-related quality of life
suggests a 34% chance that the intervention is cost-effective and an ICER of £7.6M per QALY is gained. This
figure is generated by an estimated additional cost associated with the intervention and an estimated incredibly
small additional patient benefit, both of which are highly uncertain. Based on this analysis, the intervention
cannot be considered either clinically effective or cost-effective in the UK health context. Taking a broader view
of benefits that includes any of the primary and secondary outcomes measures does not appreciably alter
this conclusion, as only one statistically significant difference between the study arms is apparent with that
result being open to considerable biases. Our updated systematic review suggests that there is too much
heterogeneity to make a pooled estimate of effect across 13 studies of inpatient care a useful basis for
decision-making and shows that large studies, and those from northern Europe, have negative results which
support the findings of the SABRE study.
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Appendix 1 Changes to protocol
TABLE 27 Changes to protocol
Changes to protocol Progress report Date Approved by
Protocol Version 0.1 (28 June 2011)
The amendment related to the following:
1. The primary outcome definition for fit for
discharge was amended from 12 hours to
6 hours. After discussion with participating
centres it was felt that 12 hours did not reflect
current practice. This was agreed by the TMG
and TSC chairperson
2. The time allowed to obtain fully informed
consent was amended from 60 minutes to
90 minutes after agreement at a TMG
that 90 minutes would be more practical
in the clinical setting
1 (dated
1 February 2012)
8 August 2011 NRES Committee
Yorkshire &
Humber –
South Yorkshire
Protocol Version 2 (28 September 2011)
This amendment related to the following:
1. The exclusion box on the CONSORT flow chart
was amended to provide clarity and reflect
the CONSORT statement requirements for
trial reporting
2. Additional text was added to clarify collection of
anonymised screening data required to inform
the CONSORT flow chart
1 (dated
1 February 2012)
7 October 2011 NRES Committee
Yorkshire &
Humber –
South Yorkshire
Protocol Version 3 (6 October 2011)
This amendment related to the following:
1. Clarification that the research nurse, not a
clinical nurse, will make the follow-up
telephone calls
2. The CONSORT chart was amended:
– The daily symptom diary box was reworded
from ‘for 28 days’ to ‘within
28 days’ for clarity
– The first follow-up telephone call ‘Approx.
14 days’ had been excluded in error
3. The nebuliser PARI LC Plus (PARI Medical Ltd,
Surrey, UK) was discontinued by the company
and they upgraded the model to the PARI Sprint
4. It was clarified ‘the saline will be discontinued
once oxygen therapy has been discontinued’
as this had not been explicitly stated in the
protocol previously
5. Clarification of one of the inclusion criteria –
‘Requiring supplemental oxygen therapy ON
ADMISSION’. This was stated on the CONSORT
chart but had not been explicitly stated here
6. Clarification of the wording for admissions to
HDU/ICU – ‘Admission per se of a study
participant to the HDU and/or ICU as a result of
normal clinical diagnosis of acute bronchiolitis will
be reported as an expected event not as a SAE’
1 (dated
1 February 2012)
13 October 2011 (REC
acknowledgement letter)
NRES Committee
Yorkshire &
Humber –
South Yorkshire
continued
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TABLE 27 Changes to protocol (continued )
Changes to protocol Progress report Date Approved by
Protocol Version 4 (17 November 2011)
This amendment related to the following:
1. Further clarification of when the saline should
be discontinued after discussion at a TMG
meeting – wording amended from ‘the saline
will be discontinued once oxygen therapy
has been discontinued’ to ‘the saline will be
discontinued once the “fit for discharge” criteria
has been met – in air for 6 hours with oxygen
saturations of at least 92% and feeding
satisfactorily’
2. Clarification that the study is unblinded.
Wording amended from ‘The study will compare
the addition of the intervention to usual care
without placebo’ to ‘The study is unblinded and
will compare the addition of the intervention to
usual care without placebo’
1 (dated
1 February 2012)
24 January 2012 (REC
acknowledgement letter)
NRES Committee
Yorkshire &
Humber –
South Yorkshire
Protocol Version 5 (6 August 2012)
This amendment related to the following:
1. The issue of deviations and violations outside
90 minutes was addressed. The protocol has
been simplified to ensure eligible babies
who are admitted on oxygen are recruited
within 90 minutes of admission. The web-based
randomisation system was also altered to limit
the number of deviations that can occur outside
90 minutes. Additional definitions were also
clarified in the protocol
2 (dated
1 October 2012)
12 September 2012 NRES Committee
Yorkshire &
Humber –
South Yorkshire
Protocol Version 6 (1 November 2012)
This amendment related to the following:
1. Clarification of permitted medications for trial
participants, to reflect local practice and how
these should be recorded
2. Inclusion criteria amended to clarify which staff
can make ‘the decision to admit’ in order to
begin the 90-minute consent/randomisation
window. Wording also amended on CONSORT
chart and the flow chart for consent and
randomisation to correlate with the inclusion
criteria
3. Protocol non-compliances ‘Deviations and
Violations’ section removed in line with
recent guidance
4. Clarification of which staff grades are able to
recruit to the trial
3 (dated
1 April 2013)
21 November 2012 NRES Committee
Yorkshire &
Humber –
South Yorkshire
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TABLE 27 Changes to protocol (continued )
Changes to protocol Progress report Date Approved by
Protocol Version 7 (11 January 2013)
This amendment related to the following:
1. Extension of the eligibility criteria for inclusion of
patients in the trial. Previously, in order for
patients to be eligible for inclusion in the trial,
they were required to be consented and
randomised within 90 minutes of a decision
to admit a patient to an inpatient ward. This
amendment extended the time-based eligibility
criterion to 4 hours. This change was proposed
for two main reasons
2. A substantial number of included trial patients
have retrospectively been identified as protocol
violations as they were randomised outside
this 90-minute cut-off point (approximately
50/172 patients randomised)
3. There is no clinical rational basis for assuming that
patients randomised in less than 90 minutes and
patients randomised between 90 minutes and
4 hours are clinically different. Previous inpatient
trials of saline in paediatric acute bronchiolitis
have not included a strict time-based cut-off point
for inclusion, as is currently operated in this study.
This extension of eligibility was supported by
the funder for the study (HTA) and also has the
support of the study sponsor. The actual changes
to the protocol are to change the eligibility
criterion from consent and randomisation within
90 minutes to consent and randomisation within
4 hours. The CONSORT chart, inclusion criteria,
protocol non-compliances, randomisation and
flow chart for consent and randomisation were
updated to reflect this
3 (dated
1 April 2013)
8 February 2012 NRES Committee
Yorkshire &
Humber –
South Yorkshire
Protocol Version 8 (4 June 2013)
This amendment related to the change in chief
investigator from Professor Mark L Everard to
Dr Kelechi Ugonna
4 (dated
1 October 2013)
23 July 2013 NRES Committee
Yorkshire &
Humber –
South Yorkshire
NRES, National Research Ethics Service; REC, Research Ethics Committee.
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Appendix 2 Symptom diary
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Appendix 3 Flow chart for consent and
randomisation
Infant at home
GP
CONSENT
DO NOT CONSENT
OR RANDOMISE
DO NOT RANDOMISE
YES YES
YES
NO
NO
NO
RANDOMISE
Emergency
department
HDU/ICU
(from Emergency 
department or 
Assessment/
Observation Unit)
DECISION TO ADMIT made by
medical paediatrician or paediatric
Advance Nursing Practitioner
(clock starts)
Is the need for oxygen
recorded at the time of
the decision to admit?
Assessment/
Observation Unit
Can you complete
consent/randomisation within
4 hours of decision to
admit?
Have > 4 hours
elapsed since the decision
to admit?
FIGURE 17 Flow chart for consent and randomisation.
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Appendix 4 Statistical analysis plan
Introduction, study design and objectives
Study background
The SABRE study is a parallel-group, RCT comparing whether or not the addition of 3% HS to usual
supportive care results in an improvement in outcomes for infants admitted to hospital with acute
bronchiolitis. It is funded by National Institute for Health Research HTA programme and sponsored by the
Sheffield Children’s Hospital Trust.
The trial has one main objective and three secondary objectives.
Primary objective
Investigate whether or not the addition of 3% HS to usual supportive care results in an improvement in
the time to being declared ‘fit for discharge’.
Secondary objectives
1. Assessment of the impact of the intervention on other clinical outcomes and the quality of life of
infants and carers at 28 days post randomisation.
2. Investigate the impact on outcomes between those infants with human RSV infection and those with
acute bronchiolitis due to other causes, including other viruses (non-RSV).
3. Assessment of the economic impact of the intervention on both the NHS and parents at 28 days
post randomisation.
Following consent, infants admitted with acute bronchiolitis will be individually randomised to one of
two groups:
l standard supportive care
l standard supportive care plus nebulised 3% HS solution.
This statistical analysis plan is written in conjunction with the International Conference for Harmonisation
E9,150 applicable standard operating procedures from the Sheffield CTRU and trial documents (protocol and
data capture forms).
Outcome measures
Primary end point
The primary end point is the time that the infants are declared ‘fit for discharge’, which will be judged to
be when the infant is feeding adequately (taking > 75% of usual intake) and has been in air with a
saturation of at least 92% for 6 hours.
Secondary end points
1. Actual time to discharge.
2. Admission to ICU/HDU.
3. Readmission within 28 days from randomisation.
4. Duration of respiratory symptoms post discharge and within 28 days from randomisation.
5. Infant and carer quality of life using the ITQoL at 28 days following randomisation.
6. Health-care utilisation, post-discharge and within 28 days from randomisation.
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Sample size, randomisation, blinding
Sample size
Based on a current time to discharge criteria of around 3 days, a 25% reduction was considered to be the
minimum clinically significant effect. This was thought to be a realistic effect, as it is the magnitude of
the effect observed in previous studies.47 Using Hospital Episode Statistics data relating to LoS, and
assuming a log-normal distribution, the SD is estimated at 32 hours. While a similar, or smaller, SD is
expected for our primary outcome measure, a slightly inflated SD of 46 hours is used because of
uncertainties over its derivation here. In order to have 90% power to detect a 25% difference in time to
meeting discharge criteria, the study will need 139 patients per group at a two-sided alpha level of 5%.
The dropout rate is thought to be negligible for the analysis of the primary outcome measure and
therefore a conservative estimate of sample size is 150 patients per group. It is expected that up to eight
centres will recruit patients into the study. Assuming that all eight recruit a similar number of patients,
each site would be expected to recruit approximately 38 patients.
Randomisation
A central web-based randomisation service delivered by the CTRU will be used after patient eligibility and
written consent have been confirmed. Patients will be randomly allocated via the online system to receive
either (1) HS with usual care (n= 150) or (2) usual care (n= 150). The randomisation schedule will be
computer generated prior to the study by the CTRU randomisation service. The allocation schedule will
be concealed through the use of the centralised web-based randomisation service, which also allows
unblinding in the case of emergency. The randomisation sequence will not be revealed to any person
involved in patient recruitment. The data analysts will be blind to treatment allocation until after the
statistical analysis plan is finalised, the database locked and the data review completed. All unblinding
(emergency and end of trial) will be automatically logged by the CTRU randomisation system, which will
include the date, time and user responsible.
Blinding
The study will compare the addition of the intervention to usual care without placebo. The use of placebo
in this setting is problematic in that this would involve an intervention that may have a significant effect on
the outcome for subjects in the ‘placebo’ arm. The extra handling involved in nebulised therapy may have
a deleterious effect, as has been shown to be associated with the increased handling associated with
physiotherapy.49 Similarly, the ‘placebo’ agent may cause harm as has been suggested in previous studies
using nebulised distilled water or may have an unexpected positive impact for an agent such as a NS.32
Interim analyses and study monitoring
Interim analyses
As the study was designed to be of short duration with the data collection period anticipated to last for only a
single bronchiolitis season, no interim analyses were planned. However, poor recruitment during the first
season resulted in a single interim analysis at the end of this first year, resulting in a decision to continue with
the trial and a small reduction in the significance threshold as detailed in Level of significance.
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Study monitoring
The trial will be monitored and audited in accordance with the monitoring standard operating procedures
of the clinical research facility and the CTRU. Three committees will be established to govern the conduct of
the trial:
1. TSC. The TSC will consist of an independent chair, the chief investigator, two independent members
(statistician and clinician) and a parent representative.
2. DMEC. The DMEC will consist of an independent statistician and two independent experts. Its
responsibilities will include reviewing the trial data at regular intervals and implementing stopping rules
in accordance with MRC guidance.151
3. TMG. The TMG will include the chief investigator, co-applicants, principal investigators, CTRU assistant
director, trial manager, research nurses, trial statistician and health economist.
Data sources, data evaluability and analysis populations
Data sources
The data used in this study will come from the following sources:
For patients who are eligible for randomisation into the study
(including patients who are randomised)
l Patient recruitment form, which contains the age, sex and details regarding entry criteria.
For patients who are randomised into the study
l Randomisation schedule, which contains randomisation codes and allocated intervention group
l Case report form, which contains patient demographics, characteristics at presentation, investigations
and events during treatment, assessment of ‘fit for discharge’, resource use and AEs over subsequent
28 days
l Post-discharge data collection forms, comprising symptom and health-service utilisation diary,
and ITQoL.
The randomisation codes are stored electronically on the CTRU randomisation system. All other electronic
data are held separately on the CTRU database system. Access to any data that would unblind the study
will be limited to members of the CTRU who are independent of the trial.
Protocol deviations
Patients who are deemed not to have adhered to the study procedures will be considered as deviations
from the protocol. Deviations will be classified as either major or minor depending on their importance,
and secondary analyses may be performed excluding patients who are considered to be major protocol
deviations. These analyses are termed ‘per-protocol’ analyses, and the set of patients who are included in
these analyses will be termed the PP analysis set. The definition of protocol deviations will be agreed and
finalised prior to final database lock. In deciding upon protocol deviation, particular weight will be given to
the following:
l randomised despite not fitting the entry criteria
l not receiving randomised treatment
l receiving concomitant medications during treatment stage.
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Analysis populations
Four analysis populations will be used in the analyses:
1. All screened patients: patients who are screened for eligibility to the study, including those randomised.
2. FAS: all randomised patients, with the following exclusions:
i. patients who have previously been randomised. Where this occurs, only data from the first admission
will be analysed.
ii. patients from whom there is no recorded informed consent obtained from carers (oral or written).
iii. patients whose carers withdraw consent before any study medications are given.
iv. patients whose carers withdraw consent retrospectively (i.e. request that their entire data
are removed).
v. patients who were randomised despite not fulfilling the inclusion criteria.
3. Per-protocol (PP): the subset of the FAS who do not deviate from the protocol, as defined in
Protocol deviations.
4. Safety: all randomised patients, with the exception of those who have no recorded informed consent.
Summaries based on the FAS and PP populations will be on an intention-to-treat basis with patients
assigned to the treatment group as originally randomised. Summaries based on the safety population will
analyse patients by the actual treatment received.
For the outputs presented to the DMEC, all outputs will be based on the FAS population unless
otherwise requested.
Outline of the analyses
General considerations
Summary information
All summaries presented to the DMEC will be by treatment group. Additional summaries may be provided
which report according to treatment centre, if requested. In order to maintain the blinding by the trial
statistician, it will be the responsibility of the CTRU to provide this by-treatment group information to the
DMEC. No member of the study team will have access to unblinded data sets or the unblinded reports
until the final analyses. Summaries of continuous variables will include the number of observations used,
mean, median, SD, interquartile range, minimum and maximum. Summaries of categorical variables will
comprise the number of observations used, and the number and percentage in each category.
Number and timing of analyses – adjustments for multiplicity
The study may stop prematurely on grounds of safety or futility, based on recommendations from the
DMEC or the funder. No formal interim analyses were planned for efficacy but due to poor recruitment in
the first season a single interim analysis at the end of this first year was carried out, resulting in a decision
to continue with the trial and a small reduction in the significance threshold as detailed in Level of
significance. No other adjustments were made for multiplicity.
Level of significance
As a result of poor recruitment in the first season, there was an unplanned interim analysis at the end
of the first year. The effect of this unplanned analysis on the overall significance level of the trial
was investigated and as a result the significance threshold has been changed to 0.045 probability of
declaring a false significance difference in the mean change in scores between the intervention arms
will be tolerated. All CIs will remain two sided 95% intervals. No further adjustments will be made for
multiple testing.
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Statistical analysis packages used
All statistical analysis will be implemented in SAS version 9.1152 and Stata version 10.
Further details of data derivations are in Further details of statistical methods and calculations.
Data completeness
The following summary will be presented for all screened patients by centre and overall:
l Enrolment: the number of days recruiting, the number of patients screened, the number of patients
recruited, the number of patients recruited per day, the number of screened patients not recruited, and
the reason for non-recruitment.
The following summary will be presented for the FAS:
l Data completeness
¢ by treatment group: the number of patients with complete data for key parameters
¢ by centre: the number of patients with complete data for key parameters
l Protocol deviations
¢ By treatment group: number of patients who deviate from the protocol
¢ By centre: the number of patients who deviate from the protocol
The inclusion of key parameters may be allowed to vary at the request of the DMEC during the trial. In
order to allow time for data to be entered onto the system, the follow-up and questionnaire data will be
considered complete if they have been entered within 30 days of the scheduled data collection time point.
Missing, spurious and unused data
Questionable data will be queried with the study manager and referred back to the site investigators
where appropriate.
Demographics, baseline characteristics and concomitant medications
The following summaries will be presented:
l demographics: centre, age, sex, ethnicity, age at admission, gestation, birth weight, current weight
l background: smoker in household, child-care method, feeding method, number of siblings, family
history of asthma, eczema and hay fever, previous illnesses, medical problems, length of current illness
prior to admission
l concomitant medications given by time period:
¢ in the 2 weeks prior to admission
¢ during admission.
Efficacy
The following summaries will be presented:
l time to being declared fit for discharge
l actual time to discharge
l percentage transferred to HDU/ICU
l percentage readmitted within 28 days from randomisation
l time from randomisation to resolution of respiratory symptoms
l health-care utilisation, post discharge and up to 28 days from randomisation.
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Primary end point (time to being declared ‘ready for discharge’)
Time to being declared ‘ready for discharge’ can be regarded as a survival time and methods appropriate
to survival data will be used to analyse these data, as these methods adjust for censoring in the
observations. The primary analysis will compare differences between treatment groups, adjusted for centre
using a cox-proportional hazards regression model. Further sensitivity analyses may be undertaken to
include additional covariates if imbalances are noted. The proportionality of the hazards will be assessed by
graphing scaled Schoenfeld residuals against time.50 In addition to study group and centre, the model will
include terms for any potential confounders in the baseline characteristics.
Secondary end points
The analysis of actual time to discharge will be similar to the primary outcome measure time to ‘fit to
discharge’. For other secondary outcomes the statistical method appropriate to the data type will be used.
For example, readmission rate will be treated as a binary outcome; although it is possible that children
could be readmitted multiple times because of their single episode of bronchiolitis, it is much more likely
that they will be readmitted just once. Thus, the percentage of children readmitted at least once will be
calculated by study group and compared, initially with a Fisher’s exact test, and, if there is a need to adjust
for covariates, using a logistic regression model. Each of the 13 dimensions of the ITQoL will be tabulated
and examined for differences between treatment groups, initially using a t-test. Where the assumptions
underlying the t-test do not hold, a Mann–Whitney U-test will be used. Where there is a need to adjust
for covariates the relationship between the groups for each dimension of the ITQoL scale will also be
compared using a linear regression model.
Safety outcomes
The following summaries will be based on the FAS population:
l study medication usage
l concomitant medications
l AEs, overall and by type
l SAEs, overall and by type
l side effects, overall and by type
l observations during trial treatment (supplemental oxygen, feeding method).
In summaries of AEs and medications, the number of patients experiencing any event will be presented by
actual treatment received; patients will be counted only once in each row, even if more than one event is
noted. Where no event is recorded the patient will be defined as having not experienced an event.
The following listings will also be provided. Note that each will contain the treatment, patient ID, event details,
date/time and time to onset. For AEs the seriousness will also be reported. For SAEs the duration, expectedness,
relationship to study drug, frequency, intensity, action taken and outcome will all be reported:
l all AEs
l all SAEs
l all side effects.
Subgroup analysis
The study will investigate outcomes between those infants with human RSV infection and those with acute
bronchiolitis due to one of the many other respiratory viruses that can cause the same clinical phenotype
(non-RSV). There is currently no evidence about whether the response to treatment would differ between these
two patient groups and if so what the probable magnitude might be. While the study has not been powered
to investigate this, it is of interest to investigate and thus the coefficient for the interaction between infection
group (RSV vs. non-RSV) and treatment group will be presented together with its 95% CIs and p-value. In
addition, results will also be reported separately for the RSV and non-RSV groups in order to provide
information for a power calculation for a future study, investigating the relative efficacy of nebulised HS for RSV
compared with non-RSV patients.
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Further details of statistical methods and calculations
Disposition and data completeness
Enrolment
The number of days recruiting will be defined for each centre as:
(date of database transfer)− (date of first patient screened). (1)
The overall number of recruiting days is defined as the total number of days recruiting, summed over
all centres.
Summaries of non-recruitment will exclude patients who do not meet the inclusion criteria, unless they are
recruited in error. Therefore, the recruitment rate will be:
Percentage recruited= (100  number recruited)/(number recruited
þnumber meeting inclusion criteria but not recruited).
(2)
This is assuming complete capture of all screened patients who meet the inclusion criteria. If it becomes
apparent that some or all centres have not done so at the time of database lock, then alternative estimates
will be investigated.
Data completion
Completeness (the appearance of any data) will be reported for selected variables, including primary
outcome and all secondary outcomes. The percentage completeness of AE data will be defined as:
Percentage complete= 100 number with AE recorded up to 28 days after
admission/(number of patients with 28 days follow-up):
(3)
For all other variables reported completeness will be among all randomised patients.
Efficacy analyses
Primary end point
‘Fit to discharge’ will be measured every 6 hours, with the first evaluation at time of randomisation.
Time to being declared ‘fit to discharge’ will be calculated as:
(time declared fit to discharge)− (time of randomisation). (4)
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Secondary end point
Time to discharge will be calculated as:
(time of discharge) − (time of randomisation). (5)
Percentage transferred to HDU/ICU = (100 number transferred to HDU/ICU)/number randomised.
(6)
Percentage readmitted within 28 days from randomisation = (100  number readmitted)
/number randomised.
(7)
Duration of respiratory symptoms post-randomisation (days) will be calculated as:
(date of first day without symptoms) − (date of randomisation). (8)
References
Trial documents
1. Trial protocol (V0.10, 28 June 2011).
2. Data collection forms:
i. Eligibility form (V1.0, 3 August 2011)
ii. Baseline information form (V1.0, 3 August 2011)
iii. Treatment data (V1.0 3 August 2011)
iv. Discharge form (V1.0, 10 August 2011)
v. Follow-up forms including symptom diary (V1.0, 10 August 2011)
vi. Study completion (V1.0, 3 August 2011)
vii. AE recording form (V1.0, 3 August 2011)
viii. 1-month questionnaire (V1.0, 3 August 2011).
Standard operating procedures
1. Statistician input and the statistical analysis plan (Shef/CTRU/ST001, version 1.1, 29 October 2007).
2. Data evaluability (Shef/CTRU/ST003, version 1.0, 15 October 2007).
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Appendix 5 PROSPERO registration
Nebulised hypertonic saline solution for acute bronchiolitis in
infants: a systematic review and meta-analysis
Chin Maguire, Hannah Cantrill
BOX 1 PROSPERO registration
Review question(s)
How safe and effective is nebulised HS solution when used to treat acute bronchiolitis in hospitalised infants
(under the age of 2 years).
Searches
The following electronic databases will be searched: MEDLINE (via Ovid) (1946 to January 2015), EMBASE
(1974 to January 2015), the Cochrane Central Register of Controlled Trials, Google Scholar (2010 to
January 2015) and Web of Science (2010 to January 2015). The full search strategy used in each database is
available in Appendix 6. No restrictions or limits (e.g. age, language or publication date) will be applied in any
of the databases other than Google Scholar where a restriction of 2010 onwards will be applied.
Trial registries: other than electronic databases, individual trial registries were searched using the terms
‘bronchiolitis’ and ‘hypertonic saline’. These included: ClinicalTrials.gov; UK Clinical Trials Gateway; Centre for
Reviews and Dissemination databases (Database of Abstracts of Reviews of Effects, NHS Economic Evaluation
Database, HTA Database); controlled-trials.com; centrewatch.com and National Research Register, to identify
any unpublished data.
Journals: the major journals identified for hand searching are Chest, Paediatrics, and Journal of Paediatrics
because these are the journals where the current articles of choice were found. Each of the journals will be
searched using the terms ‘hypertonic saline’ and ‘bronchiolitis’.
Other searches: the reference lists of all identified and suitable trials will be checked to identify any further trials
with a view to obtaining any published data in order to minimise publication bias.
Types of study to be included
Published and unpublished, RCTs and quasi-randomised trials; cohort and other observational studies will
be excluded.
Only trials which have completed recruitment will be included in the review.
No language or publication restrictions will be applied at the search stage however only those trials published
in English will be included in the review.
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Condition or domain being studied
Bronchiolitis (also known as RSV) is a very common respiratory tract infection in young children, most
commonly aged between 2 and 5 months. Acute bronchiolitis results in symptoms of swelling of the airway
wall, increased mucous production and an impairment of secretion clearance causing airway obstruction
and a combination of gas trapping and ineffective gaseous exchange. Acute bronchiolitis is widely accepted
to refer to the first episode of acute wheezing in infants younger than 24 months which may start as an
upper respiratory tract viral infection. Overall, 1–2% of children diagnosed with bronchiolitis will require
hospitalisation. Bronchiolitis is the main cause of hospital admission for respiratory tract infections with
recurrent wheezing episodes seen in up to 50% of severely infected children years after their primary diagnosis.
Participants/population
Research with children up to the age of 2 years who had been hospitalised as the result of an episode of
acute bronchiolitis will be considered for the review. Criteria for inclusion include a first episode of acute
wheezing associated with bronchiolitis. Not all cases of bronchiolitis are a result of RSV and as such all cases
of bronchiolitis regardless of organism will be included.
Intervention(s), exposure(s)
The intervention under consideration is nebulised HS with or without an adjunct treatment given versus NS or
no intervention (control). These can be summarised in the following groups:
1. Nebulised HS alone vs. NS
2. Nebulised HS plus a bronchodilator (e.g. salbutamol) vs. NS
3. Nebulised HS plus a bronchodilator (e.g. salbutamol) vs. NS plus same bronchodilator
4. Nebulised HS alone or plus a bronchodilator (e.g. salbutamol) vs. no intervention
No restrictions will be applied in terms of the concentration, dose or the way the intervention (HS) or control
(NS with or without adjunct treatment) is administered in the trials.
Comparator(s)/control
Please see Intervention(s), exposure(s) above for outline of comparators used in the review.
Context
Studies will not be excluded based on the outcomes they measure; only the population and intervention will be
used to screen trials for the review.
A systematic review by Zhang et al. conducted in 2010 suggests that HS results in improved clinical outcomes
for infants with viral bronchiolitis. The review looked at children in a number of different settings (hospitalised,
outpatients and those in the emergency department). This review will update the systematic review conducted
in 2010 (with respect to hospitalised infants only) to incorporate both new published and unpublished data
from recent clinical trials conducted since 2010.
BOX 1 PROSPERO registration (continued)
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Outcome(s)
Primary outcomes
The primary objective of this review is to determine whether or not nebulised HS results in benefits to
hospitalised children in terms of reducing the LoS typically defined as time to meeting discharge criteria.
A ‘summary of findings’ table will be included in the results section. For any dichotomous outcomes results will
be expressed as risk ratios and 95% CI. For any continuous outcomes the MD and 95% CI will be used.
Secondary outcomes
Secondary outcomes of interest include rate of readmission to hospital; any AEs however described but particularly
tachycardia, hypertension, pallor, tremor, nausea, vomiting and acute urinary retention; and final CSS scores.
Data extraction (selection and coding)
The titles and abstracts of all the studies identified by the search will be performed. The full articles of any
studies that appear to meet the inclusion criteria or those where it is unclear, or where there is insufficient
information to make a decision for their inclusion, will be retrieved. Papers that do not meet the inclusion
criteria will be excluded.
Data will be extracted onto a standardised data extraction form to both assess the methodological quality of
the studies and retrieve outcome data.
1. Key data to be extracted include:
2. study overview (country, year)
3. participant characteristics (age, number randomised, baseline imbalances assessed by the authors in trials,
withdrawals, per cent allocated completing follow-up, illness severity, eligibility)
4. intervention and control group details (number randomised in each group, intervention details: duration,
delivery, other drugs and compliance)
5. Outcomes data:
i. for continuous outcomes: LoS, typically defined as time to meeting discharge criteria (mean LoS typically
defined as time to meeting discharge criteria, SD and number of patients in each group, measured by
who); and CSS (mean final CSS score, SD, number of patients for both groups). Principal summary
measure is weighted MD in LoS typically defined as time to meeting discharge criteria
6. qualitative AE data as available.
Risk of bias (quality) assessment
Risk of bias assessment will be performed on the extracted data based on the Cochrane Collaboration’s
recommendations to assess the quality of the studies. Data will be summarised in the ‘risk of bias’ tables in the
results of the review. Trials will be graded on their quality as ‘A’ low risk of bias, ‘B’ high risk of bias or ‘C’ risk
of bias unclear. Where a ‘C’ grading is given, every effort will be made to obtain further information to
categorise the trial by contacting the trial authors within the specified time frame of this piece of work. The
funnel plot method will be used to investigate whether or not publication bias is present if sufficient studies are
included in the meta-analysis. Any unpublished results that are obtained will be incorporated.
BOX 1 PROSPERO registration (continued)
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Risk of bias assessment data items will include: sequence generation; allocation concealment; blinding
(outcome and personnel); incomplete outcome data and selective reporting
Data will be input into RevMan to generate summary statistics.
Strategy for data synthesis
The primary outcome data collected are the LoS typically defined as time to meeting discharge criteria SD and
number of participants in both intervention and control groups. A FE model will be used to analyse these
continuous data based on the assumption that LoS typically defined as time to meeting discharge criteria
outcome would estimate the same effect size in each of the studies.153 A weighted MD and associated 95% CI
will be calculated (via RevMan) in order to generate a forest plot. The FE model allows the studies to be
weighted depending on their sample size; the greater the sample size, the greater the weight assigned to
the trial.
The secondary outcomes of interest include AEs (however reported), rates of hospital readmission and final CSS
score. Data on AEs will be collected (however these are defined) and a descriptive narrative of the results will
be undertaken. These form part of the qualitative synthesis of the results.
Analysis of subgroups or subsets
None planned.
Dissemination plans
The review will form part of the HTA monograph for the SABRE clinical trial.
Contact details for further information
Chin Maguire
ScHARR, University of Sheffield
c.maguire@sheffield.ac.uk
Organisational affiliation of the review
ScHARR, University of Sheffield, 30 Regent Street, Sheffield S1 4DA, UK.
Review team
Mrs Chin Maguire, Clinical Trials Unit, University of Sheffield; Miss Hannah Cantrill, Clinical Trials Unit,
University of Sheffield, Sheffield, UK.
Collaborators
Dr Daniel Hind, ScHARR, University of Sheffield, Sheffield, UK.
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Details of any existing review of the same topic by the same authors
None.
Anticipated or actual start date
1 January 2013.
Anticipated completion date: 25 April 2014.
Funding sources/sponsors
The results of the systematic review will be presented in the monograph for the ‘SABRE (hypertonic Saline in
Acute Bronchiolitis RCT and Economic evaluation)’ trial funded by the HTA, reference 09/91/22.
Conflicts of interest
None known.
Other registration details
None.
Language
English.
Country
England.
Subject index terms status
Subject indexing to be assigned.
Subject index terms
Bronchiolitis; humans; infant; saline solution, hypertonic.
Reference and/or URL for protocol
None available.
Stage of review
Ongoing.
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Date of registration in PROSPERO
3 March 2014.
Date of publication of this revision
18 December 2014.
Stage of review at time of this submission Started Completed
Preliminary searches No Yes
Piloting of the study selection process No Yes
Formal screening of search results against eligibility criteria No Yes
Data extraction Yes No
Risk of bias (quality) assessment Yes No
Data analysis Yes No
BOX 1 PROSPERO registration (continued)
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Appendix 6 Main literature search results
MEDLINE (via Ovid)
MEDLINE was searched from 1946 (inception) to present. No limits (e.g. dates, age) or restrictions were applied.
Search date: January 2015.
Search strategy
1. Bronchiolitis/ (2310 results)
2. Bronchiolitis.mp. [mp= title, abstract, original title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique
identifier] (9842 results)
3. 1 OR 2 (9842 results)
4. Humans/ (13,622,085 results)
5. Humans.mp. [mp= title, abstract, original title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique
identifier] (13,701,574 results)
6. 4 OR 5 (13,701,574 results)
7. 3 AND 6 (8487 results)
8. Aerosols/ or “Nebulizers and Vaporizers”/ (30,740 results)
9. nebulize$.mp. [mp= title, abstract, original title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique
identifier] (11,059 results)
10. 8 OR 9 (33,444 results)
11. 7 AND 10 (238 results)
12. Sodium Chloride/ or Saline Solution, Hypertonic/ (54,351 results)
13. Hypertonic saline.mp. [mp= title, abstract, original title, name of substance word, subject heading
word, keyword heading word, protocol supplementary concept, rare disease supplementary concept,
unique identifier] (4987 results)
14. 12 OR 13 (56,498 results)
15. 11 AND 14 (43 results)
EMBASE
EMBASE was searched from 1974 (inception) to present. No limits (e.g. dates, age) or restrictions
were applied.
Search date: January 2015.
Search strategy
1. Bronchiolitis/ (9588 results)
2. Bronchiolitis.tw. (11,033 results)
3. 1 OR 2 (14,695 results)
4. Human/ (15,229,989 results)
5. Human.mp. [mp= title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword] (15981086 results)
6. 4 OR 5 (15,981,086 results)
DOI: 10.3310/hta19660 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 66
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Everard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
129
7. 3 AND 6 (12,665 results)
8. Aerosol/ or nebulizer/ or nebulization/ (50,225 results)
9. Nebulize$.mp. [mp= title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword] (11,285 results)
10. 8 OR 9 (53,556 results)
11. 7 AND 10 (413 results)
12. Sodium chloride/ (134,876 results)
13. Hypertonic saline.mp [mp= title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device trade name, keyword] (6139 results)
14. 12 OR 13 (136,836 results)
15. 11 AND 14 (102 results)
The Cochrane Central Register of Controlled Trials
The Cochrane Central Register of Controlled Trials was searched from inception to present. No limits
(e.g. dates, age) or restrictions were applied.
Search date: January 2015.
Search strategy
1. Medical subject heading (MeSH) descriptor: [Bronchiolitis] (279 results)
2. Bronchiolitis (749 results)
3. 1 OR 2 (750 results)
4. MeSH descriptor: [Humans] (1100 results)
5. Human (504536 results)
6. 4 OR 5 (504536 results)
7. 3 AND 6 (444 results)
8. MeSH descriptor: [Nebulizers and Vaporizers] (1889 results)
9. Nebulize$ (13 results)
10. MeSH descriptor: [Aerosols] (2107 results)
11. 8 OR 9 OR 10 (3713 results)
12. 7 AND 11 (78 results)
13. MeSH descriptor: [Saline Solution, Hypertonic] (404 results)
14. Hypertonic saline (949 results)
15. 13 OR 14 (949 results)
16. 12 AND 15 (18 results)
Google Scholar
Bronchiolitis AND hypertonic saline performed from 2010 to present. 915 articles were found
and reviewed.
Web of Science
Bronchiolitis AND hypertonic saline from 2010 to present. 81 articles were found and reviewed.
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